Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

ABSTRACT

The present invention relates to methods for treating Neisseria gonorrhoeae infection which comprises administering to a subject in need thereof novel Tricyclic nitrogen containing compounds and corresponding pharmaceutical compositions as described herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This Invention Was Made With Government Support Under The United StatesOf America Department Of Health And Human Services Assistant SecretaryFor Preparedness And Response, Biomedical Advanced Research andDevelopment Authority (BARDA), within the Office of the AssistantSecretary for Preparedness and Response in the U.S. Department of Healthand Human Services, Agreement No.: HHSO100201300011C. The Government mayhave certain rights in the invention.

FIELD OF THE PRESENT INVENTION

The present invention relates to methods for treating Neisseriagonorrhoeae infection which comprises administering to a subject in needthereof novel Tricyclic nitrogen containing compounds and correspondingpharmaceutical compositions as described herein.

BACKGROUND OF THE PRESENT INVENTION

Gonorrhea is the second most prevalent bacterial sexually transmittedinfection globally and remains an important clinical and public healthproblem throughout the world. Gonococcal infections following sexual andperinatal transmission are a major source of morbidity worldwide [Barry,2009]. Infections can involve cervicitis, proctitis, urethritis, pelvicinflammatory disease, epididymitis, orchitis, prostatitis,conjunctivitis, pharyngitis and other disseminated gonococcal diseases.

Neisseria gonorrhoeae, also known as gonococci (plural), GC (anabbreviation) or gonococcus (singular), is a species of Gram-negativecoffee bean-shaped diplococci bacteria responsible for the sexuallytransmitted infection gonorrhea.^([1])

Complications include infertility, ectopic pregnancy, chronic pelvicpain, adverse outcomes of pregnancy, and increased susceptibility to andtransmission of human immunodeficiency virus [Workowski, 2008; Barry,2009].

Infections due to Chlamydia trachomatis and Neisseria gonorrhoeae cancause cervicitis, urethritis, proctitis, and pelvic inflammatory disease(PID), and their complications can significantly compromise a woman'sreproductive functioning. These infections are a leading preventablecause of involuntary infertility and ectopic pregnancy and can influencepregnancy outcomes ranging from low birth weight, prematurity, fetaldemise, and congenital infection. Chlamydial and gonococcal infectionscan also increase susceptibility to and facilitate transmission of HIV.Kimberly Workowski. 2013 American College of Physicians, Annals ofInternal Medicine, In the Clinic.

A variety of antimicrobial agents have been used over the years for thetreatment of gonorrhea; however, effective treatment options forgonorrhea have diminished rapidly because of the emergence and worldwidespread of antimicrobial resistance to many drugs previously used orconsidered first line, i.e., penicillins, narrow-spectrumcephalosporins, tetracyclines, macrolides, and fluoroquinolones[Workowski, 2008; Barry, 2009].

The current Centers for Disease Control and Prevention (CDC) recommendedtreatment regimen for uncomplicated gonorrhea is combination therapywith a single intramuscular dose of ceftriaxone plus either a singledose of azithromycin or a 7-day regimen of doxycycline [CDC, 2012].While the CDC guidelines may help delay the emergence ofcephalosporin-resistant gonorrhea, they are not able to eliminate thisimpending threat.

Therefore, the CDC has urged scientists and private-sector drugdevelopers to prioritize the identification and study of new, effectiveantibiotic treatment options for gonorrhea [CDC, 2013].

WO02/08224, WO02/50061, WO02/56882, WO02/96907, WO2003087098,WO2003010138, WO2003064421, WO2003064431, WO2004002992, WO2004002490,WO2004014361, WO2004041210, WO2004096982, WO2002050036, WO2004058144,WO2004087145, WO2006002047, WO2006014580, WO2006010040, WO2006017326,WO2006012396, WO2006017468, WO2006020561, WO2006081179, WO2006081264,WO2006081289, WO2006081178, WO2006081182, WO01/25227, WO02/40474,WO02/07572, WO2004024712, WO2004024713, WO2004035569, WO2004087647,WO2004089947, WO2005016916, WO2005097781, WO2006010831, WO2006021448,WO2006032466, WO2006038172, WO2006046552, WO06099884, WO06126171,WO06137485, WO06105289, WO06125974, WO06134378, WO07016610, WO07081597,WO07071936, WO07115947, WO07118130, WO07122258, WO08006648, WO08003690and WO08009700 disclose quinoline, naphthyridine, morpholine,cyclohexane, piperidine and piperazine derivatives having antibacterialactivity. WO2004104000 discloses tricyclic condensed ring compoundscapable of selectively acting on cannabinoid receptors. WO2003048081,WO2003048158 and US2003232804 disclose glycinamides as Factor Xainhibitors.

SUMMARY OF THE PRESENT INVENTION

In general, the present invention relates to methods for treatingNeisseria gonorrhoeae infection which comprises administering to asubject in need thereof novel Tricyclic nitrogen containing compoundsand corresponding pharmaceutical compositions as described herein.

DETAILED DESCRIPTION OF THE PRESENT INVENTION Compounds

In general, the present invention relates to methods for treatingNeisseria gonorrhoeae infection which comprises administering to asubject in need thereof novel Tricyclic nitrogen containing compoundsand corresponding pharmaceutical compositions as described herein.

In particular, the present invention provides for use of a compound offormula (I) or a pharmaceutically acceptable salt and/or N-oxidethereof:

wherein:Z¹ and Z² are independently selected from CH and N;R^(1a) and R^(1b) are independently selected from hydrogen; halogen;cyano; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; trifluoromethoxy;carboxy; hydroxy optionally substituted with (C₁₋₆)alkyl or(C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl;(C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; hydroxy (C₁₋₆)alkyl; an amino groupoptionally N-substituted by one or two (C₁₋₆)alkyl, formyl,(C₁₋₆)alkylcarbonyl or (C₁₋₆)alkylsulphonyl groups; and aminocarbonylwherein the amino group is optionally substituted by (C₁₋₄)alkyl;provided that R^(1a) and R^(1b) are H when Z² or Z¹ is N, respectively;R² is hydrogen, or (C₁₋₄)alkyl, or together with R⁶ forms Y as definedbelow;A is a group (i):

in which: R³ is as defined for R^(1a) and R^(1b) or is oxo and n is 1 or2:or A is a group (ii)

-   -   W¹, W² and W³ are CR⁴R⁸

or W² and W³ are CR⁴R⁸ and W¹ represents a bond between W³ and N.

X is O, CR⁴R⁸, or NR⁶;

one R⁴ is as defined for R^(1a) and R^(1b) and the remainder and R⁸ arehydrogen or one R⁴ and R⁸ are together oxo and the remainder arehydrogen;

R⁶ is hydrogen or (C₁₋₆)alkyl; or together with R² forms Y;

R⁷ is hydrogen; halogen; hydroxy optionally substituted with(C₁₋₆)alkyl; or (C₁₋₆)alkyl;

Y is CR⁴R⁸CH₂; CH₂CR⁴R⁸; (C═O); CR⁴R⁸; CR⁴R⁸(C═O); or (C═O)CR⁴R⁸;

or when X is CR⁴R⁸, R⁸ and R⁷ together represent a bond;

U is selected from CO, and CH₂ andR⁵ is an optionally substituted bicyclic carbocyclic or heterocyclicring system (B):

containing up to four heteroatoms in each ring in which

at least one of rings (a) and (b) is aromatic;

X¹ is C or N when part of an aromatic ring, or CR¹⁴ when part of anon-aromatic ring;

X² is N, NR¹³, O, S(O)_(X), CO or CR¹⁴ when part of an aromatic ornon-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of a nonaromatic ring;

X³ and X⁵ are independently N or C;

Y¹ is a 0 to 4 atom linker group each atom of which is independentlyselected from N, NR¹³, O, S(O)_(X), CO and CR¹⁴ when part of an aromaticor non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of anonaromatic ring;

Y² is a 2 to 6 atom linker group, each atom of Y² being independentlyselected from N, NR¹³, O, S(O)_(X), CO, CR¹⁴ when part of an aromatic ornon-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of anonaromatic ring;

each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio;halo; carboxy(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₁₋₄)alkoxycarbonyl;(C₁₋₄)alkylcarbonyl; (C₁₋₄)alkoxy (C₁₋₄)alkyl; hydroxy;hydroxy(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino oraminocarbonyl optionally mono- or di-substituted by (C₁₋₄)alkyl; or

R¹⁴ and R¹⁵ may together represent oxo;

each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl optionallysubstituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo ortrifluoromethyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl;(C₁₋₄)alkylcarbonyl; (C₁₋₆)alkylsulphonyl; aminocarbonyl wherein theamino group is optionally mono or disubstituted by (C₁₋₄)alkyl; and

each x is independently 0, 1 or 2.

The invention also provides a pharmaceutical composition comprising acompound of formula (I), or a pharmaceutically acceptable salt and/orN-oxide thereof, and a pharmaceutically acceptable carrier.

In one aspect one of Z¹ and Z² is CH or N and the other is CH.

In particular aspects:

(i) Z¹ and Z² are both CH;

(ii) Z¹ is N and Z² is CH;

(iii) Z¹ is CH and Z² is N.

In a particular aspect R^(1a) and R^(1b) are independently hydrogen,(C₁₋₄)alkoxy, (C₁₋₄)alkylthio, (C₁₋₄)alkyl, cyano, carboxy,hydroxymethyl or halogen; more particularly hydrogen, methoxy, methyl,cyano, or halogen.

In particular embodiments R^(1a) and R^(1b) are hydrogen.

In a particular aspect R² is hydrogen.

Particular examples of R³ include hydrogen; optionally substitutedhydroxy; optionally substituted amino; halogen; (C₁₋₄) alkyl;1-hydroxy-(C₁₋₄) alkyl; optionally substituted aminocarbonyl. Moreparticular R³ groups are hydrogen; CONH₂; 1-hydroxyalkyl e.g. CH₂OH;optionally substituted hydroxy e.g. methoxy; optionally substitutedamino; and halogen, in particular fluoro. Most particularly R³ ishydrogen, hydroxy or fluoro.

In a particular aspect, when A is (ia), n is 1. In a further aspect R³is in the 3- or 4-position. In a more particular aspect, A is (ia), n is1 and R³ is in the 3-position, and more particularly is cis to the NR²group. In particular embodiments, A is a group (ia) in which n is 1 andR³ is hydrogen or hydroxy. More particularly where A is3-hydroxy-piperidin-4-yl the configuration is (3R,4S) or (3S,4R).Alternatively and more particularly where A is piperidin-4-yl theconfiguration is (3R,4S).

In an alternative more particular aspect, when A is (ia), n is 1, R³ isin the 4-position and is methyl.

In a particular aspect, when A is (ii), X is CR⁴R⁸ and R⁸ is H and R⁴ isH or OH and more particularly OH is trans to R⁷. In a further aspect W¹is a bond. In another aspect R⁷ is H. In an additional aspect WI is abond, W² and W³ are both CH₂ and R⁷ is H. Where A is4-hydroxypyrrolidin-3-ylmethyl, in a particular aspect the configurationis (3S,4S). Where A is pyrrolidin-3-ylmethyl, in a particular aspect theconfiguration is 3S.

In a particular aspect, when A is (ii), X is O, R⁷ is H and WI, W² andW³ are each CH₂.

In certain embodiments U is CH₂.

In certain embodiments R⁵ is an aromatic heterocyclic ring (B) having8-11 ring atoms including 2-4 heteroatoms of which at least one is N orNR¹³ in which, in particular embodiments, Y² contains 2-3 heteroatoms,one of which is S and 1-2 are N, with one N bonded to X³.

In alternative embodiments the heterocyclic ring (B) has ring (a)aromatic selected from optionally substituted benzo, pyrido, pyridazinoand pyrimidino and ring (b) non aromatic and Y² has 3-5 atoms, moreparticularly 4 atoms, including at least one heteroatom, with O, S, CH₂or NR¹³ bonded to X⁵ where R¹³ is other than hydrogen, and either NHCObonded via N to X³, or O, S, CH₂ or NH bonded to X³. In a particularaspect the ring (a) contains aromatic nitrogen, and more particularlyring (a) is pyridine or pyrazine. Examples of rings (B) includeoptionally substituted:

(a) and (b) Aromatic

-   1H-pyrrolo[2,3-b]-pyridin-2-yl, 1H-pyrrolo[3,2-b]-pyridin-2-yl,    3H-imidazo[4,5-b]-pyrid-2-yl, 3H-quinazolin-4-one-2-yl,    benzimidazol-2-yl, benzo[1,2,3]-thiadiazol-5-yl,    benzo[1,2,5]-oxadiazol-5-yl, benzofur-2-yl, benzothiazol-2-yl,    benzo[b]thiophen-2-yl, benzoxazol-2-yl, chromen-4-one-3-yl,    imidazo[1,2-a]pyridin-2-yl, imidazo-[1,2-a]-pyrimidin-2-yl,    indol-2-yl, indol-6-yl, isoquinolin-3-yl, [1,8]-naphthyridine-3-yl,    oxazolo[4,5-b]-pyridin-2-yl, quinolin-2-yl, quinolin-3-yl,    quinoxalin-2-yl, naphthalen-2-yl, 1,3-dioxo-isoindol-2yl,    1H-benzotriazol-5-yl, 1H-indol-5-yl, 3H-benzooxazol-2-one-6-yl,    3H-benzooxazol-2-thione-6-yl, 3H-benzothiazol-2-one-5-yl,    3H-quinazolin-4-one-6-yl, pyrido[1,2-a]pyrimidin-4-one-3-yl    (4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl), benzo[1,2,3]thiadiazol-6-yl,    benzo[1,2,5]thiadiazol-5-yl, benzo[1,4]oxazin-2-one-3-yl,    benzothiazol-5-yl, benzothiazol-6-yl, cinnolin-3-yl,    imidazo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyrazin-2-yl,    pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyrimidin-6-yl,    pyrazolo[5,1-c][1,2,4]triazin-3-yl, pyrido[1,2-a]pyrimdin-4-one-2-yl    (4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl), quinazolin-2-yl,    quinoxalin-6-yl, thiazolo[3,2-a]pyrimidin-5-one-7-yl,    thiazolo[5,4-b]pyridin-2-yl, thieno[3,2-b]pyridin-6-yl,    thiazolo[5,4-b]pyridin-6-yl, thiazolo[4,5-b]pyridin-5-yl,    [1,2,3]thiadiazolo[5,4-b]pyridin-6-yl, 2H-isoquinolin-1-one-3-yl    (1-oxo-1,2-dihydro-isoquinolin-3-yl),    [1,2,3]thiadiazolo[5,4-b]pyridine-6-yl

→ is the point of attachment

(a) Is Non Aromatic

-   (2S)-2,3-dihydro-1H-indol-2-yl,    (2S)-2,3-dihydro-benzo[1,4]dioxine-2-yl,    3-(R,S)-3,4-dihydro-2H-benzo[1,4]thiazin-3-yl,    3-(R)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl,    3-(S)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl,    2,3-dihydro-benzo[1,4]dioxan-2-yl,    3-substituted-3H-quinazolin-4-one-2-yl,

→ is the point of attachment

(b) Is Non Aromatic

-   1,1,3-trioxo-1,2,3,4-tetrahydrol l⁶-benzo[1,4] thiazin-6-yl,    benzo[1,3]dioxol-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl,    3-substituted-3H-benzooxazol-2-one-6-yl,    3-substituted-3H-benzooxazole-2-thione-6-yl,    3-substituted-3H-benzothiazol-2-one-6-yl,    4H-benzo[1,4]oxazin-3-one-6-yl    (3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl),    4H-benzo[1,4]thiazin-3-one-6-yl    (3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl),    4H-benzo[1,4]oxazin-3-one-7-yl,    4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine-7-yl,    5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidin-6-yl,    1H-pyrido[2,3-b][1,4]thiazin-2-one-7-yl    (2-oxo-2,3-dihydro-1H-pyrido[2,3-b]thiazin-7-yl),    2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl,    2-oxo-2,3-dihydro-1H-pyrido[3,4-b]thiazin-7-yl,    2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl,    2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl,    2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl,    3,4-dihydro-2H-benzo[1,4]oxazin-6-yl,    3,4-dihydro-2H-benzo[1,4]thiazin-6-yl,    3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl,    3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl,    3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl,    3,4-dihydro-1H-quinolin-2-one-7-yl,    3,4-dihydro-1H-quinoxalin-2-one-7-yl,    6,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-5-one-2-yl,    5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl    (1,2,3,4-tetrahydro-[1,8]naphthyridin-7-yl),    2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-6-yl,    6-oxo-6,7-dihydro-5H-pyridazino[3,4-b][1,4]thiazin-3-yl    (6-oxo-6,7-dihydro-5H-8-thia-1,2,5-triaza-naphthalen-3-yl),    2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yl,    2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl,    6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-yl,    [1,3]oxathiolo[5,4-c]pyridin-6-yl,    3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl,    2,3-dihydro[1,4]oxathiino[2,3-c]pyridin-7-yl,    6,7-dihydro[1,4]dioxino[2,3-c]pyridazin-3-yl,    5,6,7,8-tetrahydroisoquinolin-3-yl,    6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl,    1,3-dihydrofuro[3,4-c]pyridin-6-yl,    3,4-dihydro-2H-[1,4]oxathiepino[2,3-c]pyridin-8-yl,    [1,3]oxathiolo[4,5-c]pyridin-6-yl,    6,7-dihydro[1,4]oxathiino[2,3-c]pyridazin-3-yl,    6,7-dihydro-5H-pyrano[2,3-c]pyridazin-3-yl,    5,6-dihydrofuro[2,3-c]pyridazin-3-yl,    2,3-dihydrofuro[2,3-c]pyridin-5-yl, 2-substituted    1H-pyrimido[5,4-b][1,4]oxazin-7(6H)-one, 2-substituted    5,6-dihydropyrido[2,3-d]pyrimidin-7(1H)-one, 7-substituted    2H-chromen-2-one, 7-substituted 2H-pyrano[2,3-b]pyridin-2-one,    2-substituted 6,7-dihydro-5H-pyrano[2,3-d]pyrimidine, 8-substituted    2H-pyrido[1,2-a]pyrimidin-2-one, 2,3-dihydro-1-benzofuran-5-yl,    1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one-2-yl,    3,4-dihydro-2H-chromen-7-yl, 2,3-dihydro-1-benzofuran-6-yl,    3,4-dihydro-2H-chromen-6-yl,    3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-yl, 3,4-dihydro-2H-pyrido    [3,2-b][1,4]thiazine-6-yl, 6,7-dihydro-5H-thieno[3,2-b]pyran-2-yl,    2,3,4,5-tetrahydro-1,5-benzothiazepine-7-yl.

where R is an optional substituent→ is the point of attachment

In some embodiments R¹³ is H if in ring (a) or in addition (C₁₋₄)alkylsuch as methyl or isopropyl when in ring (b). More particularly, in ring(b) R¹³ is H when NR¹³ is bonded to X³ and (C₁₋₄)alkyl when NR¹³ isbonded to X⁵.

In further embodiments R¹⁴ and R¹⁵ are independently selected fromhydrogen, halo, hydroxy, (C₁₋₄) alkyl, (C₁₋₄)alkoxy, nitro and cyano.More particularly R¹⁵ is hydrogen.

More particularly each R¹⁴ is selected from hydrogen, chloro, fluoro,hydroxy, methyl, methoxy, nitro and cyano. Still more particularly R¹⁴is selected from hydrogen, fluorine or nitro.

Most particularly R¹⁴ and R¹⁵ are each H.

Particular groups R⁵ include.

-   [1,2,3]thiadiazolo[5,4-b]pyridin-6-yl-   1H-pyrrolo[2,3-b]pyridin-2-yl-   2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl-   2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl-   2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl-   2,3-dihydro-benzo[1,4]dioxin-6-yl-   2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl-   2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl-   3,4-dihydro-2H-benzo[1,4]oxazin-6-yl-   3-methyl-2-oxo-2,3-dihydro-benzooxazol-6-yl-   3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl-   3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl    (4H-benzo[1,4]thiazin-3-one-6-yl)-   4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl-   6-nitro-benzo[1,3]dioxol-5-yl-   7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl-   8-hydroxy-1-oxo-1,2-dihydro-isoquinolin-3-yl-   8-hydroxyquinolin-2-yl-   benzo[1,2,3]thiadiazol-5-yl-   benzo[1,2,5]thiadiazol-5-yl-   benzothiazol-5-yl-   thiazolo-[5,4-b]pyridin-6-yl-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl-   7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl-   7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl-   7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl-   2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]thiazin-7-yl-   [1,3]oxathiolo[5,4-c]pyridin-6-yl-   3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl-   5-carbonitro-2,3-dihydro-1,4-benzodioxin-7-yl-   2,3-dihydro[1,4]oxathiino[2,3-c]pyridin-7-yl-   6,7-dihydro[1,4]dioxino[2,3-c]pyridazin-3-yl-   5,6,7,8-tetrahydroisoquinolin-3-yl-   6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl-   1,3-dihydrofuro[3,4-c]pyridin-6-yl-   6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl-   3,4-dihydro-2H-[1,4]oxathiepino[2,3-c]pyridin-8-yl,-   [1,3]oxathiolo[4,5-c]pyridine-6-yl-   2,3-dihydro-1-benzofuran-5-yl-   6,7-dihydro[1,4]oxathiino[2,3-c]pyridazin-3-yl-   6,7-dihydro-5H-pyrano[2,3-c]pyridazin-3-yl-   5,6-dihydrofuro[2,3-c]pyridazin-3-yl-   2-substituted 1H-pyrimido[5,4-b][1,4]oxazin-7(6H)-one-   2-substituted 4-chloro-1H-pyrimido[5,4-b][1,4]oxazin-7(6H)-one-   2-substituted 5,6-dihydropyrido[2,3-d]pyrimidin-7(1H)-one-   2-substituted 4-chloro-5,6-dihydropyrido[2,3-d]pyrimidin-7(1H)-one-   2-substituted 4-methyl-5,6-dihydropyrido[2,3-d]pyrimidin-7(1H)-one-   2-substituted    4-methyloxy-5,6-dihydropyrido[2,3-d]pyrimidin-7(1H)-one-   7-substituted 2H-chromen-2-one-   7-substituted 2H-pyrano[2,3-b]pyridin-2-one-   4-chloro-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl-   8-substituted 2H-pyrido[1,2-a]pyrimidin-2-one-   6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)-   5-chloro-1-benzothiophen-2-yl-   6-chloro-1-benzothiophen-2-yl-   1-benzothiophen-5-yl-   1-methyl-1H-1,2,3-benzotriazol-6-yl-   imidazo[2,1-b][1,3]thiazol-6-yl-   4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl-   1-methy-1H-indol-2-yl-   1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one-2-yl-   [1,2,5]thiadiazolo[3,4-b]pyridine-6-yl-   4-fluoro-1H-benzimidazol-2-yl-   3,4-dihydro-2H-chromen-7-yl-   2,3-dihydro-1-benzofuran-6-yl-   3,4-dihydro-2H-chromen-6-yl-   6-chloro-2,3-dihydro-1,4-benzodioxin-7-yl-   7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-yl-   7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-yl-   3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl-   5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl-   5-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl-   8-fluoro-2H-1,4-benzoxazin-3(4H)-one-6-yl-   8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-6-yl-   7,8-difluoro-3,4-dihydro-2H-1,4-benzoxazin-6-yl-   6,7-dihydro-5H-thieno[3,2-b]pyran-2-yl-   5-methyl-2,3-dihydro-1,4-benzodioxin-7-yl-   4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-7-yl-   3,4-dihydro-2H-1,4-benzothiazine-6-yl-   2,3,4,5-tetrahydro-1,5-benzothiazepine-7-yl-   7-fluoro-3,4-dihydro-2H-1,4-benzoxazine-6-yl

→ is the point of attachmentespecially

-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl-   2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl-   [1,3]oxathiolo[5,4-c]pyridin-6-yl-   6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl-   2,3-dihydro[1,4]oxathiino[2,3-c]pyridin-7-yl-   3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl-   5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl-   5-carbonitro-2,3-dihydro-1,4-benzodioxin-7-yl-   2,3-dihydro-benzo[1,4]dioxin-6-yl

→ is the point of attachment

Definitions

When used herein, the term “alkyl” includes groups having straight andbranched chains, for instance, and as appropriate, methyl, ethyl,n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, pentyl andhexyl. The term ‘alkenyl’ should be interpreted accordingly.

Halo or halogen includes fluoro, chloro, bromo and iodo.

Haloalkyl moieties include 1-3 halogen atoms.

Compounds within the invention contain a heterocyclyl group and mayoccur in two or more tautomeric forms depending on the nature of theheterocyclyl group; all such tautomeric forms are included within thescope of the invention.

Some of the compounds of this invention may be crystallised orrecrystallised from solvents such as aqueous and organic solvents. Insuch cases solvates may be formed. This invention includes within itsscope stoichiometric solvates including hydrates as well as compoundscontaining variable amounts of water that may be produced by processessuch as lyophilisation.

Furthermore, it will be understood that phrases such as “a compound offormula (I) or a pharmaceutically acceptable salt or N-oxide thereof”are intended to encompass the compound of formula (I), an N-oxide offormula (I), a pharmaceutically acceptable salt of the compound offormula (I), a solvate of formula (I), or any pharmaceuticallyacceptable combination of these. Thus by way of non-limiting exampleused here for illustrative purpose, “a compound of formula (I) or apharmaceutically acceptable salt thereof” may include a pharmaceuticallyacceptable salt of a compound of formula (I) that is further present asa solvate.

Since the compounds of formula (I) are intended for use inpharmaceutical compositions it will readily be understood that inparticular embodiments they are provided in substantially pure form, forexample at least 60% pure, more suitably at least 75% pure andparticularly at least 85%, especially at least 98% pure (% are on aweight for weight basis). Impure preparations of the compounds may beused for preparing the more pure forms used in the pharmaceuticalcompositions; these less pure preparations of the compounds shouldcontain at least 1%, more suitably at least 5% and more particularlyfrom 10% of a compound of the formula (I) or pharmaceutically acceptablesalt and/or N-oxide thereof.

Particular compounds according to the invention include those mentionedin the examples and their pharmaceutically acceptable N-oxides, saltsand solvates.

Pharmaceutically acceptable salts of the above-mentioned compounds offormula (I) include the acid addition or quaternary ammonium salts, forexample their salts with mineral acids e.g. hydrochloric, hydrobromic,sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic,fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic,methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compoundsof formula (I) may also be prepared as the N-oxide. The inventionextends to all such derivatives.

Certain of the compounds of formula (I) may exist in the form of opticalisomers, e.g. diastereoisomers and mixtures of isomers in all ratios,e.g. racemic mixtures. The invention includes all such forms, inparticular the pure isomeric forms. For example the invention includesenantiomers and diastereoisomers at the attachment point of NR² and R³.The different isomeric forms may be separated or resolved one from theother by conventional methods, or any given isomer may be obtained byconventional synthetic methods or by stereospecific or asymmetricsyntheses. Certain compounds of formula (I) may also exist inpolymorphic forms and the invention includes such polymorphic forms.

Processes for Making Compounds Used in Present Invention

The compounds according to the present invention or pharmaceuticallyacceptable salts thereof, are prepared using conventional organicsyntheses.

Suitable synthetic routes are depicted below in the following generalreaction schemes. The skilled artisan will appreciate that if asubstituent described herein is not compatible with the syntheticmethods described herein, the substituent may be protected with asuitable protecting group that is stable to the reaction conditions. Theprotecting group may be removed at an necessary or suitable point in thereaction sequence to provide a desired intermediate or target compound.

Suitable protecting groups and the methods for protecting andde-protecting different substituents using such suitable protectinggroups are well known to those skilled in the art; examples of which maybe found in T. Greene and P. Wuts, Protecting Groups in ChemicalSynthesis (3rd ed.), John Wiley & Sons, NY (1999). In some instances, asubstituent may be specifically selected to be reactive under thereaction conditions used. Under these circumstances, the reactionconditions convert the selected substituent into another substituentthat is either useful as an intermediate compound or is a desiredsubstituent in a target compound.

In a further aspect of the invention there is provided a process forpreparing compounds of formula (I) where Z² is nitrogen, andpharmaceutically acceptable salts and/or N-oxides thereof, which processcomprises reacting a compound of formula (IIA):

in which L is a leaving group or -A(Q¹)(Q²), where Q¹ and Q² are bothattached to the same carbon atom on A, Q¹ is H and Q² is N(R²⁰)R^(2′) orQ¹ and Q² together form ethylenedioxy or oxo, R²⁰ is UR⁵ or a groupconvertible thereto and R^(2′) is R² or a group convertible thereto, A,R^(1b), R², U and R⁵, are as defined in formula (I), with (i) ethylbromoacetate followed by cyclisation and oxidation or (ii) ethyloxoacetate followed by cyclisation, to give a compound of formula(IIIA):

and thereafter optionally or as necessary converting L to -A-NR²—UR⁵,interconverting any variable groups, and/or forming a pharmaceuticallyacceptable salt and/or N-oxide thereof.

The reaction variant (i) is a selective alkylation with ethylbromoacetate under basic conditions (such as potassium carbonate) (seeYoshizawa, H. et al., Heterocycles (2004), 63(8), 1757-1763 for anexample of this selectivity in the alkylation of 2,3-diaminopyridines),thermal cyclisation under strong basic conditions (such as potassiumt-butoxide) and then oxidation with manganese dioxide under conventionalconditions (see for examples Smith, M. B.; March, J. M. Advanced OrganicChemistry, Wiley-Interscience 2001).

The reaction variant (ii) may be carried out in toluene and thecyclisation effected under strongly basic conditions (such as potassiumt-butoxide).

L may be a hydroxy group which can be oxidised to the aldehyde byconventional means such as1,1,1-tris-(acetyloxy)-1,1-dihydro-1,2-benziodooxol-3-(1H)-one forreductive alkylation with HA-N(R²⁰)R^(2′) under conventional conditions(see for examples Smith, M. B.; March, J. M. Advanced Organic Chemistry,Wiley-Interscience 2001).

Alternatively L may be bromo which can be alkylated with HA-N(R²⁰)R^(2′)under conventional conditions.

Where Q¹ and Q² together form ethylenedioxy the ketal may be convertedto the ketone (Q¹ and Q² together form oxo) by conventional acidhydrolysis treatment with eg aqueous HCl or trifluoroacetic acid and theconversion to NR²UR⁵ by conventional reductive alkylation with amineNHR^(2′)R²⁰ (see for example Nudelman, A., et al, Tetrahedron 60 (2004)1731-1748) and subsequent conversion to the required substituted amine,or directly with NHR²UR⁵, such as with sodium triacetoxyborohydride indichloromethane/methanol.

Conveniently one of R²⁰ and R^(2′) is an N-protecting group, such assuch as t-butoxycarbonyl, benzyloxycarbonyl or9-fluorenylmethyloxycarbonyl. This may be removed by several methodswell known to those skilled in the art (for examples see “ProtectiveGroups in Organic Synthesis, T. W. Greene and P. G. M. Wuts,Wiley-Interscience, 1999), for example conventional acid hydrolysiswith, for example trifluoroacetic acid or hydrochloric acid. Theinvention further provides compounds of formula (IIIA) in which L is-A-N(R²⁰)R^(2′) and R²⁰ is hydrogen.

The free amine of formula (IIIA) in which R²⁰ is hydrogen may beconverted to NR²UR⁵ by conventional means such as amide formation withan acyl derivative R⁵COW, for compounds where U is CO or, where U isCH₂, by alkylation with an alkyl halide R⁵CH₂-halide in the presence ofbase, acylation/reduction with an acyl derivative R⁵COW or reductivealkylation with an aldehyde R⁵CHO under conventional conditions (see forexamples Smith, M. B.; March, J. M. Advanced Organic Chemistry,Wiley-Interscience 2001). The appropriate reagents containing therequired R⁵ group are known compounds or may be prepared analogously toknown compounds, see for example WO02/08224, WO02/50061, WO02/56882,WO02/96907, WO2003087098, WO2003010138, WO2003064421, WO2003064431,WO2004002992, WO2004002490, WO2004014361, WO2004041210, WO2004096982,WO2002050036, WO2004058144, WO2004087145, WO06002047, WO06014580,WO06010040, WO06017326, WO06012396, WO06017468, WO06020561,WO2004/035569, WO2004/089947, WO2003082835, WO06002047, WO06014580,WO06010040, WO06017326, WO06012396, WO06017468, WO06020561, WO06132739,WO06134378, WO06137485, WO06081179, WO06081264, WO06081289, WO06081178,WO06081182, WO07016610, WO07081597, WO07071936, WO07115947, WO07118130,WO07122258, WO08006648, WO08003690, WO08009700, WO2007067511 andEP0559285.

Where R⁵ contains an NH group, this may be protected with a suitableN-protecting group such as t-butoxycarbonyl, benzyloxycarbonyl or9-fluorenylmethyloxycarbonyl during the coupling of the R⁵ derivativewith the free amine of formula (IIB). The protecting group may beremoved by conventional methods, such as by treatment withtrifluoroacetic acid.

In a further aspect of the invention there is provided a process forpreparing compounds of formula (I) where Z¹ is nitrogen, andpharmaceutically acceptable salts and/or N-oxides thereof, which processcomprises reacting a compound of formula (IIB):

in which L is a leaving group or -A(Q¹)(Q²), where Q¹ and Q² are bothattached to the same carbon atom on A, Q¹ is H and Q² is N(R²⁰)R^(2′) orQ¹ and Q² together form ethylenedioxy or oxo, R²⁰ is UR⁵ or a groupconvertible thereto and R^(2′) is R² or a group convertible thereto, A,R^(1a), R², U and R⁵, are as defined in formula (I), with (i) ethylbromoacetate followed by cyclisation and oxidation or (ii) ethyloxoacetate followed by cyclisation, to give a compound of formula(IIIB):

and thereafter optionally or as necessary converting L to -A-NR²—UR⁵,interconverting any variable groups, and/or forming a pharmaceuticallyacceptable salt and/or N-oxide thereof.

The reaction and subsequent transformations is carried out as for thepreparation of compounds of formula (IIIA).

The invention further provides compounds of formula (IIIB) in which L is-A-N(R²⁰)R^(2′) and R²⁰ is hydrogen.

Compounds of formula (IIB) (L=-A(Q¹)(Q²)) may be prepared by Scheme 1:

Compounds of formula (IIIA) may be prepared by Scheme 2 utilisingcompounds of formula (IVA):

The starting material may be prepared by reduction of compound (3) fromScheme 1 with sodium methoxide and then reduction with tin (II) chlorideor sodium dithionite. Cyclisation of (IVA) with propiolate esters gives(19) (Scheme 2) (see Kalyanam, N. et al, Indian Journal of Chemistry,Section B: Organic Chemistry Including Medicinal Chemistry (1992),31B(7), 415-420). Standard protection to give (20) then cyclisation withbromine (see Schmid, S et al, Synthesis, 2005 (18), 3107) may thenaccess bromomethyl analogue (21) which may be deprotected with TFA to(22) and oxidised with hydrogen peroxide or manganese (II) oxide to give(23) (see Sakata, G., Heterocycles (1985), 23(1), 143-51).

Compounds of formula (I) in which Z¹ and Z² are both CH may be preparedby Scheme 3:

Metallation of (1) (commercially available) with n-butyl lithiumfollowed by bromination with dibromoethane affords bromopyridinederivative (2) (see Zhichkin, P. et al, Synlett (2006), (3), 379-382 forexamples of this type of metallation chemistry). Heck reaction of (2)using palladium catalysis (see Sydorenko, N, et al, Organic &Biomolecular Chemistry (2005), 3(11), 2140-2144 for an example of thistype of catalysis in a Heck reaction) gives acryate (3). Hydrogenationof the double bond of (3) followed by acid treatment to remove thepivalate residue and effect lactamisation yields the bicyclic lactam(4). Conversion to the epoxide (5) can be effected in a number ofways—reaction with epichlorohydrin under basic conditions affordsracemic epoxide. Reaction with (commercially available) R or S-glycidylnosylate ((2R)- or (2S)-2-oxiranylmethyl 3-nitrobenzenesulfonate) or(2R)- or (2S)-2-oxiranylmethyl 4-methylbenzenesulfonate, with base egsodium hydride or potassium t-butoxide, gives the corresponding chiralepoxides. Alternatively, allylation with allyl bromide under basicconditions affords the corresponding N-allyl material which can beepoxidised under standard achiral or chiral conditions to give thecorresponding achiral or chiral epoxides. The epoxide(s) (5) may beopened with amine H-A(Q¹)(Q²) such as 1,1-dimethylethyl4-piperidinylcarbamate by heating in DMF to afford (6) which can then becyclised with methanesulphonic anhydride to give (7). Alternatively, theepoxide (5) may be opened and cyclised directly with heating, to afford(7) (L=OH). Oxidation to (8) may be carried out by oxidation with2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Subsequent conversionto compounds of formula (I) may be carried out as generally describedherein. In particular, conversion of L to A(Q¹)(Q²) may be carried outon (7) or (8). As a further variation to Scheme 3, epoxide (5) may beprepared from (2) by first introducing a suitable epoxide precursorgroup (—CH₂—CHOH—CH₂OH, protected as a cyclic ester) before carrying outthe steps (b) and (c).

The invention further provides compounds of formula (8) from Scheme 3 inwhich L is -A-N(R²⁰)R^(2′) and R²⁰ is hydrogen.

Compounds of formula (I) in which Z² is N may alternatively be preparedby Scheme 4:

Reaction of nitropyridine (1) with 2-amino-1,3-propanediol affords diol(2) which is protected as acetal (3). Reduction of the nitro group givesamine (4) which is alkylated to yield ester (5). Cyclisation can beeffected with sodium hydride to give (6). This is protected with acarboxybenzyl (CBz) group (7) then cleaved to give the diol (8).Cyclisation with methanesulphonic anhydride affords the mesylate (9),then hydrogenolysis of the CBz group (10) and subsequent oxidation withmanganese(II)oxide gives the key dione intermediate mesylate (11). Theorder of steps may be changed to go via (7a). The mesylate (11) may beconverted to the compound of formula (I) as generally described herein.

Chiral compounds of formula (I) in which Z² is N may alternatively beprepared by Scheme 4a:

Reaction of nitropyridine (1) with chiral amine (2) gives intermediate(3). Protection of (3) with tert-butyl-dimethylsilylchloride gives (4).Reduction of the nitro group gives amine (5), which is alkylated toyield ester (6). Cyclisation of (6) can be effected with sodium hydrideand then treatment with hydrogen over a palladium/charcoal catalystgives intermediate (7). Oxidation with manganese(II)oxide and treatmentwith methanesulfonic anhydride gives (8). This intermediate can bedeprotected with TFA to give (9) and reacted with methanesulfonicanhydride to give (10). The mesylate (10) formed may then be convertedto the compound of formula (I) as generally described herein.

Compounds of formula (I) in which Z¹ is N may alternatively be preparedby Scheme 5:

Reaction of nitropyridine (1) with ammonia affords nitro-pyridine (2)which is reduced to bis-aniline (3). Alkyation with ethyl bromoacetatefollowed by cyclisation with potassium tert-butoxide gives (5). This isprotected with a carboxybenzyl group to give (6) which can then bereacted with (commercially available) S-glycidyl nosylate((2S)-2-oxiranylmethyl 3-nitrobenzenesulfonate) to give (7). Cyclisationunder thermal conditions gives (8). Mesylation, displacement with anappropriate amine, hydrogenolysis of the CBz group (10) and subsequentoxidation with manganese(II)oxide gives (13). Alternativelyhydrogenolysis of the CBz group (10) and subsequent oxidation withmanganese(II)oxide, followed by mesylation and displacement with anappropriate amine also gives (13). This may be converted to the compoundof formula (I) as generally described herein.

Compounds of formula (I) in which Z¹ and Z² are both N may be preparedby Scheme 6:

Compound (1) (Bioorganic & Medicinal Chemistry Letters (2005), 15 (24),5446-5449) is converted to (2) by acylation with chloroacetyl chloridefollowed by treatment with ammonia to give (4). Alternatively (1) may beconverted to (3) by coupling with Boc-glycine followed by acidicdeprotection to give (4). Compound (4) may then be converted to acompound of formula (I) by analogy with the conversion of compound (5)of Scheme 5.

Interconversions of R^(1a), R^(1b), R², A and R⁵ are conventional. Incompounds which contain an optionally protected hydroxy group, suitableconventional hydroxy protecting groups which may be removed withoutdisrupting the remainder of the molecule include acyl and alkylsilylgroups. N-protecting groups are removed by conventional methods.

Interconversion of R^(1a) and R^(1b) groups may be carried outconventionally, on compounds of formula (I). For example R^(1a) orR^(1b) methoxy is convertible to R^(1a) or R^(1b) hydroxy by treatmentwith lithium and diphenylphosphine (general method described in Irelandet al, J. Amer. Chem. Soc., 1973, 7829) or HBr. Alkylation of thehydroxy group with a suitable alkyl derivative bearing a leaving groupsuch as halide, yields R^(1a) or R^(1b) substituted alkoxy. R^(1a) orR^(1b) halo such as bromo may be converted to cyano by treatment withcopper (I) cyanide in N,N-dimethylformamide. R^(1a) or R^(1b) carboxymay be obtained by conventional hydrolysis of R^(1a) or R^(1b) cyano,and the carboxy converted to hydroxymethyl by conventional reduction.

Compounds of formula HA-N(R²⁰)R^(2′) are known compounds or may beprepared analogously to known compounds, see for example WO2004/035569,WO2004/089947, WO02/08224, WO02/50061, WO02/56882, WO02/96907,WO2003087098, WO2003010138, WO2003064421, WO2003064431, WO2004002992,WO2004002490, WO2004014361, WO2004041210, WO2004096982, WO2002050036,WO2004058144, WO2004087145, WO2003082835, WO2002026723, WO06002047 andWO06014580, WO06134378, WO06137485, WO07016610, WO07081597, WO07071936,WO07115947, WO07118130, WO07122258, WO08006648, WO08003690 andWO08009700.

Further details for the preparation of compounds of formula (I) arefound in the examples.

Pharmaceutical Compositions and Formulations

The antibacterial compounds according to the invention may be formulatedfor administration in any convenient way for use in human or veterinarymedicine, by analogy with other antibacterials/antitubercular compounds.

The pharmaceutical compositions of the invention may be formulated foradministration by any route and include those in a form adapted fororal, topical or parenteral use and may be used for the treatment ofbacterial infection including tuberculosis in mammals including humans.

The compositions may be in the form of tablets, capsules, powders,granules, lozenges, suppositories, creams or liquid preparations, suchas oral or sterile parenteral solutions or suspensions.

The topical formulations of the present invention may be presented as,for instance, ointments, creams or lotions, eye ointments and eye or eardrops, impregnated dressings and aerosols, and may contain appropriateconventional additives such as preservatives, solvents to assist drugpenetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, suchas cream or ointment bases and ethanol or oleyl alcohol for lotions.Such carriers may be present as from about 1% up to about 98% of theformulation. More usually they will form up to about 80% of theformulation.

Tablets and capsules for oral administration may be in unit dosepresentation form, and may contain conventional excipients such asbinding agents, for example syrup, acacia, gelatin, sorbitol,tragacanth, or polyvinylpyrrolidone; fillers, for example lactose,sugar, maize-starch, calcium phosphate, sorbitol or glycine; tablettinglubricants, for example magnesium stearate, talc, polyethylene glycol orsilica; disintegrants, for example potato starch; or acceptable wettingagents such as sodium lauryl sulphate. The tablets may be coatedaccording to methods well known in normal pharmaceutical practice. Oralliquid preparations may be in the form of, for example, aqueous or oilysuspensions, solutions, emulsions, syrups or elixirs, or may bepresented as a dry product for reconstitution with water or othersuitable vehicle before use. Such liquid preparations may containconventional additives, such as suspending agents, for example sorbitol,methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose,carboxymethyl cellulose, aluminium stearate gel or hydrogenated ediblefats, emulsifying agents, for example lecithin, sorbitan monooleate, oracacia; non-aqueous vehicles (which may include edible oils), forexample almond oil, oily esters such as glycerine, propylene glycol, orethyl alcohol; preservatives, for example methyl or propylp-hydroxybenzoate or sorbic acid, and, if desired, conventionalflavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g.cocoa-butter or other glyceride.

For parenteral administration, fluid unit dosage forms are preparedutilizing the compound and a sterile vehicle, water being preferred. Thecompound, depending on the vehicle and concentration used, can be eithersuspended or dissolved in the vehicle. In preparing solutions thecompound can be dissolved in water for injection and filter sterilisedbefore filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative andbuffering agents can be dissolved in the vehicle. To enhance thestability, the composition can be frozen after filling into the vial andthe water removed under vacuum. The dry lyophilized powder is thensealed in the vial and an accompanying vial of water for injection maybe supplied to reconstitute the liquid prior to use. Parenteralsuspensions are prepared in substantially the same manner except thatthe compound is suspended in the vehicle instead of being dissolved andsterilization cannot be accomplished by filtration. The compound can besterilised by exposure to ethylene oxide before suspending in thesterile vehicle. Advantageously, a surfactant or wetting agent isincluded in the composition to facilitate uniform distribution of thecompound.

Moreover, the quantity of the compound or composition of the presentinvention administered will vary depending on the patient and the modeof administration and can be any effective amount.

Treatment regimen for the administration of the compounds and/orcompositions of the present invention can also be determined readily bythose with ordinary skill in art. The quantity of the compound and/orcomposition of the present invention administered may vary over a widerange to provide in a unit dosage an effective amount based upon thebody weight of the patient per day to achieve the desired effect.

The compositions may contain from 0.1% by weight, preferably from 10-60%by weight, of the active material, depending on the method ofadministration. Where the compositions comprise dosage units, each unitwill preferably contain from 50-1000 mg of the active ingredient.

The dosage as employed for adult human treatment will preferably rangefrom 100 to 3000 mg per day, for instance 1500 mg per day depending onthe route and frequency of administration. Such a dosage corresponds toabout 1.5 to about 50 mg/kg per day. Suitably the dosage is from 5 to 30mg/kg per day.

In particular, a composition of the present invention is presented as aunit dose and taken preferably from 1 to 5 times daily, most preferablyonce daily to achieve the desired effect.

Conventional administration methods may be suitable for use in thepresent invention.

Depending upon the treatment being effected, the compounds, and/or orcompositions of the present invention can be administered orally,intravascularly, intraperitoneally, subcutaneously, intramuscularly ortopically. Preferably, the composition is adapted for oraladministration.

The compounds and/or compositions prepared according to the presentinvention can be used to treat warm blooded animals, such as mammals,which include humans.

The compound of formula (I) may be the sole therapeutic agent in thecompositions of the invention or a combination with other antibacterialsincluding antitubercular compounds. If the other antibacterial is aβ-lactam then a β-lactamase inhibitor may also be employed.

Compounds of formula (I) may be used in the treatment of bacterialinfections caused by a wide range of organisms including bothGram-negative and Gram-positive organisms, such as upper and/or lowerrespiratory tract infections, skin and soft tissue infections and/orurinary tract infections. Compounds of formula (I) may be also used inthe treatment of tuberculosis caused by Mycobacterium tuberculosis. Somecompounds of formula (I) may be active against more than one organism.This may be determined by the methods described herein.

Treatment Methods

The present invention relates to methods for treating Neisseriagonorrhoeae infection which comprises administering to a subject in needthereof novel Tricyclic nitrogen containing compounds and correspondingpharmaceutical compositions as described herein.

In one aspect the present invention relates to a method for treatingNeisseria gonorrhoeae infection which comprises administering to asubject in need thereof an effective amount of a compound of Formula(I):

where:Z¹ and Z² are independently selected from CH and N;R^(1a) and R^(1b) are independently selected from hydrogen; halogen;cyano; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; trifluoromethoxy;carboxy; hydroxy optionally substituted with (C₁₋₆)alkyl or(C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl;(C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; hydroxy (C₁₋₆)alkyl; an amino groupoptionally N-substituted by one or two (C₁₋₆)alkyl, formyl,(C₁₋₆)alkylcarbonyl or (C₁₋₆)alkylsulphonyl groups; and aminocarbonylwherein the amino group is optionally substituted by (C₁₋₄)alkyl;provided that R^(1a) and R^(1b) are H when Z² or Z¹ is N, respectively;R² is hydrogen, or (C₁₋₄)alkyl, or together with R⁶ forms Y as definedbelow;A is a group (i):

in which: R³ is as defined for R^(1a) and R^(1b) or is oxo and n is 1 or2: orA is a group (ii)

W¹, W² and W³ are CR⁴R⁸

or W² and W³ are CR⁴R⁸ and W¹ represents a bond between W³ and N.

X is O, CR⁴R⁸, or NR⁶;

one R⁴ is as defined for R^(1a) and R^(1b) and the remainder and R⁸ arehydrogen or one R⁴ and R⁸ are together oxo and the remainder arehydrogen;

R⁶ is hydrogen or (C₁₋₆)alkyl; or together with R² forms Y;

R⁷ is hydrogen; halogen; hydroxy optionally substituted with(C₁₋₆)alkyl; or (C₁₋₆)alkyl;

Y is CR⁴R⁸CH₂; CH₂CR⁴R⁸; (C═O); CR⁴R⁸; CR⁴R⁸(C═O); or (C═O)CR⁴R⁸;

or when X is CR⁴R⁸, R⁸ and R⁷ together represent a bond;

U is selected from CO, and CH₂ and

R⁵ is an optionally substituted bicyclic carbocyclic or heterocyclicring system (B):

containing up to four heteroatoms in each ring in which

at least one of rings (a) and (b) is aromatic;

X¹ is C or N when part of an aromatic ring, or CR¹⁴ when part of anon-aromatic ring;

X² is N, NR¹³, O, S(O)_(X), CO or CR¹⁴ when part of an aromatic ornon-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of anonaromatic ring;

X³ and X⁵ are independently N or C;

Y¹ is a 0 to 4 atom linker group each atom of which is independentlyselected from N, NR¹³, O, S(O)_(X), CO and CR¹⁴ when part of an aromaticor non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of anonaromatic ring;

Y² is a 2 to 6 atom linker group, each atom of Y² being independentlyselected from N, NR¹³, O, S(O)_(X), CO, CR¹⁴ when part of an aromatic ornon-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of anonaromatic ring;

each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio;halo; carboxy(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₁₋₄)alkoxycarbonyl;(C₁₋₄)alkylcarbonyl; (C₁₋₄)alkoxy (C₁₋₄)alkyl; hydroxy;hydroxy(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino oraminocarbonyl optionally mono- or di-substituted by (C₁₋₄)alkyl; or

R¹⁴ and R¹⁵ may together represent oxo;

each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl optionallysubstituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo ortrifluoromethyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl;(C₁₋₄)alkylcarbonyl; (C₁₋₆)alkylsulphonyl; aminocarbonyl wherein theamino group is optionally mono or disubstituted by (C₁₋₄)alkyl; and

each x is independently 0, 1 or 2; or

a pharmaceutically acceptable salt thereof.

In another aspect, the present invention relates to a method, where inthe compound of Formula I:

-   -   (i) Z¹ and Z² are both CH;    -   (ii) Z¹ is N and Z² is CH; or    -   (iii) Z¹ is CH and Z² is N.

In another aspect, the present invention relates to a method, whereR^(1a) is hydrogen and R^(1b) is hydrogen as defined for compound ofFormula I.

In another aspect, the present invention relates to a method, wherein inthe compound of Formula I:

A is (ia), n is 1 and R³ is H or hydroxy in the 3-position;

A is (ii), X is CR⁴R⁸ and R⁸ is H and R⁴ is H or OH; or

A is (ii), X is O, R⁷ is H and WI, W² and W³ are each CH₂.

In another aspect, the present invention relates to a method, where A ispiperidin-4-yl or pyrrolidin-4-ylmethyl as defined for compound ofFormula I.

In another aspect, the present invention relates to a method, wherein Uis CH₂ as defined for compound of Formula I.

In another aspect, the present invention relates to a method, where inthe compound of Formula I:

R⁵ is an aromatic heterocyclic ring (B) having 8-11 ring atoms including2-4 heteroatoms of which at least one is N or NR¹³ in which Y² contains2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded toX³, or

the heterocyclic ring (B) has ring (a) aromatic selected from optionallysubstituted benzo, pyrido, pyridazino and pyrimidino and ring (b) nonaromatic and Y² has 3-5 atoms, including at least one heteroatom, withO, S, CH₂ or NR¹³ bonded to X⁵ where R¹³ is other than hydrogen, andeither NHCO bonded via N to X³, or O, S, CH₂ or NH bonded to X³.

In another aspect, the present invention relates to a method, where inthe compound of Formula I:

R⁵ is selected from:

-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl;-   3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl;-   2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl;-   [1,3]oxathiolo[5,4-c]pyridin-6-yl;-   6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl;-   2,3-dihydro[1,4]oxathiino[2,3-c]pyridin-7-yl;-   3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl;-   5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl;-   5-carbonitro-2,3-dihydro-1,4-benzodioxin-7-yl; or-   2,3-dihydro-benzo[1,4]dioxin-6-yl.

In another aspect, the present invention relates to a method, wherein inthe compound of Formula I: A is selected from:

-   1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(5,6,7,8-Tetrahydro-3-isoquinolinylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(6,7-Dihydro-5H-cyclopenta[c]pyridin-3-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(1,3-Dihydrofuro[3,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   7-[({1-[(4,9-Dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}amino)methyl]-2,3-dihydro-1,4-benzodioxin-5-carbonitrile;-   1-[(4-{[(3-Oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2S)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2S)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   2-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-4-methyl-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-Methyl-4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (2R)-2-({4-[(2,1,3-Benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-[(4-{[(7-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[(3,4-Dihydro-2H-[1,4]oxathiepino[2,3-c]pyridin-8-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[([1,3]Oxathiolo[4,5-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-[(4-{[(3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(7-Chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(4-Chloro-7-oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]oxazin-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(7-Oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]thiazin-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(1,2,3-Benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(2,3-Dihydro-1-benzofuran-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydrofuro[2,3-c]pyridin-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (2R)-2-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   7-{[(1-{[(2R)-3,8-Dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl]methyl}-4-piperidinyl)amino]methyl}-2,3-dihydro-1,4-benzodioxin-5-carbonitrile;-   (2R)-2-({4-[(2,3-Dihydrofuro[2,3-c]pyridin-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[([1,2,5]Thiadiazolo[3,4-b]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(4-Fluoro-1H-benzimidazol-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[((2S)-2-{[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]methyl}-4-morpholinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-{[(2S)-2-({[(7-Chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}methyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (2R)-2-({4-[([1,2,5]Thiadiazolo[3,4-b]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-({4-[(3,4-Dihydro-2H-chromen-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(2,3-Dihydro-1-benzofuran-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(3,4-Dihydro-2H-chromen-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (2R)-2-[(4-{[(5-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-{[(2S)-2-({[(7-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}methyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[((3S)-3-{[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]methyl}-1-pyrrolidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   7-{[(1-{[(1R)-3,8-Dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)amino]methyl}-2,3-dihydro-1,4-benzodioxin-5-carbonitrile;-   (1R)-1-[(4-{[(7-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;-   (1R)-1-[(4-{[(2-Oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(2-oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-[(4-{[(2-oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   (1R)-1-({4-[(3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;-   or    1-[(4-{[(3-Oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione;    or a free base of a compound of Table 1;    or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof a pharmaceutical composition whichcomprises an effective amount of a compound of Formula (I):

wherein substituents A, R^(1a), R^(1b), R², R⁵, Z¹ and Z² are as definedin claim 1; and pharmaceutically acceptable excipient(s).

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof an effective amount of a compound of:

in which L is -A-N(R²⁰)R^(2′) and R²⁰ is hydrogen, R^(2′) is R² or agroup convertible thereto and A, R², R^(1a) and R^(1b) are as defined inclaim 1.

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof a pharmaceutical composition comprising aneffective amount of a compound of:

in which L is -A-N(R²⁰)R^(2′) and R²⁰ is hydrogen, R^(2′) is R² or agroup convertible thereto and A, R², R^(1a) and R^(1b) are as defined inclaim 1; and pharmaceutically acceptable excipient(s).

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof an effective amount of a compound as shownbelow:

ora pharmaceutically acceptable salt thereof.

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof an effective amount of a compound as shownbelow:

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof a pharmaceutical composition whichcomprises:

a compound:

or

a pharmaceutically acceptable salt thereof; and

pharmaceutically acceptable excipient(s).

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof an effective amount of a compound(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione:

ora pharmaceutically acceptable salt thereof.

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof an effective amount of a compound(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione:

In another aspect, the present invention relates to a method fortreating Neisseria gonorrhoeae infection which comprises administeringto a subject in need thereof a pharmaceutical composition whichcomprises:

a compound(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione:

or

a pharmaceutically acceptable salt thereof, and

pharmaceutically acceptable excipient(s).

The Examples set forth below are illustrative of the present inventionand are not intended to limit, in any way, the scope of the presentinvention.

EXAMPLES

The following examples illustrate the invention. These examples are notintended to limit the scope of the present invention, but rather toprovide guidance to the skilled artisan to prepare and use thecompounds, compositions, and methods of the present invention. Whileparticular embodiments of the present invention are described, theskilled artisan will appreciate that various changes and modificationscan be made without departing from the spirit and scope of theinvention.

The following examples illustrate the preparation of certain compoundsof Formula (I) and the activity of certain compounds of Formula (I)against various bacterial organisms including Neisseria gonorrhoeae.

Examples and Experimental General Abbreviations in the Examples

MS=mass spectrumES=Electrospray mass spectroscopyLCMS/LC-MS=Liquid chromatography mass spectroscopyHPLC=high performance liquid chromatographyrt=room temperatureRf=retention factor

Certain reagents are also abbreviated herein. TFA refers totrifluoroacetic acid, THF refers to tetrahydrofuran, Pd/C refers topalladium on carbon catalyst, DCM refers to dichloromethane, MeOH refersto methanol, DMF refers to dimethylformamide, EtOAc refers toethylacetate, DDQ refers to 2,3-dichloro-5,6-dicyano-1,4-benzoquinone,NaBH(OAc)₃ refers to sodium triacetoxyborohydride, Pd₂(dba)₃ refers totris(dibenzylideneacetone)dipalladium (0).

Proton nuclear magnetic resonance (¹H NMR) spectra were recorded at 400or 250 MHz, and chemical shifts are reported in parts per million (ppm)downfield from the internal standard tetramethylsilane (TMS).Abbreviations for NMR data are as follows: s=singlet, d=doublet,t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, dt=doublet oftriplets, td=triplet of doublets, app=apparent, br=broad. J indicatesthe NMR coupling constant measured in Hertz. CDCl₃ is deuteriochloroformand CD₃OD is tetradeuteriomethanol. Mass spectra were obtained usingelectrospray (ES) ionization techniques. All temperatures are reportedin degrees Celsius.

MP-carbonate refers to macroporous triethylammonium methylpolystyrenecarbonate (Argonaut Technologies). Amberlyst® A21 is a weakly basic,macroreticular resin with alkyl amine functionality, ® Registeredtrademark of Rohm & Haas Co.

AD mix alpha is prepared by mixing potassium osmate (K₂OsO₄.2H₂O) (0.52g),(3a,9R,3′″a,4′″b,9′″R)-9,9′-[1,4-phthalazinediylbis(oxy)]bis[6′-(methyloxy)-10,11-dihydrocinchonan][(DHQ)₂PHAL] (5.52 g), then adding potassium ferricyanide [K₃Fe(CN)₆](700 g) and powdered potassium carbonate (294 g). This mixture isstirred in a blender for 30 minutes. This provides approximately 1 kg ofAD mix alpha, which is commercially available from Aldrich. See K. BarrySharpless et al, J. Org. Chem., 1992, 57 (10), 2771. AD mix beta is thecorresponding mixture prepared with(9S,9′″S)-9,9′-[1,4-phthalazinediylbis(oxy)]bis[6′-(methyloxy)-10,11-dihydrocinchonan][(DHQD)₂PHAL].Where AD mix alpha/beta is referred to, this is a 1:1 mixture of thealpha and beta mix.

Celite® is a filter aid composed of acid-washed diatomaceous silica, andis a trademark of Manville Corp., Denver, Colo.

SCX Cartridge is an ion exchange column containing strong cationexchange resin (benzene sulfonic acid) supplied by Varian, USA.

Chiralpak IA and Chiralpak AS-H are polysaccharide based chiral HPLCcolumns (Chiral Technologies Inc.). Chiralpak AS-H column compriseamylose tris [(S)-alpha-methylbenzylcarbamate) coated onto 5 μm silica.Chiralpak IA column comprise silica for preparative column (5 μmparticle size, 21 mm ID×250 mm L) immobilized with Amylose tris(3,5-dimethylphenylcarbamate). Chiralpak AD and AD-H columns comprisesilica for preparative columns (5 μm particle size AD-H and 10 μmparticle size AD, 21 mm ID×250 mm L; 20 M particle size AD, 101 mmID×250 mm L) coated with Amylose tris (3,5-dimethylphenylcarbamate)(Chiral Technologies USA). Measured retention times are dependent on theprecise conditions of the chromatographic procedures. Where quoted belowin the Examples they are indicative of the order of elution. Kromasil 5micron C-18 column (21 mm×250 mm) comprises octadecylsilane chemicallybonded to 5 micron porous silica gel.

As will be understood by the skilled chemist, references to preparationscarried out in a similar manner to, or by the general method of, otherpreparations, may encompass variations in routine parameters such astime, temperature, workup conditions, minor changes in reagent amountsetc.

Reactions involving metal hydrides including lithium hydride, lithiumaluminium hydride, di-isobutylaluminium hydride, sodium hydride, sodiumborohydride and sodium triacetoxyborohydride are carried out under argonor other inert gas.

Example 11-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride

(a) 6-Chloro-3-nitro-N-2-propen-1-yl-2-pyridinamine

This was prepared by a modification of the method of Schmid, S., et al,Synthesis (2005), (18), 3107-3118. A solution of2,6-dichloro-3-nitropyridine (8.0 g, 41.45 mmol) in anhydrousdichloromethane (180 ml) was cooled to −15° C., under argon.Triethylamine (6.0 ml, 43 mmol) was added and then allylamine (3.23 ml,43 mmol) was added in small portions over 3 hours, keeping thetemperature at −15° C. The reaction mixture was stirred overnight duringwhich time it warmed to room temperature. The reaction mixture waswashed with 0.2M aqueous citric acid (100 ml), saturated aqueous NaHCO₃solution (100 ml), passed through a hydrophobic frit and evaporated to ayellow oil which was purified by chromatography on silica eluting with a0 to 50% ethyl acetate in hexane giving a yellow solid (7.49 g, 85%).

C₈H₈ClN₃O₂ requires 213, MS (ES+) m/z 214, 216 (MH⁺).

(b) 3-(Bromomethyl)-8-nitro-2,3-dihydroimidazo[1,2-a]pyridin-5(1H)-one

This was prepared by a modification of the method of Schmid, S., et al,Synthesis (2005), (18), 3107-3118. A solution of6-chloro-3-nitro-N-2-propen-1-yl-2-pyridinamine (20 g, 93.6 mmol) inchlorobenzene (500 ml) was treated with a solution containing bromine(4.75 ml, 92.7 mmol) in chlorobenzene (100 ml), dropwise over 4.5 hours,keeping T<26° C. with cooling when required. The thick suspension wasstirred at room temperature for 18 hours and diluted with hexane (200ml) and then the reaction mixture was then pored into hexane (1000 ml).After 15 minutes the orange precipitate was collected by filtration andwashed with hexane (250 ml) to give 26.6 g of an orange solid(3-(bromomethyl)-5-chloro-8-nitro-2,3-dihydroimidazo[1,2-a]pyridin-1-iumbromide). This intermediate was added, over 45 minutes, to a rapidlystirred mixture of saturated aqueous NaHCO₃ solution (1000 ml) and ethylacetate (500 ml). The bright red mixture was stirred for 1 hour, dilutedwith ethyl acetate (200 ml) and the layers were separated. The aqueouslayer was washed with ethyl acetate (200 ml) and the organic extractswere combined, dried (anhydrous sodium sulphate), filtered andevaporated to give the product as a brown solid (18.3 g, contains 40%6-bromo-3-(bromomethyl)-8-nitro-2,3-dihydroimidazo[1,2-a]pyridin-5(1H)-one).

C₈H₈BrN₃O₃ requires 273, MS (ES+) m/z 274, 276 (MH⁺).

(c) 1,1-Dimethylethyl{1-[(8-nitro-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyridin-3-yl)methyl]-4-piperidinyl}carbamate

A suspension of a 3:2 mixture of3-(bromomethyl)-8-nitro-2,3-dihydroimidazo[1,2-a]pyridin-5(1H)-one and6-bromo-3-(bromomethyl)-8-nitro-2,3-dihydroimidazo[1,2-a]pyridin-5(1H)-one(18.2 g) was treated with 1,1-dimethylethyl 4-piperidinylcarbamate (26.6g, 132.8 mmole) in acetonitrile (900 ml) then pyridine (10.7 ml, 132mmol). The mixture was heated at 60° C. under argon for 17 hours andthen heated at 70° C. for 2 hours, cooled and evaporated to about halfthe volume. The thick yellow precipitate was removed by filtration andwashed well with diethyl ether. The filtrate was evaporated to drynessand the residue partitioned between chloroform (500 ml) and water (200ml). The undissolved material was removed by filtration and washed withchloroform (100 ml). The layers in the filtrate were separated and theaqueous layer was washed with chloroform (200 ml). The combined organicextracts were passed through a hydrophobic frit and evaporated to a darkyellow gum which was chromatographed eluting with 0 to 100% ethylacetate in hexane then 0 to 30% methanol in ethyl acetate to give ayellow solid (10.98 g).

C₁₈H₂₇N₅O₅ requires 393, MS (ES+) m/z 394 (MH⁺).

(d) 1,1-Dimethylethyl{1-[(3,8-dioxo-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl)methyl]-4-piperidinyl}carbonate

A suspension of 1,1-dimethylethyl{1-[(8-nitro-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyridin-3-yl)methyl]-4-piperidinyl}carbamate(2.0 g, 5.08 mmol) and anhydrous potassium carbonate (700 mg, 5.06 mmol)in absolute alcohol (150 ml) was hydrogenated at atmospheric pressure inthe presence of 10% Pd on C (1 g) for 4 hours. The reaction was filteredthrough Keiselguhr, washed through with ethanol (100 ml) and the darkpurple mixture was reacted immediately by treating with anhydrouspotassium carbonate (1.4 g, 10 mmol) and ethyl bromoacetate (550 ul,4.95 mmol) and stirred at room temperature for 20 hours and then heatedat 60° C. for 30 minutes. After 45 minutes a further 0.25 ml of ethylbromacetate was added and heated at 60° C. for 1.5 hours. 0.25 ml ofethyl bromacetate was added and the reaction was again heated at 60° C.for 1. hour. The reaction was filtered through Keiselguhr and evaporatedto dryness. The mixture was azeotroped with chloroform and thenchromatographed eluting with 0 to 100% ethyl acetate in hexane and thenwith 0 to 20% methanol in ethyl acetate. A second purification elutingwith 0 to 50% methanol in ethyl acetate gave a dark gum (37 mg, 1.6%).

C₂₀H₂₇N₅O₂ requires 401, MS (ES+) m/z 402 (MH⁺).

(e)1-[(4-Amino-1-piperidinyl)methyl]-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

A solution of 1,1-dimethylethyl{1-[(3,8-dioxo-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl)methyl]-4-piperidinyl}carbamate(37 mg, 0.092 mmol) in anhydrous dichloromethane (2 ml) was treated withTFA (1 ml) and stirred at room temperature for 1 hour, evaporated todryness, mixed with anhydrous dichloromethane and evaporated to a darkgum. This gum was dissolved in 1:1 dichloromethane:methanol (10 ml) andtreated with MP-carbonate resin (600 mg) and stirred for 1.5 hours. Thereaction was filtered and the resin was washed with 1:1dichloromethane:methanol (30 ml) and the filtrate was evaporated todryness. Purification on a 5 g SCX column eluting with a methanol to 2Nmethanolic ammonia gradient gave the product as a gum. Furtherevaporation from diethyl ether gave the product as a brown solid (22.8mg, 82%). C₁₅H₁₉N₅O₂ requires 301, MS (ES+) m/z 302 (MH⁺).

(f) Title Compound

A solution of1-[(4-amino-1-piperidinyl)methyl]-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(22.8 mg, 0.0757 mmol) in anhydrous dichloromethane (3 ml) and anhydrousmethanol (0.6 ml) was treated with2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde (12.5 mg, 0.076mmol) (for a synthesis see WO2004058144 Example 2(c) or WO03/087098Example 19(d)) and stirred, under argon, for 15 minutes and then treatedwith sodium triacetoxyborohydride (48 mg, 0.226 mmol) and stirred atroom temperature for 17 hours. The reaction was then treated with afurther portion of 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde(2 mg) and sodium triacetoxyborohydride (10 mg) and the mixture wasstirred for 4 hours, treated with saturated aqueous NaHCO₃ solution (1ml) and stirred for 10 minutes. The layers were separated and theaqueous layer was washed with 9:1 dichloromethane:methanol (2×10 ml).The combined organic extracts were passed through a hydrophobic frit andevaporated to a brown gum which was chromatographed eluting with 0 to30% methanol in dichloromethane to give the free base of the titlecompound as a yellow gum (20.6 mg, 60%).

C₂₃H₂₆N₆O₄ requires 450, MS (ES+) m/z 451 (MH⁺).

¹H NMR (250 MHz) δ (CDCl₃) 1.38-1.54 (2H, m), 1.83-1.93 (2H, m),2.19-2.36 (2H, m), 2.54-2.73 (3H, m), 2.93-2.98 (1H, m), 3.09-3.15 (1H,m), 3.85 (2H, s), 4.26-4.61 (6H, m), 4.96-5.05 (1H, m), 6.33 (1H, d),6.82 (1H, s), 7.76 (1H, d), 7.87 (1H, s) and 8.10 (1H, s)

The free base of the title compound was dissolved in anhydrousdichloromethane (2 ml) and anhydrous methanol (0.5 ml) and treated with1M HCl in diethyl ether (0.5 ml). Diethyl ether was added (5 ml) and thesuspension was cooled. After centrifuging the solvent was removed andthe solid was dried to give the title compound as a brown solid (23.5mg).

C₂₃H₂₆N₆O₄ requires 450, MS (ES+) m/z 451 (MH⁺).

Example 21-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

(a) N-(6-Chloro-2-pyridinyl)-2,2-dimethylpropanamide

A solution of 6-chloro-2-pyridinamine (13.776 g, 107 mmol) in toluene(100 ml) and triethylamine (16.28 ml, 118 mmol) at 50° C. under argonwas treated with 2,2-dimethylpropanoyl chloride (13.81 ml, 112 mmol).The reaction was then stirred at 50° C. for 4 h and then at rt for 18 h.2M HCl (200 ml) was then added and the mixture was extracted withdiethyl ether (3×500 ml). The organic extracts were dried (MgSO₄),filtered and evaporated to give the product as a brown solid (21.005 g,92%).

MS (ES+) m/z 213/215 (MH⁺).

(b) N-(3-Bromo-6-chloro-2-pyridinyl)-2,2-dimethylpropanamide

A solution of N-(6-chloro-2-pyridinyl)-2,2-dimethylpropanamide (4.83 g,22.7 mmol) in THF (40 ml) at −78° C. under argon was treated withn-butyl lithium (20 ml, 2.5M in Hexanes, 50 mmol) over 10 min and thenallowed warm to 0° C., stirred at 0° C. for 3 h and then recooled to−78° C. The reaction was then treated dropwise with dibromoethane (2.057ml, 23.9 mmol) and the reaction was allowed warm to rt and stirred at rtfor 0.5 h. The reaction was then treated with water (5 ml), stirred atrt for 5 min, treated with more water (500 ml) and extracted withdiethyl ether (3×500 ml). The organic extracts were dried (MgSO₄),filtered, evaporated and the residue chromatographed (0-25% ethylacetate:Hexane) to give the product as a yellow solid (3.489 g, 53%).

MS (ES+) m/z 291/293/295 (MH⁺).

(c)N-(3-Bromo-6-chloro-2-pyridinyl)-2,2-dimethyl-N-2-propen-1-ylpropanamide

A solution of N-(3-bromo-6-chloro-2-pyridinyl)-2,2-dimethylpropanamide(2.305 g, 7.907 mmol) in DMF (40 ml) at 0° C. under argon was treatedwith sodium hydride (0.696 g, 17.395 mmol) and then allowed warm to rtover 0.25 h, stirred at rt for 0.25 h and then treated with allyl iodide(1.61 ml, 17.395 mmol) and stirred at rt for 1 h. The reaction was thentreated with water (10 ml), concentrated to approximately 5 ml, treatedwith more water (200 ml) and extracted with DCM (3×200 ml). The organicextracts were dried (MgSO₄), filtered, evaporated and the residuechromatographed (0-20% ethyl acetate:Hexane) to give the product as ayellow oil which solidified to an off white solid (5.324 g, 67%).

MS (ES+) m/z 331/333/335 (MH⁺).

(d)N-[3-Bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethyl-N-2-propen-1-ylpropanamide

A solution ofN-(3-bromo-6-chloro-2-pyridinyl)-2,2-dimethyl-N-2-propen-1-ylpropanamide(12.388 g, 37.370 mmol) in methanol (100 ml) at rt under argon wastreated with sodium methoxide solution (25% w/v in methanol, 17.76 g,82.212 mmol) and then heated at reflux for 42 h. The reaction was thencooled, treated with water (500 ml), and extracted with diethyl ether(3×200 ml). The organic extracts were dried (MgSO₄), and evaporated togive the product (10.918 g, 89%).

MS (ES+) m/z 327/329 (MH⁺).

(e)N-[3-Bromo-6-(methyloxy)-2-pyridinyl]-N-(2,3-dihydroxypropyl)-2,2-dimethylpropanamide

A solution ofN-[3-bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethyl-N-2-propen-1-ylpropanamide(1.246 g, 3.81 mmol) in tert-butanol (40 ml) at rt under argon wastreated with water (40 ml) and then with AD-mix α (2.86 g) and AD-mix β(2.86 g) and stirred at rt for 18 h. The reaction was then treated withsaturated aqueous sodium sulfite (40 ml), stirred for 10 min, extractedwith 20% methanol/DCM (3×100 ml). The organic extracts were dried(MgSO₄), and evaporated to give the crude product (1.728 g, 126%)containing residual tert-butanol.

MS (ES+) m/z 361/363 (MH⁺).

(f)N-[3-Bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethyl-N-[(2-oxo-1,3-dioxolan-4-yl)methyl]propanamide

A solution ofN-[3-bromo-6-(methyloxy)-2-pyridinyl]-N-(2,3-dihydroxypropyl)-2,2-dimethylpropanamide(7.628 g, 21.130 mmol) in DCM (100 ml) and pyridine (3.407 ml, 42.26mmol) at −78° C. under argon was treated with a solution of triphosgene(6.27 g, 21.130 mmol) in DCM (20 ml) over 5 min and the reaction wasthen allowed warm to rt and stirred at rt for 30 min. The reaction wasthen carefully treated with saturated sodium bicarbonate solution (200ml), extracted with DCM (3×200 ml). The organic extracts were dried(MgSO₄), and evaporated and chromatographed (0-50% ethyl acetate:Hexane)to give the product as a white solid (5.722 g, 70%).

MS (ES+) m/z 387/389 (MH⁺).

(g) Butyl(2E)-3-[2-{(2,2-dimethylpropanoyl)[(2-oxo-1,3-dioxolan-4-yl)methyl]amino}-6-(methyloxy)-3-pyridinyl]-2-propenoate

A mixture ofN-[3-bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethyl-N-[(2-oxo-1,3-dioxolan-4-yl)methyl]propanamide(5.722 g, 14.722 mmol), Pd(PtBu₃)₂ (151 mg, 0.296 mmol), Pd₂(dba)₃ (135mg, 0.149 mmol), in 1,4-dioxane (40 ml) was treated withN,N′-dicyclohexylmethylamine (3.48 ml, 16.265 mmol) and n-butyl acrylate(2.54 ml, 17.743 mmol) and the mixture was then heated at 80° C. for 1h. The reaction was then cooled, treated with water (200 ml), extractedwith DCM (3×200 ml). The organic extracts were dried (MgSO₄), andevaporated and chromatographed (0-50% ethyl acetate:Hexane) to give theproduct as a yellow oil (6.156 g, 96%).

MS (ES+) m/z 435 (MH⁺).

(h) Butyl3-[2-{(2,2-dimethylpropanoyl)[(2-oxo-1,3-dioxolan-4-yl)methyl]amino}-6-(methyloxy)-3-pyridinyl]propanoate

A solution of butyl(2E)-3-[2-{(2,2-dimethylpropanoyl)[(2-oxo-1,3-dioxolan-4-yl)methyl]amino}-6-(methyloxy)-3-pyridinyl]-2-propenoate(6.156 g, 14.184 mmol) in ethanol (200 ml) was treated with palladium oncarbon (10% paste, 1.23 g) and the mixture was then stirred at rt under1 atmosphere of hydrogen for 18 h. The reaction mixture was thenfiltered through a thin pad of Celite, eluting with more ethanol (200ml). The organic filtrate was then evaporated to give the product as ayellow oil (6.065 g, 98%).

MS (ES+) m/z 437 (MH⁺).

(i)1-(2,3-Dihydroxypropyl)-7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

A solution of butyl3-[2-{(2,2-dimethylpropanoyl)[(2-oxo-1,3-dioxolan-4-yl)methyl]amino}-6-(methyloxy)-3-pyridinyl]propanoate(6.065 g, 13.911 mmol) in methanol (100 ml) was treated withconcentrated aqueous HCl (12M, 50 ml) and then heated at reflux for 48h. The reaction mixture was then concentrated to approximately 50 ml,neutralised with potassium carbonate and extracted with 20% methanol/DCM(3×100 ml). The organic extracts were dried (MgSO₄), and evaporated togive the crude product as a yellow oil (2.325 g, 66%).

MS (ES+) m/z 279 (MH⁺).

(j)7-(Methyloxy)-1-(2-oxiranylmethyl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

A solution of1-(2,3-dihydroxypropyl)-7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(2.325 g, 9.226 mmol) in DCM (40 ml) and triethylamine (1.915 ml, 13.839mmol) at 0° C. under argon was treated with methanesulfonyl chloride(0.714 ml, 9.226 mmol) and stirred at 0° C. for 0.5 h. The reactionmixture was then treated with water (100 ml), extracted with DCM (3×100ml). The organic extracts were dried (MgSO₄), and evaporated. Theresidue was then dissolved in methanol (50 ml) and treated withpotassium carbonate (6.366 g, 46.130 mmol) and stirred at rt for 15 min.The reaction mixture was then treated with water (100 ml), extractedwith DCM (3×200 ml). The organic extracts were dried (MgSO₄), evaporatedand chromatographed (0-100% ethyl acetate:Hexane) to give the product asa yellow oil (428 mg, 20%).

MS (ES+) m/z 235 (MH⁺).

(k) 1,1-Dimethylethyl(1-{2-hydroxy-3-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]propyl}-4-piperidinyl)carbamate

A solution of7-(methyloxy)-1-(2-oxiranylmethyl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(428 mg, 1.829 mmol) and 1,1-dimethylethyl 4-piperidinylcarbamate (366mg, 1.829 mmol) in DMF (2 ml) under argon was heated at 120° C. for 1 h.The mixture was then evaporated and chromatographed (0-10% methanol/DCM)to give the product as a yellow oil (301 mg, 38%).

MS (ES+) m/z 435 (MH⁺).

(l) 1,1-Dimethylethyl{1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl)methyl]-4-piperidinyl}carbamate

A solution of 1,1-dimethylethyl(1-{2-hydroxy-3-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]propyl}-4-piperidinyl)carbamate(301 mg, 0.694 mmol) in chloroform (10 ml) and triethylamine (0.24 ml,1.735 mmol) at rt under argon was treated with methanesulfonic anhydride(242 mg, 1.388 mmol) and heated at reflux for 2 h. The reaction mixturewas then evaporated and dissolved in acetonitrile (10 ml), treated withsodium iodide (520 mg, 3.47 mmol) and heated at 80° C. for 0.25 h. Themixture was then cooled, evaporated was then treated with water (200ml), extracted with 20% methanol/DCM (3×200 ml). The organic extractswere dried (MgSO₄), evaporated and chromatographed (0-10% methanol/DCM)to give the product as an orange oil (194 mg, 70%).

MS (ES+) m/z 403 (MH⁺).

(m) 1,1-Dimethylethyl{1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate

A solution of 1,1-dimethylethyl{1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(194 mg, 0.0.483 mmol) (301 mg, 0.694 mmol) in 1,4-dioxane (5 ml) wastreated with DDQ (164 mg, 0.724 mmol) and stirred at 60° C. for 24 h.Further DDQ (164 mg, 0.724 mmol) was added and the reaction was stirredfor a further 2 h. The reaction was then treated with 5% aqueouspotassium carbonate (100 ml), extracted with 20% methanol/DCM (3×200ml). The organic extracts were dried (MgSO₄) and evaporated to give theproduct as an orange oil (159 mg, 82%).

MS (ES+) m/z 401 (MH⁺).

(n)1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

A solution of 1,1-dimethylethyl{1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(159 mg, 0.398 mmol) in chloroform (2 ml) and methanol (2 ml) underargon at rt was treated with 4M HCl in 1,4-dioxane (2 ml) and stirred atrt for 0.5 h. The reaction was then dried and evaporated to give theproduct as a yellow solid (138 mg, 93%).

MS (ES+) m/z 301 (MH⁺).

(o) Title Compound

A mixture of1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (49 mg, 0.131 mmol) in DCM (2 ml) and methanol (0.1 ml)under argon at rt was treated with triethylamine (58 μl, 0.419 mmol) andstirred at rt for 0.25 h before addition of[1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (for a synthesis seeWO2004058144 Example 61) (22 mg, 0.131 mmol). The mixture was thenstirred at rt for 1 h before addition of NaBH(OAc)₃ (56 mg, 0.262 mmol).The reaction was stirred at rt for a further 0.5 h before addition ofsaturated aqueous sodium bicarbonate (20 ml). The mixture was extractedwith 20% methanol/DCM (3×100 ml). The organic extracts were dried(MgSO₄), evaporated and chromatographed (0-20% methanol/DCM) to give theproduct as a clear oil (28 mg, 47%).

MS (ES+) m/z 452 (MH⁺).

δH (CDCl₃, 400 MHz) 1.38-1.48 (2H, m), 1.78-1.95 (2H, m), 2.15-2.37 (2H,m) 2.45-2.60 (1H, m), 2.61-2.72 (2H, m), 2.92-3.02 (1H, m), 3.05-3.12(1H, m), 3.83 (2H, s), 4.32-4.42 (1H, m), 4.52-4.61 (1H, m), 4.96-5.05(1H, m), 5.74 (2H, s), 6.22-6.32 (2H, m), 7.20 (1H, s), 7.45-7.52 (2H,m), 7.99 (1H, s).

The free base of the title compound in methanol and chloroform wasconverted to the hydrochloride salt by adding an equivalent of 4Mhydrogen chloride in 1,4-dioxane, followed by evaporation to dryness.

Example 31-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

Method A

A mixture of1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (36 mg, 0.0965 mmol) (for a preparation see Example 2(n)in DCM (2 ml) and methanol (0.1 ml) under argon at rt was treated withtriethylamine (43 μl, 0.309 mmol) and stirred at rt for 0.25 h beforeaddition of 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carboxaldehyde (fora synthesis see WO2004058144 Example 2(c) or WO03/087098 Example 19(d)))(16 mg, 0.0965 mmol). The mixture was then stirred at rt for 1 h beforeaddition of NaBH(OAc)₃ (41 mg, 0.193 mmol). The reaction was stirred atrt for a further 0.5 h before addition of saturated aqueous sodiumbicarbonate (20 ml). The mixture was extracted with 20% methanol/DCM(3×100 ml). The organic extracts were dried (MgSO₄), evaporated andchromatographed (0-20% methanol/DCM) to give the free base of the titlecompound as a clear oil (24 mg, 55%).

MS (ES+) m/z 450 (MH⁺).

δH (CDCl₃, 400 MHz) 1.30-1.50 (2H, m), 1.80-1.92 (2H, m), 2.19-2.35 (2H,m) 2.49-2.72 (3H, m), 2.92-3.02 (1H, m), 3.07-3.13 (1H, m), 3.81 (2H,s), 4.22-4.51 (5H, m) 4.52-4.60 (1H, m), 4.96-5.04 (1H, m), 6.22-6.32(2H, m), 6.81 (1H, s), 7.45-7.53 (2H, m), 8.04 (1H, s).

The free base of the title compound in methanol and chloroform wasconverted to the hydrochloride salt by adding an equivalent of 4Mhydrogen chloride in 1,4-dioxane, followed by evaporation to dryness.

Method B (a) 2-Bromo-3-[(phenylmethyl)oxy]propanoic acid

Racemic O-(phenylmethyl)serine (5 g, 25.6 mmol) and potassium bromide(10.7 g, 89.6 mmol) were dissolved in ice-cooled H₂SO₄ (2.5N) andtreated with an solution of sodium nitrite (2.65 g) in water (30 ml)over 50 minutes (keeping the reaction temperature<4° C.). The reactionwas then stirred at 0° C. for 45 minutes and then at rt for 1 h,extracted with ethyl acetate (3×100 ml). The combined organic extractswere washed with water, brine, dried (MgSO₄), filtered and evaporated togive the product as a yellow oil (6 g, 90%).

MS (ES+) m/z 259/261 (MH⁺).

(b) Methyl 2-bromo-3-[(phenylmethyl)oxy]propanoate

A solution of 2-bromo-3-[(phenylmethyl)oxy]propanoic acid (6 g, 23.2mmol) in methanol (40 ml) at rt under argon was treated with thionylchloride (1.7 ml, 23.2 mmol) and the reaction was then stirred at rt for3 h and then evaporated to give product as a yellow oil (6.3 g, 99%).

MS (ES+) m/z 273/275 (MH⁺).

(c) Methyl2-[4-((2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]-3-[(phenylmethyl)oxy]propanoate

A mixture of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)4-piperidinylcarbamate(1.087 g, 3.11 mmol) (for a synthesis see WO2004/058144 Example 99(h)),methyl 2-bromo-3-[(phenylmethyl)oxy]propanoate (1.0 g, 3.66 mmol) andpotassium carbonate (0.860 g, 6.22 mmol) in DMF (50 ml) was heated to80° C. and stirred under argon for 2.5 h. The solvents were removedunder reduced pressure and the residue treated with saturated aqueoussodium bicarbonate. The aqueous was extracted with DCM (5×100 ml) driedMgSO₄, filtered and concentrated under reduced pressure. The crudeproduct was chromatographed, eluting with 0-100% EtOAc/40-60 petroleumether. Appropriate fractions were combined and evaporated under reducedpressure. The residue was then dissolved in DCM (50 ml) and washed withwater (20 ml). The organic layer was separated, dried MgSO₄ andevaporated under reduced pressure to afford product (618 mg, 35% yield).

MS (ES+) m/z 542 (MH⁺).

(d) 1,1-Dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-hydroxy-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl]carbamate

A solution of methyl2-[4-((2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]-3-[(phenylmethyl)oxy]propanoate(618 mg, 1.141 mmol) in dry THF (8 ml) at −78° C. under Ar was addedLiAlH₄ (1.312 ml, 1.312 mmol) dropwise. The reaction mixture was allowedto warm to ˜−10° C. over 2 h. The mixture was then stirred at 0° C. for2 h before addition of water (0.1 ml), then sodium hydroxide (0.18 ml,0.360 mmol) and then water (0.2 ml). The mixture was then stirred for afurther 2 h at rt. The resulting mixture was filtered and washed withTHF (100 ml). The combined filtrate and washings were evaporated underreduced pressure to afford the product (0.519 g, 89% yield).

MS (ES+) m/z 514 (MH⁺).

(e) 1,1-Dimethylethyl[1-(2-chloro-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl](2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)carbamate

A solution of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-hydroxy-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl]carbamate(150 mg, 0.292 mmol) and triethylamine (0.049 ml, 0.350 mmol), in DCM (5ml) at 0° C. was treated with methanesulfonyl chloride (0.025 ml, 0.321mmol). The solution was allowed to warm to room temperature and stirredat this temperature for 1 h. A further 0.2 eq of triethylamine and 0.4eq of methanesulfonyl chloride was added and the reaction stirred for 30mins. The reaction mixture was diluted with DCM (20 ml) and treated withwater (2 ml). The aqueous layer was extracted again with DCM (50 ml).The organic layers were combined and dried MgSO₄, filtered andevaporated under reduced pressure to the crude product (101 mg, 65%),which was used without further purification.

MS (ES+) m/z 532/534 (MH⁺).

(f) 1,1-Dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl]carbamate

Method 1: A solution of 1,1-dimethylethyl[1-(2-chloro-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl](2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)carbamate(101 mg, 0.190 mmol) in DMF (10 ml) was added dropwise to a solution ofthe sodium salt of 7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(33.8 mg, 0.190 mmol) in DMF) (10 ml) (prepared from addition of sodiumhydride (9.11 mg, 0.228 mmol) to7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one (33.8 mg, 0.190mmol) (for a preparation see Example 5(e)) in DMF (10 ml)). The solutionwas stirred at room temperature overnight under Ar. The reaction wasthen heated to 60° C. and stirred at this temperature under Ar for 1 h.The reaction was cooled to rt and a further eq of sodium hydride (9.11mg, 0.228 mmol) was added with stirring under argon. The reaction wasstirred at rt for 72 h.

Method 2: A solution of 1,1-dimethylethyl[1-(2-chloro-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl](2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)carbamate(343 mg, 0.645 mmol) in DMF (10 ml) was added dropwise to a solution ofthe sodium salt of 7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(138 mg, 0.774 mmol) (prepared from the addition of sodium hydride (60%,38.7 mg, 0.967 mmol) to7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one (138 mg, 0.774mmol) (for a preparation see Example 5(e)) in DMF (10 ml)). The solutionwas stirred at room temperature overnight under argon.

The reaction mixtures from Method 1 and Method 2 were combined and theDMF was removed under reduced pressure. The residue was treated withsaturated aqueous sodium bicarbonate solution (10 ml) and water (20 ml)and extracted with DCM (3×100 ml). The combined organic layers weredried (MgSO₄), filtered and removed under reduced pressure. The crudeproduct was chromatographed, eluting with 0-100% EtOAc/hexane.Appropriate fractions were combined to give two batches of product(batch1: 167 mg, 38%) and (batch2: lower purity, 78 mg, 18%).

MS (ES+) m/z 674 (MH⁺).

(g) 1,1-Dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-hydroxy-1-{[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]methyl}ethyl)-4-piperidinyl]carbamate

A solution of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]-1-{[(phenylmethyl)oxy]methyl}ethyl)-4-piperidinyl]carbamate(167 mg, 0.248 mmol) in ethanol (20 ml) was hydrogenated at 1 atmospherehydrogen pressure for approximately 9 days. The reaction was filteredthrough Celite and washed with ethanol. The combined filtrate andwashings were evaporated under reduced pressure to afford the product(162 mg, 91%).

MS (ES+) m/z 584 (MH⁺).

(h) 1,1-Dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate

A solution of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)[1-(2-hydroxy-1-{[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]methyl}ethyl)-4-piperidinyl]carbamate(162 mg, 0.278 mmol) in DCM (10 ml) under argon was cooled to 0° C. andtreated with triethylamine (0.046 ml, 0.333 mmol) and methanesulfonylchloride (0.026 ml, 0.333 mmol). The reaction was allowed to warm to rtand stirred at this temperature for 1 h. A further 1.2 eq oftriethylamine (0.046 ml, 0.333 mmol) and methanesulfonyl chloride (0.026ml, 0.333 mmol) were added and the solution stirred at rt overnight. Afurther 1.2 eq of triethylamine (0.046 ml, 0.333 mmol) andmethanesulfonyl chloride (0.026 ml, 0.333 mmol) were added and thesolution heated to 50° C. for 6 h. The solution was cooled to rt,saturated aqueous NaHCO₃ (10 ml) was added and the aqueous extractedwith 20% MeOH/DCM (3×100 ml). The organic phases were combined, driedMgSO₄, filtered and concentrated. The crude product was thenchromatographed, eluting with 0-15% MeOH/DCM. Appropriate fractions werecombined and evaporated under reduced pressure to afford the product (80mg, 48%).

MS (ES+) m/z 552 (MH⁺).

(i) 1,1-Dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate

A solution of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(80 mg, 0.145 mmol) and DDQ (49.4 mg, 0.218 mmol) in 1,4-dioxane (5 ml)was stirred at 120° C. for 2 h. A further 0.5 eq of DDQ (17 mg) wasadded and the solution stirred for a further 2 h. The mixture wasallowed to cool to rt and was treated with sat NaHCO₃ (10 ml). Theaqueous layer was extracted with 20% MeOH/DCM (3×100 ml). The organiclayers were combined, dried MgSO₄, filtered and concentrated to affordthe crude product (64 mg, 83%).

MS (ES+) m/z 550 (MH⁺).

(j) Title Compound

A solution of 1,1-dimethylethyl(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl){1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(64 mg, 0.116 mmol) in DCM (2 ml) and HCl in 1,4-dioxane (0.291 ml,1.164 mmol) was stirred at rt for 2 h. The solvents were removed underreduced pressure. The crude product was added to an ion exchange columnand was eluted with MeOH (20 ml) and then 2M NH₃ in MeOH (15 ml) to givethe free base of the title compound (34 mg, 65%).

¹H NMR and LC-MS identical to product of Example 3A.

The free base of the title product was then converted into the HCl saltby dissolving in DCM (2 ml) and treating with 1 eq 1M HCl in ether.Solvents were removed under reduced pressure to afford the titlehydrochloride salt.

Example 41-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride 1

A mixture of1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (51 mg, 0.136 mmol) (for a preparation see Example 2(n))in DCM (2 ml) and methanol (0.1 ml) under argon at rt was treated withtriethylamine (60 μl, 0.438 mmol) and stirred at rt for 0.25 h beforeaddition of7-bromo-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde(for a synthesis, see WO 2002056882 Example 33(e)) (37 mg, 0.136 mmol).The mixture was then stirred at rt for 1 h before addition of NaBH(OAc)₃(86 mg, 0.408 mmol). The reaction was stirred at rt for a further 0.5 hbefore addition of saturated aqueous sodium bicarbonate (20 ml). Themixture was extracted with 20% methanol/DCM (3×100 ml). The organicextracts were dried (MgSO₄), evaporated and chromatographed (0-20%methanol/DCM) to give the free base of the title compound as a clear oil(36 mg, 48%).

MS (ES+) m/z 558 (MH⁺).

δH (CDCl₃, 400 MHz) 1.32-1.51 (2H, m), 1.81-2.00 (2H, m), 2.20-2.41 (2H,m) 2.50-2.75 (3H, m), 2.93-3.03 (1H, m), 3.04-3.15 (1H, m), 3.46 (2H,s), 3.98 (2H, s), 4.32-4.41 (1H, m) 4.52-4.61 (1H, m), 4.98-5.04 (1H,m), 6.22-6.32 (2H, m), 7.48-7.51 (2H, m), 7.75 (1H, s).

The free base in methanol and chloroform was converted to the titlehydrochloride salt by adding an equivalent of 4M hydrogen chloride in1,4-dioxane, followed by evaporation to dryness.

Example 5A(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-j]-1,8-naphthyridine-4,9-dionehydrochloride

(a) 2,2-Dimethyl-N-[6-(methyloxy)-2-pyridinyl]propanamide

A suspension of trimethylacetamide (18.08 g, 178.744 mmol), Cs₂CO₃(68.823 g, 211.242 mmol), Pd₂(dba)₃ (1.488 g, 1.625 mmol) and Xantphos(4,5-bis-(diphenylphosphino)-9,9-dimethylxanthene)(1.880 g, 3.249 mmol)in dry, degassed 1,4-dioxane (800 ml) under argon was sonicated for 0.25h and then treated with 2-chloro-6-(methyloxy)pyridine (19.32 ml,162.494 mmol). The mixture was then heated at reflux for 24 h. Themixture was evaporated, treated with water (1 L) and extracted 3×DCM (1L and then 2×500 ml). The organic extracts were dried (MgSO₄),evaporated and chromatographed (50-100% DCM/40-60 Petroleum ether then0-5% methanol/DCM) to give title compound as a yellow solid (25.191 g,121.111 mmol, 75%). Impure fractions were recolumed (eluting as above)to give more product (4.990 g, 23.990 mmol, 15%).

Total yield of 90%.

MS (ES+) m/z 209 (MH⁺, 100%).

(b) N-[3-Bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethylpropanamide

A solution of 2,2-dimethyl-N-[6-(methyloxy)-2-pyridinyl]propanamide(55.011 g, 264.467 mmol) in THF (450 ml) in a three necked 1 L flaskwith an internal thermometer under argon was cooled to −78° C. andtreated with n-butyl lithium (232 ml, 581.847 mmol) over 15 minutes andthen allowed to warm to 0° C. and stirred at 0° C. for 7 h. The mixturewas then recooled to −78° C. and treated with 1,2-dibromoethane (27.3ml, 317 mmol) over 10 minutes and then the solution was allowed warm toroom temperature and stirred at room temperature for 30 minutes by whichtime all the solid which had formed dissolved again. Gas was evolved atthis stage so a gas bubbler was placed on one of the flasks necks. Water(100 ml) was then carefully added over 10 minutes. Further water (500ml) was then added and the mixture was extracted with diethyl ether(3×500 ml). The combined organic solvents were then dried (MgSO₄),filtered, evaporated to give the crude product. This was then dissolvedin warm ethyl acetate (100 ml) and allowed to stand in the freezerovernight. The resultant solid which crystallised out was filtered off,washed with ice-cooled diethyl ether (20 ml) and dried in vacuo to giveproduct as a white solid (45.660 g, 159.011 mmol, 60% yield). Thefiltrate was evaporated and the residue was chromatographed (0-25% ethylacetate/40-60 petroleum ether) to give recovered starting material(7.264 g, 34.9 mmol), and product as a white solid (8.038 g, 27.992mmol, 10% yield). The product from recrystallisation and silicachromatography were identical by NMR and LC-MS and so were combined.

MS (ES+) m/z 287/289 (MH⁺, 100%).

(c) Butyl(2E)-3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-2-propenoate

A mixture ofN-[3-bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethylpropanamide (78.783 g,274 mmol), bis(tri-t-butylphosphine)palladium(0) (1 g, 1.957 mmol) andtris(dibenzylideneacetone)dipalladium(0) (0.892 g, 0.974 mmol) in dry,degassed 1,4-dioxane (600 ml) was treated with n-butyl acrylate (47.1ml, 329 mmol) and dicyclohexylmethylamine (64.5 ml, 302 mmol). Thereaction mixture was then heated at 80° C. for 4 h and then at 120° C.for 3 h. The reaction was then evaporated and water (1000 ml) was addedand the mixture was extracted with diethyl ether (3×500 ml). Thecombined organic solvents were then dried (MgSO₄), filtered, evaporatedto give the crude product. This was then dissolved in DCM (300 ml) andchromatographed (10-30% ethyl acetate:40-60 petroleum ether) and thendried in vacuo to give product as a white solid (87.412 g, 95%).

MS (ES+) m/z 335 (MH⁺, 100%).

(d) Butyl3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]propanoate

A solution of butyl(2E)-3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-2-propenoate(43.706 g, 131 mmol) in ethanol (450 ml) under argon at rt was treatedwith palladium on carbon (5.0 g, 47.0 mmol) and then stirred at rt under1 atmosphere of hydrogen for 90 h. The reaction mixture was thenfiltered through a thin pad of Kieselguhr, washing the product throughwith further ethanol (200 ml). The solvent was then evaporated to giveproduct as a yellow oil (43.549, 99%).

MS (ES+) m/z 337 (MH⁺, 100%).

(e) 7-(Methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one

A mixture of butyl3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]propanoate(86.01 g, 256 mmol) in hydrochloric acid (500 ml, 3000 mmol)(6Maqueous), was heated at 80° C. for 6 h. Reaction was cooled, treatedwith water (500 ml), transferred to a 5 L conical flask and carefullyneutralised with solid potassium carbonate (requires around 250 g)(mucheffervescence was observed). The mixture was then extracted with 20%MeOH/DCM (3×500 ml). The combined organic solvents were then dried(MgSO₄), filtered and evaporated to give the crude product as a yellowsolid (35.84 g, 79%).

MS (ES+) m/z 179 (MH⁺, 100%).

(f)7-(Methyloxy)-1-[(2R)-2-oxiranylmethyl]-3,4-dihydro-1,8-naphthyridin-2(1H)-one

A solution of 7-(methyloxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(4.974 g, 27.9 mmol) in DMF (100 ml) at 0° C. under argon was treatedwith sodium hydride (60%, 1.340 g, 33.5 mmol) and allowed to stir at 0°C. for 20 min. The reaction mixture was then treated with(2S)-2-oxiranylmethyl 3-nitrobenzenesulfonate (7.60 g, 29.3 mmol),stirred at 0° C. and then allowed warm to rt and stirred at rt for 1 h.Water (5 ml) was then added. Reaction was evaporated, saturated aqueousbicarbonate (500 ml) was then added and the mixture was extracted withDCM (3×500 ml). The combined organic solvents were then dried (MgSO₄),filtered and evaporated to give the crude product.

MS (ES+) m/z 235 (MH⁺, 100%).

(g)(1S)-1-(Hydroxymethyl)-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

A solution of7-(methyloxy)-1-[(2R)-2-oxiranylmethyl]-3,4-dihydro-1,8-naphthyridin-2(1H)-one(1.167 g, 4.98 mmol) in DMF (20 ml) under argon was heated to 120° C.for 6 h. Reaction was then evaporated and chromatographed (0-20%methanol/DCM) to give product as an orange solid (339 mg, 31%).

MS (ES+) m/z 221 (MH⁺, 100%).

Alternatively the reaction can be heated with microwave power at 160° C.for 40 mins.

(h) 1,1-Dimethylethyl(1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-piperidinyl)carbamate

A solution of(1S)-1-(hydroxymethyl)-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(1.909 g, 8.67 mmol) in DCM (100 ml) at 0° C. under argon was treatedwith triethylamine (1.450 ml, 10.40 mmol) and then methanesulfonylchloride (0.743 ml, 9.54 mmol) and then allowed to warm to rt andstirred at rt for 1 h. The reaction mixture was then treated withsaturated aqueous bicarbonate (100 ml) and the mixture was extractedwith DCM (2×100 ml). The combined organic solvents were then dried(MgSO₄), filtered and evaporated to give the crude intermediate[(2S)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methylmethanesulfonate. This was dissolved in dry acetonitrile (100 ml) andthen treated with pyridine (1.402 ml, 17.34 mmol) and 1,1-dimethylethyl4-piperidinylcarbamate (3.47 g, 17.34 mmol) and heated at 70° C. for 20h. After 20 h more 1,1-dimethylethyl 4-piperidinylcarbamate (3.47 g,17.34 mmol) and pyridine (1.402 ml, 17.34 mmol) were added and thetemperature was increased to reflux (heating block 95° C.) and reactionwas stirred at this temperature for a further 4 h. The reaction mixturewas then evaporated, saturated aqueous NaHCO₃ (200 ml) was then addedand the mixture was extracted with DCM (3×200 ml). The combined organicsolvents were then dried (MgSO₄), filtered and evaporated to give thecrude product as a brown solid.

MS (ES+) m/z 403 (MH⁺, 100%).

(i) 1,1-Dimethylethyl(1-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-4-piperidinyl)carbamate

A solution of 1,1-dimethylethyl(1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-piperidinyl)carbamate(5.710 g, 14.19 mmol) in 1,4-dioxane (50 ml) at rt was treated with DDQ(4.83 g, 21.28 mmol) and then heated at 120° C. for 1 h. The reactionwas then cooled to rt. The reaction mixture was treated with saturatedaqueous K₂CO₃ (5%, 1000 ml) and extracted with DCM (3×500 ml). Thecombined organic solvents were then dried (MgSO₄), filtered andevaporated to give the crude product as a brown solid. The reaction wasrepeated using a further portion of carbamate (2.889 g, 7.18 mmol) in1,4-dioxane (50 ml) with DDQ (2.444 g, 10.77 mmol). The reaction wasperformed and worked up as above and the combined residues werechromatographed (0-100% ethyl acetate:40-60 Petroleum ether then 0-20%methanol:ethyl acetate) to give the product as a brown solid (1.532 g).

MS (ES+) m/z 401 (MH⁺, 100%).

(j)(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

A solution of 1,1-dimethylethyl(1-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-4-piperidinyl)carbamate(1.532 g, 3.83 mmol) in chloroform (20 ml) under argon at rt was treatedwith 4M HCl in 1,4-dioxane (10 ml, 40.0 mmol) and stirred at rt for 0.25h. Methanol (20 ml) was then added and reaction was stirred for afurther 0.25 h. The reaction was then evaporated and triturated withdiethyl ether (20 ml). The solid was then dried in vacuo to give theimpure product as a brown solid (1.443 g, 101%).

MS (ES+) m/z 301 (MH⁺, 100%)

1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride made by this general method (Example 5(a)-(j)) wasanalyzed via chiral HPLC (Chiralpak AS-H (5 microns) and found to be asingle enantiomer, presumed to be R.

(k) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (impure product) (575 mg, 1.540 mmol) in chloroform (20ml) and methanol (1 ml) at rt under argon was treated with triethylamine(0.644 ml, 4.62 mmol) and stirred at rt for 0.25 h. The solution wasthen treated with [1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (for asynthesis see WO2004058144 Example 61) (258 mg, 1.540 mmol) and stirredfor a further 0.5 h. The solution was then treated with NaBH(OAc)₃ (979mg, 4.62 mmol) and stirred at rt for 0.5 h. The reaction was thentreated with saturated aqueous NaHCO₃ (100 ml) and extracted with 20%methanol/DCM (3×200 ml). The combined organic extracts were dried(MgSO₄), filtered, evaporated and chromatographed (0-20% methanol/DCM)to give the free base of the title compound as a light brown solid (574mg, 1.273 mmol, 83%).

δH (CDCl₃, 250 MHz) 1.25-1.45 (2H, m), 1.75-1.95 (2H, m), 2.20-2.45 (2H,m), 2.45-2.55 (1H, m), 2.60-2.75 (2H, m), 2.90-3.00 (1H, m), 3.05-3.15(1H, dd), 3.85 (2H, s), 4.30-4.40 (1H, m), 4.55-4.65 (1H, m), 4.95-5.05(1H, m), 5.75 (2H, s), 6.25 (1H, m), 6.30 (1H, m), 7.20 (1H, s),7.45-7.52 (2H, m), 8.00 (1H, s)

MS (ES+) m/z 452 (MH⁺).

The free base in DCM/MeOH 2:1 (15 ml) was treated with 1M HCl in diethylether and then evaporated to give the title monohydrochloride salt.

Example 5B(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionebenzoate

(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionewas dissolved in methanol and treated with benzoic acid (1 equivalent).Concentration, treatment with diethyl ether and evaporation of thesolvents under reduced pressure gave the product as the benzoate salt.

Example 5C(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionedi-trifluoroacetate

(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride in eluent [10% MeCN in water (containing 0.1% TFA)] wasapplied to a preparative reverse phase HPLC column. Product-containingfractions were combined, concentrated and concentrate lyophilized. Theproduct was isolated as a sticky white foam following desiccation(weekend) over P₂O₅.

Example 6A(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (511 mg, 1.369 mmol) (for a preparation see Example5(j)) in chloroform (20 ml) and methanol (1 ml) at rt under argon wastreated with triethylamine (0.572 ml, 4.11 mmol) and stirred at rt for0.25 h. The solution was then treated with2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for a synthesissee WO2004058144, Example 60) (248 mg, 1.369 mmol) and stirred for afurther 0.5 h. The solution was then treated with NaBH(OAc)₃ (870 mg,4.11 mmol) and stirred at rt for 0.5 h. The reaction was then treatedwith saturated aqueous NaHCO₃ (100 ml) and extracted with 20%methanol/DCM (3×200 ml). The combined organic extracts were dried(MgSO₄), filtered, evaporated and chromatographed (0-20% methanol/DCM)to give the free base of the title compound as a light brown solid (499mg, 78%).

MS (ES+) m/z 466 (MH⁺).

δH (CDCl₃, 250 MHz) 1.21-1.48 (2H, m), 1.72-1.92 (2H, m), 2.12-2.39 (2H,m) 2.41-2.78 (3H, m), 2.89-3.22 (4H, m), 3.78 (2H, s), 4.28-4.48 (3H, m)4.50-4.61 (1H, m), 4.96-5.04 (1H, m), 6.19-6.32 (2H, m), 7.01 (1H, s),7.42-7.53 (2H, m), 8.00 (1H, s).

The free base in DCM/MeOH 2:1 (15 ml) was treated with one equivalent of1M HCl in diethyl ether and then evaporated to give the titlemonohydrochloride salt.

Example 6B(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride

(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionewas dissolved in methanol and treated with benzoic acid (1 equivalent).Evaporation of the solvents under reduced pressure gave the product asthe benzoate salt.

Example 6C(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dioneditrifluoroacetate

(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride was applied to a preparative reverse phase HPLC column ina mixture of 10% MeCN in water containing 0.1% TFA. Product-containingfractions were combined, concentrated and concentrate lyophilized. Theproduct (bis-TFA salt) was isolated as a white solid followingdesiccation over P₂O₅.

Example 7(1R)-1-({4-[(5,6,7,8-Tetrahydro-3-isoquinolinylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride

(a) Ethyl 5,6,7,8-tetrahydro-3-isoquinolinecarboxylate

A solution of 1,7-octadiyne (4.00 ml, 30.1 mmol) and ethyl cyanoformate(2.95 ml, 30.1 mmol) in dry degassed 1,4-dioxane (500 ml) under argon atrt was treated with cyclopentadienyl-Cobalt(I)-dicarbonyl (0.814 g, 4.52mmol) and then heated at reflux for 18 h. Reaction was then evaporated,treated with toluene (100 ml), re-evaporated, dissolved in DCM (100 ml),filtered through a short pad of Kieselguhr, eluting with DCM, organicextracts evaporated, chromatographed (0-100% DCM:40-60 Petroleum etherthen 0-10% methanol/DCM) to give product as an impure brown oil (1.27 g,21%).

MS (ES+) m/z 206 (MH⁺).

(b) 5,6,7,8-Tetrahydro-3-isoquinolinylmethanol

A solution of ethyl 5,6,7,8-tetrahydro-3-isoquinolinecarboxylate (1.27g, 6.19 mmol) in THF (50 ml) at −78° C. under argon was treated withLiAlH₄ (1M solution in THF, 6.19 ml, 6.19 mmol) and allowed warm to rt.After 10 min at rt, water (1 ml), 2M aq NaOH (1 ml) and water (1 ml)were sequentially added and the mixture stirred at rt for 0.5 h. Themixture was then filtered through a short pad of Kieselguhr, elutingwith THF (50 ml), organic extracts were then evaporated, chromatographed(0-20% methanol/DCM) to give product as an orange oil (0.572 g, 57%).

MS (ES+) m/z 164 (MH⁺).

(c) 5,6,7,8-Tetrahydro-3-isoquinolinecarbaldehyde

A solution of 5,6,7,8-tetrahydro-3-isoquinolinylmethanol (572 mg, 3.50mmol) in (DCM) (10 ml) at rt under argon was treated with manganesedioxide (3.047 g, 35.0 mmol) and then stirred at rt for 2 h. Thereaction mixture was then filtered through a thin pad of Kieselguhr,eluting with DCM (50 ml), the organic extracts were evaporated to givethe crude product as a brown oil (435 mg, 77%).

MS (ES+) m/z 162 (MH⁺).

(d) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (87 mg, 0.233 mmol) (for a preparation see Example 5(j))in chloroform (5 ml) and methanol (0.2 ml) at rt under argon was treatedwith triethylamine (97 μl, 0.699 mmol) and stirred at rt for 0.25 h. Thesolution was then treated with5,6,7,8-tetrahydro-3-isoquinolinecarbaldehyde (37.6 mg, 0.233 mmol) andstirred for a further 0.5 h. The solution was then treated withNaBH(OAc)₃ (148 mg, 0.699 mmol) and stirred at rt for 0.5 h. Thereaction was then treated with saturated aqueous NaHCO₃ (100 ml) andextracted with 20% methanol/DCM (3×200 ml). The combined organicextracts were dried (MgSO₄), filtered, evaporated and chromatographed(0-20% methanol/DCM) to give the free base of the title compound as alight brown solid (66 mg, 64%).

MS (ES+) m/z 446 (MH⁺).

δH (CDCl₃, 250 MHz) 1.22-1.51 (2H, m), 1.71-1.99 (7H, m), 2.15-2.38 (2H,m) 2.45-2.82 (4H, m), 2.61-3.22 (4H, m), 3.85 (2H, s), 4.29-4.42 (1H, m)4.50-4.61 (1H, m), 4.96-5.04 (1H, m), 6.18-6.32 (2H, m), 7.00 (1H, s),7.47-7.59 (2H, m), 8.21 (1H, s).

The free base in DCM/MeOH 2:1 (15 ml) was treated with one equivalent of1M HCl in diethyl ether and then evaporated to give the titlemonohydrochloride salt.

Example 8(1R)-1-({4-[(6,7-Dihydro-5H-cyclopenta[c]pyridin-3-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

(a) Ethyl 6,7-dihydro-5H-cyclopenta[c]pyridine-3-carboxylate

A solution of 1,6-heptadiyne (1.242 ml, 10.85 mmol) and ethylcyanoformate (1.063 ml, 10.85 mmol) in dry degassed 1,4-dioxane (100 ml)under argon at rt was treated with cyclopentadienyl-Cobalt(I)-dicarbonyl(0.293 g, 1.628 mmol) and then heated at reflux for 18 h. Reaction wasthen evaporated, treated with toluene (100 ml), re-evaporated, dissolvedin DCM (100 ml), filtered through a short pad of Kieselguhr, elutingwith DCM, organic extracts evaporated, chromatographed (0-100% DCM:40-60Petroleum ether then 0-10% methanol/DCM) to give product as an impurebrown oil (427 mg, 21%).

MS (ES+) m/z 192 (MH⁺).

(b) 6,7-Dihydro-5H-cyclopenta[c]pyridin-3-ylmethanol

A solution of ethyl 6,7-dihydro-5H-cyclopenta[c]pyridine-3-carboxylate(427 mg, 2.233 mmol) in (THF) (20 ml) at −78° C. under argon was treatedwith LiAlH₄ (1M in THF)(2.233 ml, 2.233 mmol) and allowed warm to rt.After 10 min at rt, water (1 ml), 2M aq NaOH (1 ml) and water (1 ml)were sequentially added and the mixture stirred at rt for 0.5 h. Themixture was then filtered through a short pad of Kieselguhr, elutingwith THF (50 ml), organic extracts were then evaporated, chromatographed(0-20% methanol/DCM) to give product as an orange oil (189 mg, 57%).

MS (ES+) m/z 150 (MH⁺).

(c) 6,7-Dihydro-5H-cyclopenta[c]pyridine-3-carbaldehyde

A solution of 6,7-dihydro-5H-cyclopenta[c]pyridin-3-ylmethanol (189 mg,1.267 mmol) in DCM (10 ml) at rt under argon was treated with manganesedioxide (1.101 g, 12.67 mmol) and then stirred at rt for 2 h, filteredthrough a thin pad of Kieselguhr, eluting with DCM (40 ml), the organicextracts were evaporated to give the crude product as a brown oil (110mg, 59%).

MS (ES+) m/z 148 (MH⁺).

(d) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (82 mg, 0.220 mmol) (for a preparation see Example 5(j))in chloroform (5 ml) and methanol (0.2 ml) at rt under argon was treatedwith triethylamine (92 μl, 0.659 mmol) and stirred at rt for 0.25 h. Thesolution was then treated with6,7-dihydro-5H-cyclopenta[c]pyridine-3-carbaldehyde (32.3 mg, 0.220mmol) and stirred for a further 0.5 h. The solution was then treatedwith NaBH(OAc)₃ (140 mg, 0.659 mmol) and stirred at rt for 0.5 h. Thereaction was then treated with saturated aqueous NaHCO₃ (100 ml) andextracted with 20% methanol/DCM (3×200 ml). The combined organicextracts were dried (MgSO₄), filtered, evaporated and chromatographed(0-20% methanol/DCM) to give the free base of the title compound as alight brown solid (39 mg, 41%).

MS (ES+) m/z 432 (MH⁺).

δH (CDCl₃, 250 MHz) 1.32-1.59 (2H, m), 1.82-2.40 (6H, m) 2.51-2.72 (3H,m), 2.82-3.18 (6H, m), 3.95 (2H, s), 4.31-4.42 (1H, m), 4.50-4.61 (1H,m), 4.92-5.08 (1H, m), 6.19-6.32 (2H, m), 7.23 (1H, s), 7.42-7.53 (2H,m), 8.38 (1H, s).

The free base in DCM/MeOH 2:1 (15 ml) was treated with one equivalent of1M HCl in diethyl ether and then evaporated to give the titlemonohydrochloride salt.

Example 9(1R)-1-({4-[(1,3-Dihydrofuro[3,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

(a) Ethyl 1,3-dihydrofuro[3,4-c]pyridine-6-carboxylate

A solution of di-2-propyn-1-yl ether (5.01 g, 53.2 mmol) and ethylcyanoformate (5.21 ml, 53.2 mmol) in dry degassed 1,4-dioxane (500 ml)under argon at rt was treated with cyclopentadienyl-Cobalt(I)-dicarbonyl(1.437 g, 7.98 mmol) and then heated at reflux (heating block temp 120°C.) for 18 h. The reaction was evaporated, treated with toluene (100ml), re-evaporated, dissolved in DCM (100 ml), filtered through a shortpad of Kieselguhr, eluting with DCM, organic extracts evaporated,chromatographed (0-100% DCM:40-60 Petroleum ether then 0-10%methanol/DCM) to give product as an impure brown solid (0.871 g) andimpure product as a black oil (2.684 g) which was re-chromatographed(0-10-10% methanol/DCM,) to give more material as a brown solid (1.261g). Total product obtained was (2.132 g, 21%).

MS (ES+) m/z 194 (MH⁺).

(b) 1,3-Dihydrofuro[3,4-c]pyridin-6-ylmethanol

A solution of ethyl 1,3-dihydrofuro[3,4-c]pyridine-6-carboxylate (0.871g, 4.51 mmol) in THF (20 ml) at −78° C. under argon was treated withLiAlH₄ (1M in THF) (4.51 ml, 4.51 mmol) and allowed warm to rt. After 10min at rt, water (1 ml), 2M aq NaOH (1 ml) and water (1 ml) weresequentially added and the mixture stirred at rt for 0.5 h. The mixturewas then filtered through a short pad of Kieselguhr, eluting with THF(50 ml), organic extracts were then evaporated, chromatographed (0-20%methanol/DCM) to give product as an orange oil (66 mg, 10%).

MS (ES+) m/z 152 (MH⁺).

(c) 1,3-Dihydrofuro[3,4-c]pyridine-6-carbaldehyde

A solution of 1,3-dihydrofuro[3,4-c]pyridin-6-ylmethanol (66 mg, 0.437mmol) in DCM (5 ml) at rt under argon was treated with manganese dioxide(380 mg, 4.37 mmol) and then stirred at rt for 2 h, filtered through athin pad of Kieselguhr, eluting with DCM (40 ml) and methanol (10 ml),the organic extracts were evaporated to give the crude product as abrown oil (65 mg, 100%)

MS (ES+) m/z 150 (MH⁺).

(d) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(121 mg, 0.324 mmol) (for a preparation see Example 5(j)) in chloroform(5 ml) and methanol (0.2 ml) at rt under argon was treated withtriethylamine (0.136 ml, 0.972 mmol) and stirred at rt for 0.25 h. Thesolution was then treated with1,3-dihydrofuro[3,4-c]pyridine-6-carbaldehyde (48.3 mg, 0.324 mmol) andstirred for a further 0.5 h. The solution was then treated withNaBH(OAc)₃ (206 mg, 0.972 mmol) and stirred at rt for 0.5 h. Thereaction was then treated with saturated aqueous NaHCO₃ (100 ml) andextracted with 20% methanol/DCM (3×200 ml).

The combined organic extracts were dried (MgSO₄), filtered, evaporatedand chromatographed (0-20% methanol/DCM) to give the free base of thetitle compound as a light brown solid (37 mg, 26%)

MS (ES+) m/z 434 (MH⁺).

δH (CDCl₃, 250 MHz) 1.21-1.52 (2H, m), 1.78-2.00 (2H, m), 2.15-2.40 (2H,m) 2.49-3.15 (5H, m), 3.95 (2H, s), 4.31-4.48 (1H, m) 4.50-4.62 (1H, m),4.92-5.19 (5H, m), 6.19-6.32 (2H, m), 7.27 (1H, s), 7.41-7.54 (2H, m),8.45 (1H, s).

The free base in DCM/MeOH 2:1 (15 ml) was treated with one equivalent 1MHCl in diethyl ether and then evaporated to give the title mono salt.

Example 10(1R)-1-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5(j)) (51 mg, 0.14 mmol) inchloroform:methanol (9:1, 3 ml) at rt under argon was treated withtriethylamine (0.06 ml) and stirred at rt for 10 min. The solution wasthen treated with 1,3-dihydrofuro[3,4-c]pyridine-6-carbaldehyde (for asynthesis see WO2004058144, Example 126(e)) (21 mg, 0.133 mmol) andstirred for a further 2 h. The solution was then treated with NaBH(OAc)₃(87 mg) and stirred at rt for 2 h. The reaction was then treated withsaturated aqueous NaHCO₃ (10 ml) and extracted with 20% methanol/DCM(3×50 ml). The combined organic extracts were dried (MgSO₄), filtered,evaporated and chromatographed (0-20% methanol/DCM) to give the freebase of the title compound as a light brown solid (20 mg, 32%)

MS (ES+) m/z 448 (MH⁺).

δH (CDCl₃, 400 MHz) 1.15-1.49 (2H, m), 1.61-1.95 (2H, m), 1.99-2.09 (2H,m) 2.20-2.38 (1H, m), 2.45-2.85 (6H, m), 2.92-3.02 (1H, m), 3.05-3.15(1H, m), 3.78 (2H, s), 4.20 (2H, t), 4.30-4.42 (1H, m), 4.52-4.61 (1H,m), 4.95-5.05 (1H, m), 6.23-6.32 (2H, m), 7.00 (1H, s), 7.47-7.50 (2H,m), 8.07 (1H, s).

The free base in DCM was treated with one equivalent 1M HCl in diethylether and then evaporated to give the title monohydrochloride salt.

Example 117-[({1-[(4,9-Dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-j]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}amino)methyl]-2,3-dihydro-1,4-benzodioxin-5-carbonitrilehydrochloride (2:1 Mixture of R:S)

(a) 1,1-Dimethylethyl(1-{(2R)-2-hydroxy-3-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]propyl}-4-piperidinyl)carbamate

A mixture of7-(methyloxy)-1-[(2S)-2-oxiranylmethyl]-3,4-dihydro-1,8-naphthyridin-2(1H)-one(made according to the general method of Example 5(f) but using(2R)-2-oxiranylmethyl 3-nitrobenzenesulfonate) (3.1 g, 13.3 mmol) and1,1-dimethylethyl 4-piperidinylcarbamate (2.7 g, 13.3 mmol) in DMF (3ml) was heated at 110° C. for 1 h. DMF was then evaporated. The crudeproduct was purified by silica chromatography using a 0-10%methanol/dichlormethane gradient to provide the desired compound as apale yellow solid, presumed R enantiomer (3.9 g; 89%; 90% purity).

MS (ES+) m/z 435 (MH⁺).

(b) 1,1-Dimethylethyl{1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl)methyl]-4-piperidinyl}carbamate(2:1 Mixture of R:S)

A solution of 1,1-dimethylethyl(1-{(2R)-2-hydroxy-3-[7-(methyloxy)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl]propyl}-4-piperidinyl)carbamate(3.9 g, 8.97 mmol) in chloroform (150 ml) and triethylamine (3.1 ml)under argon was treated with methanesulfonic anhydride (3.1 g, 17.94mmol) at room temperature and then heated at reflux for 2.5 h. Thesolvents were evaporated and the residue dissolved in acetonitrile (150ml) and treated with sodium iodide (6.7 g, 44.85 mmol) and heated at 80°C. After 45 minutes acetonitrile was evaporated and the residue waspartitioned between water (250 ml) and 20% methanol/dichloromethane (250ml); the layers were separated and the aqueous layer was extracted with20% methanol/dichloromethane (4×250 ml). The combined organic extractswere dried on magnesium sulphate, filtered and evaporated. The crude waspurified by silica chromatography using a 0-10% methanol/dichloromethanegradient to provide the desired compound as a bright orange foam (1.83g; 57%, impure with triethylamine residues). The aqueous layer wasevaporated and then treated with chloroform; the solid was filtered offand the chloroform was evaporated to give 2.77 g of a yellow solid. Thesolid was dissolved in methanol and loaded onto a SCX cartridge whichwas pre-wet with methanol. The cartridge was washed with methanol (50ml) and then with 2M ammonia in methanol (50 ml). The 2M ammonia inmethanol was evaporated to afford the pure product as a white solid (220mg), presumed 2:1 mixture of R:S).

MS (ES+) m/z 403 (MH⁺).

(c) 1,1-Dimethylethyl{1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(2:1 Mixture of R:S)

A mixture of 1,1-dimethylethyl{1-[(4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl)methyl]-4-piperidinyl}carbamate(2:1 mixture of R:S) (1.83 g, 4.55 mmol) and DDQ (1.6 g, 6.83 mmol) in1,4-dioxane (100 ml) was stirred at 60° C. under argon overnight. MoreDDQ (1.6 g, 6.83 mmol) was added and the reaction was stirred at 60° C.for another 1 h. The reaction was cooled to room temperature, treatedwith 5% aqueous solution of potassium carbonate (600 ml) and extractedwith 20% methanol/dichloromethane (3×500 ml). The combined organicextracts were dried over magnesium sulphate, filtered and evaporated toafford the crude as a brown oil. LCMS showed that there was still 8% ofstarting material left so the oil was combined with more startingmaterial (220 mg) recovered from the aqueous in the previous step andwas dissolved in 1,4-dioxane (100 ml), treated with 1 eq. of DDQ andheated at 60° C. for 1 h. LCMS showed that the reaction was not completeso 0.5 g of DDQ was added and the reaction was stirred at 60° C. for 0.5h. A small work-up showed that the reaction was complete so the reactionwas treated with 5% aqueous solution of potassium carbonate (500 ml) andextracted with 20% methanol/dichloromethane (2×500 ml). The combinedorganic extracts were dried over magnesium sulphate, filtered andevaporated to afford the product as a light brown foam (1 g, 50%).

MS (ES+) m/z 401 (MH⁺).

(d)1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(2:1 Mixture of R:S)

1,1-Dimethylethyl{1-[(4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl)methyl]-4-piperidinyl}carbamate(2:1 mixture of R:S) (1 g, 2.5 mmol) was dissolved in chloroform (10 ml)and treated with 4M HCl in 1,4-dioxane solution (10 ml) at roomtemperature. A solid precipitated so some methanol was added to dissolveit. After 1 h LCMS showed that the reaction was complete so moremethanol was added to dissolve all the solids, followed by toluene (50ml). All the solvents were evaporated under reduced pressure to afford ayellow solid. The solid was dissolved in 100 ml of methanol and stirredwith Amberlyst A21 resin for 1 h. The resin was then filtered off andthe methanol removed to afford 0.7 g of a brown gum. The gum wasdissolved in methanol and loaded onto a SCX cartridge that was pre-wetwith methanol. The cartridge was washed with methanol and then with 2Mammonia in methanol. The 2M ammonia in methanol was evaporated to affordthe product as a light brown gum (0.6 g, 80%).

MS (ES+) m/z 301 (MH⁺).

Product made by this general method was analyzed via chiral HPLC(Chiralpak AS-H (5 microns) with 90:10:0.1acetonitrile:methanol:isopropylamine as the mobile phase.). The ratio ofisomers (presumed R:S) was approximately 2:1.

(e) Title Compound

1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(2:1 mixture of R:S) (60 mg, 0.2 mmol) and7-formyl-2,3-dihydro-1,4-benzodioxin-5-carbonitrile (for a synthesis seeWO06014580 Preparation 13 or WO2007122258 Example 31(d)) (37.8 mg, 0.2mmol) were dissolved in dichloromethane/methanol (2/0.1 ml) at roomtemperature under argon and stirred at room temperature for 1 h. Thiswas then treated with NaBH(OAc)₃ (85 mg, 0.4 mmol) and left to stir for1 hour. A saturated solution of sodium bicarbonate (15 ml) was thenadded and the aqueous was extracted with 20% methanol/dichloromethane(3×35 ml). The combined organic extracts were dried on magnesiumsulphate, filtered and evaporated. The crude was purified by silicachromatography using a 0-20% methanol/dichloromethane gradient toprovide the free base of the title compound as a pale yellow gum (26 mg,27%).

δH CDCl₃, (250 MHz) 1.15-1.45 (m, 2H), 1.53 (bs, 1H), 1.70-1.90 (m, 2H),2.15-2.35 (m, 1H), 2.35-2.55 (m, 1H), 2.55-2.75 (m, 2H), 2.85-3.00 (m,2H), 3.00-3.15 (m, 1H), 3.68 (s, 2H), 4.25-4.45 (m, 5H), 4.50-4.65 (m,1H), 4.90-5.10 (m, 1H), 6.20-6.35 (m, 2H), 7.00-7.10 (m, 2H), 7.40-7.55(m, 2H).

MS (ES+) m/z 474 (MH⁺).

The title compound was prepared by dissolving the free base in DCM andtreating it with 1 equivalent of 1M HCl in diethyl ether. This was thenevaporated to dryness and dried in the vacuum desiccator in the presenceof P₂O₅.

Example 121-[(4-{[(3-Oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride (2:1 Mixture of R:S)

1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(2:1 mixture of R:S, for a preparation see Example 11(d)) (60 mg, 0.2mmol) and 3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carbaldehyde (for asynthesis see WO2002056882, Example 6(c) (38.6 mg, 0.2 mmol) weredissolved in dichloromethane/methanol (2/0.1 ml) at room temperatureunder argon and stirred at room temperature for 1 h. This was thentreated with NaBH(OAc)₃ (85 mg, 0.4 mmol) and left to stir for 1 hour. Asaturated solution of sodium bicarbonate (20 ml) was then added and theaqueous was extracted with 20% methanol/dichloromethane (3×35 ml). Thecombined organic extracts were dried on magnesium sulphate, filtered andevaporated. The crude product was purified by silica chromatographyusing a 0-20% methanol/dichloromethane gradient to provide the free baseof the title compound as a yellow solid (37 mg, 39%).

δH CDCl₃, (250 MHz) 1.20-1.45 (m, 2H), 1.70-2.15 (m, 4H), 2.15-2.40 (m,2H), 2.40-2.75 (m, 3H), 2.95 (d, 1H), 3.05-3.15 (m, 1H), 3.40 (s, 2H),3.76 (s, 2H), 4.30-4.45 (m, 1H), 4.50-4.65 (m, 1H), 4.90-5.10 (m, 1H),6.20-6.35 (m, 2H), 6.85-7.00 (m, 2H), 7.25 (d, 1H), 7.40-7.60 (m, 2H),8.53 (bs, 1H).

MS (ES+) m/z 478 (MH⁺).

The title compound was prepared by dissolving the free base in DCM/MeOHand treating it with 1 equivalent of 1M HCl in diethyl ether. This wasthen evaporated to dryness and dried in the vacuum desiccator in thepresence of P₂O₅ for 4 days.

Example 13A(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(a) 6-(Methyloxy)-3-nitro-2-pyridinamine

A solution/suspension of 2-chloro-6-(methyloxy)-3-nitropyridine (65.7 g,348 mmol) in 2M ammonia in methanol (500 ml, 1000 mmol) and aqueousammonia (500 ml, 348 mmol) was stirred at 65° C. for 18 h. The reactionwas cooled down and the solid filtered off and washed with water (2×100ml). The solid was dried in the vacuum oven at 40° C. overnight toafford the product as a bright yellow solid (52.14 g, 84% purity by NMR,74%).

MS (ES+) m/z 170 (MH⁺).

(b) 6-(Methyloxy)-2,3-pyridinediamine

6-(Methyloxy)-3-nitro-2-pyridinamine (26 g, 129 mmol) was suspended inethanol (500 ml) at room temperature under argon and then treated withpalladium on carbon (15 g, 14.10 mmol) (10% paste). The reaction wasstirred under 1 atm of hydrogen overnight. The reaction was filteredthrough a Celite pad and the pad washed with ethanol (500 ml). Ethanolwas evaporated to afford the product as a purple oil (20.68 g, slightlyimpure).

MS (ES+) m/z 140 (MH⁺).

(c) Ethyl N-[2-amino-6-(methyloxy)-3-pyridinyl]glycinate

6-(Methyloxy)-2,3-pyridinediamine (21.7 g, estimated 87% purity, 136mmol) was dissolved in acetonitrile (500 ml) at room temperature underargon and then treated with potassium carbonate (24.38 g, 176 mmol) andethyl bromoacetate (18.13 ml, 163 mmol). The reaction was stirred atroom temperature overnight. The acetonitrile was then removed in vacuo.The reaction was repeated using more 6-(methyloxy)-2,3-pyridinediamine(20.68 g, 87% purity, 129 mmol), in acetonitrile (500 ml), potassiumcarbonate (23.23 g) and ethyl bromoacetate (17.27 g) and the reactionwas again stirred at room temperature overnight and the acetonitrile wasthen removed in vacuo. The residues were partitioned between water (1 L)and ethyl acetate (1 L) and the layers separated. The aqueous layer wasextracted once more with ethyl acetate (1 L) and the combined organicextracts were dried over MgSO₄, filtered and evaporated to afford apurple oil (64 g). The oil was treated with DCM (300 ml) and theinsoluble impurities filtered off. The DCM solution was loaded onto a800 g silica column and eluted with 0-2% MeOH/DCM to afford 40.6 g ofdesired product as a brown solid (LCMS and NMR consistent with 75%desired product with 15% cyclized product6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one and 6.4 g ofcyclized product 6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-oneas a purple solid.

MS (ES+) m/z 226 (MH⁺).

(d) 6-(Methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one

Ethyl N-[2-amino-6-(methyloxy)-3-pyridinyl]glycinate (40.6 g, 135 mmol)was dissolved in tetrahydrofuran (THF) (1 L) at room temperature underargon and treated with potassium tert-butoxide (15.17 g, 135 mmol).After 2 h at room temperature saturated NH₄Cl (500 ml) was added and theTHF evaporated. Water (500 ml) was added followed by 20% MeOH/DCM (1 L);the insoluble material was filtered off, washed with diethyl ether anddried in the vacuum oven at 40° C. overnight to afford the desiredproduct as a yellow solid (15.3 g): LCMS and NMR consistent with product(9% of oxidized material present by NMR).

The two phases were transferred to a separating funnel and separated.The aqueous layer was extracted twice more with 20% MeOH/DCM (2×500 ml)and the combined organic extracts were dried, MgSO₄ filtered andevaporated to afford a brown solid which was washed with plenty ofdiethyl ether to afford more of the desired product as a pale greensolid (7.7 g): LCMS and NMR consistent with product (20% of oxidizedmaterial present by NMR).

MS (ES+) m/z 180 (MH⁺).

Alternative Procedure:

Ethyl N-[2-amino-6-(methyloxy)-3-pyridinyl]glycinate (16.2 g, 72 mmol)was dissolved in tetrahydrofuran (500 ml) and cooled to 0° C. (ice bathcooling) under argon. This was then treated with potassium tert-butoxide(1M in THF, 80 ml, 80 mmol). After 1.5 h the reaction was treated withacetic acid (80 mmol) and evaporated to give a dark solid. This wastriturated with water (200 ml), filtered and dried in vacuo (˜13 g,quant.), which may be used without further purification

(e) Phenylmethyl6-(methyloxy)-3-oxo-3,4-dihydropyrido[2,3-b]pyrazine-1(2H)-carboxylate

To 6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one (6.35 g, 35.4mmol) in ethyl acetate (600 ml)/sodium bicarbonate (sat. solution) (200ml) stirred vigorously was added at room temperature benzylchloroformate (5.31 ml, 37.2 mmol). After 45 minutes the reaction wascomplete. The layers were separated and the organic layer was dried onmagnesium sulphate, filtered and evaporated to afford the desiredproduct as an off-white solid (11 g, 99%).

MS (ES+) m/z 314 (MH⁺).

(f) Phenylmethyl6-(methyloxy)-4-[(2R)-2-oxiranylmethyl]-3-oxo-3,4-dihydropyrido[2,3-b]pyrazine-1(2H)-carboxylate

Phenylmethyl6-(methyloxy)-3-oxo-3,4-dihydropyrido[2,3-b]pyrazine-1(2H)-carboxylate(11 g, 35.1 mmol) was dissolved in DMF (300 ml) at room temperatureunder argon to give a yellow solution. The solution was then cooled withan ice bath and treated with sodium hydride (1.685 g, 42.1 mmol). Thesolution was allowed to warm to room temperature. After 20 minutes(2S)-2-oxiranylmethyl 3-nitrobenzenesulfonate (9.56 g, 36.9 mmol) wasadded. After 1 h all the starting material was consumed so the reactionwas treated with a saturated solution of sodium bicarbonate (350 ml) andthe aqueous layer was extracted with DCM (3×400 ml). The combinedorganic layers were dried on magnesium sulphate, filtered and evaporatedto afford a light brown oil (16.93 g). The product was used as crude inthe next step.

MS (ES+) m/z 370 (MH⁺).

(g) Phenylmethyl(1S)-1-(hydroxymethyl)-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate

Phenylmethyl6-(methyloxy)-4-[(2R)-2-oxiranylmethyl]-3-oxo-3,4-dihydropyrido[2,3-b]pyrazine-1(2H)-carboxylate(crude, 15.93 g, estimated 32.8 mmol) was dissolved in DMF (250 ml) atroom temperature and heated at 130° C. for 2 nights and at 120° C. forone night. The reaction was complete so DMF was evaporated and theresidue treated with water/brine (350/50 ml) and DCM (500 ml). Thelayers were separated and the aqueous layer was extracted once more withDCM (500 ml). The combined organic extracts were dried on magnesiumsulphate, filtered and evaporated to afford a brown oil which was driedunder high vacuum over the weekend. The crude product was purified bysilica chromatography using a 0-10% methanol/dichloromethane gradient toafford the desired product as a golden foam (3.6 g, 30.9%).

MS (ES+) m/z 356 (MH⁺).

(h)(1S)-1-(Hydroxymethyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

Phenylmethyl(1S)-1-(hydroxymethyl)-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate(1.6 g, 4.50 mmol) was dissolved in ethanol (100 ml) at room temperatureand then treated with palladium on carbon (10% paste) (1 g, 0.940 mmol).Everything was stirred at room temperature under 1 atm of hydrogen for 3hours. The reaction was then filtered through a Celite pad and theimpurities washed with more ethanol. The product was then eluted withDMF (400 ml) and the DMF evaporated to afford a brown solid (780 mg).The solid was then suspended in 30% MeOH/DCM (150 ml) and stirred withmanganese dioxide (1.174 g, 13.51 mmol) at room temperature for 5 h andthen filtered through a pad of Celite which was washed with 20%methanol/dichloromethane (100 ml). The solvents were evaporated toafford the desired compound as a brown solid (750 mg, 76%).

MS (ES+) m/z 220 (MH⁺).

(i)[(1S)-3,8-Dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methylmethanesulfonate

(1S)-1-(Hydroxymethyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(750 mg, 3.42 mmol) was suspended in dry DCM (100 ml) at roomtemperature under argon and then treated with triethylamine (0.572 ml,4.11 mmol). The mixture was then cooled using an ice-water bath.Methanesulfonyl chloride (0.293 ml, 3.76 mmol) was then added and thereaction was allowed to warm up to room temperature. After 50 minutesthere was no starting material left so the mixture was washed withsaturated NaHCO₃ (100 ml). The aqueous layer was extracted with 20%MeOH/DCM (2×100 ml); the combined organic extracts were dried onmagnesium sulphate, filtered and evaporated to afford the product as abrown foam (1.05 g, 90% purity by LCMS).

MS (ES+) m/z 297.9 (MH⁺).

(j) 1,1-Dimethylethyl(1-{[(1R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)carbamate

A solution of[(1S)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methylmethanesulfonate (1.05 g, 3.53 mmol) in dry acetonitrile (50 ml) at roomtemperature under argon was treated with pyridine (0.343 ml, 4.24 mmol),followed by 1,1-dimethylethyl 4-piperidinylcarbamate (0.884 g, 4.24mmol). The mixture was heated at 70° C. for 1.5 h and then at 90° C. for3 h. LCMS showed 25% of product. So 0.5 eq of pyridine and 0.5 eq of1,1-dimethylethyl 4-piperidinylcarbamate were added and the reaction washeated at 90° C. overnight and then stirred at room temperature for 2days. The reaction was complete. The solvent was evaporated and theresidue partitioned between sat NaHCO₃ and 20% methanol/dichloromethane(100 ml/100 ml). The layers were separated and the aqueous layer wasextracted with 20% methanol/dichloromethane again (2×100 ml). Thecombined organic extracts were dried on magnesium sulphate, filtered andevaporated to afford 1.7 g of crude which was purified by silicachromatography using a 0-5% methanol/dichloromethane gradient to affordthe product as a yellow solid (0.57 g, 40.2%).

MS (ES+) m/z 402 (MH⁺).

(k)(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride

A solution of 1,1-dimethylethyl(1-{[(1R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)carbamate(0.57 g, 1.420 mmol) in chloroform (7 ml) at room temperature wastreated with 4M HCl in 1,4-dioxane (7 ml). A solid precipitated out andthe mixture was stirred at room temperature. After 0.5 h some methanolwas added to dissolve most of the solid, followed by toluene and all thesolvents were removed to afford the product as a yellow solid (0.53 g,100%).

MS (ES+) m/z 302 (MH⁺).

(l) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (165 mg, 0.441 mmol) in chloroform (10 ml) and methanol(0.4 ml) at room temperature under argon was treated with triethylamine(0.184 ml, 1.323 mmol) and stirred for 0.25 h (the suspension turnedinto a solution). [1,3]Oxathiolo[5,4-c]pyridine-6-carbaldehyde (for asynthesis see WO2004058144 Example 61) (73.7 mg, 0.441 mmol) was thenadded and the reaction was stirred at room temperature for 0.5 h. Sodiumtriacetoxyborohydride (280 mg, 1.323 mmol) was then added and thereaction was stirred at room temperature. After 1.5 h LCMS showed thatthere was still some imine present in the mixture so 1 eq of sodiumtriacetoxyborohydride was added. After 1 h saturated NaHCO₃ (50 ml) wasadded followed by 20% methanol/dichloromethane (80 ml) and the aqueouslayer was extracted and then separated from the organic layer. Theaqueous layer was extracted again twice with 20%methanol/dichloromethane (2×80 ml). The combined organic extracts weredried on magnesium sulphate, filtered and evaporated to afford 215 mg ofcrude product which was purified by silica chromatography using a 0-20%methanol/dichloromethane gradient to afford the free base of the titlecompound as a yellow solid (185 mg, 93%).

δH CDCl₃, (250 MHz) 1.20-1.45 (m, 2H), 1.75-2.75 (m, 8H), 2.94 (d, 1H),3.00-3.15 (m, 1H), 3.81 (s, 2H), 4.30-4.45 (m, 1H), 4.50-4.65 (m, 1H),4.90-5.10 (m, 1H), 5.74 (s, 2H), 6.34 (d, 1H), 7.19 (s, 1H), 7.77 (d,1H), 7.87 (s, 1H), 7.99 (s, 1H).

MS (ES+) m/z 453 (MH⁺).

The title compound was prepared by dissolving the free base inmethanol/dichloromethane and treating it with 1 equivalent of 1M HCl indiethyl ether. This was then evaporated to dryness and dried in thevacuum desiccator in the presence of P₂O₅.

Example 13B(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionebenzoate

(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride (45 mg, 0.092 mmol) was purified using an AD-H column withCH₃CN:CH₃OH:0.1% isopropylamine. The major peak was collected and thesolvent was removed. The benzoate salt was made by dissolving thecompound in MeOH and adding one equivalent of the benzoic acid. Thesolution stirred for 1 hour, the solvent was removed to give theproduct.

Example 13C(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionefumarate

(1R)-1-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride (49 mg, 0.100 mmol) was dissolved in MeOH 10 mL and loadedonto a SCX cartridge 2 g (pre-wet with methanol). The crude was adsorbedonto the cartridge and then the cartridge was washed with methanol (15mL). The product was eluted using 2M NH₃ in methanol (15 mL); thefraction containing the product was evaporated to afford free amineproduct (41.5 mg, 92% recovery). LCMS and NMR consistent with product.The free amine was dissolved in a small amount of DCM/MeOH, treated with1 eq of fumaric acid (10.6 mg) and stirred for 10 minutes. Solvents wereremoved and the solid dried in the desiccator (P₂O₅) overnight to affordthe product as a white solid (51 mg, LCMS and NMR consistent withproduct).

Example 14(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (160 mg, 0.428 mmol) (for a preparation see Example13(k) or 15(d)) in chloroform (10 ml) and methanol (0.400 ml) underargon at room temperature was treated with triethylamine (0.179 ml,1.283 mmol) and stirred for 0.25 h at room temperature (everything wentinto solution). 2,3-Dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde(for a synthesis see WO2004058144, Example 60) (77 mg, 0.428 mmol) wasthen added and the reaction was stirred at room temperature for 0.5 h.Sodium triacetoxyborohydride (272 mg, 1.283 mmol) was then added and thereaction was stirred at room temperature. After 1.5 h there was stillsome imine present by LCMS so 1 equivalent of sodiumtriacetoxyborohydride was added. After 1 h sat NaHCO₃ (50 ml) was addedfollowed by 20% methanol/dichloromethane (80 ml) and the aqueous wasextracted and then separated from the organic layer. The aqueous layerwas extracted again twice with 20% methanol/dichloromethane (2×80 ml).The combined organic extracts were dried on MgSO₄, filtered andevaporated to afford 215 mg of crude product which was purified bysilica chromatography using a 0-20% methanol/dichloromethane gradient toafford the free base of the title compound as yellow foam (179 mg, 90%).

δH CDCl₃, (250 MHz) 1.20-1.50 (m, 2H), 1.85 (t, 2H), 1.95-2.40 (m, 3H),2.45-2.75 (m, 3H), 2.94 (d, 1H), 3.05-3.20 (m, 3H), 3.69 (s, 2H),4.30-4.50 (m, 3H), 4.50-4.65 (m, 1H), 4.90-5.10 (m, 1H), 6.33, (d, 1H),6.99 (s, 1H), 7.67 (d, 1H), 7.86 (s, 1H), 8.01 (s, 1H).

MS (ES+) m/z 467 (MH⁺).

The title compound was prepared by dissolving the free base in DCM/MeOHand treating it with 1 equivalent of 1M HCl in diethyl ether. This wasthen evaporated to dryness and dried in the vacuum desiccator in thepresence of P₂O₅.

Example 15(1R)-1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride

(a) Phenylmethyl(1S)-1-{[(methylsulfonyl)oxy]methyl}-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate

Phenylmethyl(1S)-1-(hydroxymethyl)-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate(242 mg, 0.681 mmol) (for a preparation see Example 13(g)) was dissolvedin DCM (10 ml) at room temperature under argon and then treated withtriethylamine (0.114 ml, 0.817 mmol). The mixture was then cooled usingan ice-water bath. Methanesulfonyl chloride (0.058 ml, 0.749 mmol) wasthen added and the reaction was allowed to warm up to room temperature.After 1 h the mixture was washed with sat NaHCO₃ (10 ml). The aqueouslayer was extracted with DCM (2×50 ml) and the combined organic extractsdried on MgSO₄, filtered and evaporated to afford the product as ayellow foam (232 mg, 95% purity by LCMS, 74.7%).

MS (ES+) m/z 434 (MH⁺).

(b) phenylmethyl(1R)-1-{[4-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]methyl}-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate

Phenylmethyl(1S)-1-{[(methylsulfonyl)oxy]methyl}-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate(232 mg, 0.508 mmol) was dissolved in dry acetonitrile (10 ml) at roomtemperature under argon and treated with pyridine (0.049 ml, 0.610mmol). 1,1-Dimethylethyl 4-piperidinylcarbamate (127 mg, 0.610 mmol) wasthen added and the reaction was heated at 70° C. overnight. Then 0.049ml of pyridine and 127 mg of 1,1-dimethylethyl 4-piperidinylcarbamatewere added to the reaction and the temperature was increased to 80° C.for 8 h and then the reaction was stirred at room temperature overnight.The solvent was evaporated and the residue partitioned between satNaHCO₃ and DCM (50/50 ml). The layers were separated and the aqueouslayer was extracted with DCM again (2×50 ml). The combined organicextracts were dried (MgSO₄) filtered and evaporated to afford 280 mg ofcrude product which was purified by silica chromatography using a 0-5%methanol/dichloromethane gradient to afford the product as a yellow gum(130 mg, 47.6%).

MS (ES+) m/z 538 (MH⁺).

(c) 1,1-Dimethylethyl(1-{[(1R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)carbamate

Phenylmethyl(1R)-1-{[4-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]methyl}-3,8-dioxo-1,2,3,4-tetrahydro-5H,8H-2a,5,8a-triazaacenaphthylene-5-carboxylate(130 mg, 0.242 mmol) was dissolved in ethanol (10 ml) at roomtemperature and then treated with palladium on carbon (10% paste) (100mg, 0.094 mmol). Everything was stirred at room temperature under 1 atmof hydrogen for 3 hours. The reaction was then filtered through a Celitepad and washed with more ethanol (50 ml). The ethanol was evaporated toafford a yellow gum (79 mg) which was dissolved in DCM (˜10 ml) andstirred with manganese dioxide (63.1 mg, 0.725 mmol) at room temperatureovernight. Then 1.5 equivalents more of manganese dioxide were added (32mg) and reaction was stirred at room temperature for 3 h. There wasstill starting material present by LCMS so 2 equivalents of manganesedioxide were added. The reaction was stirred at room temperature for 2 hthen filtered through a Celite pad. The Celite pad was washed with DCMand the solvents were evaporated to afford the product as a brown solid(76 mg, 78%).

MS (ES+) m/z 402 (MH⁺).

(d)(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride

A solution of 1,1-dimethylethyl(1-{[(1R)-3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)carbamate(76 mg, 0.189 mmol) in chloroform (2 ml) at room temperature was treatedwith 4M HCl in 1,4-dioxane (2 ml). A solid precipitated out and themixture was stirred room temperature. After 0.5 h the reaction wascomplete so some methanol was added to dissolve most of the solid,followed by toluene and all the solvents were removed to afford theproduct as a dark yellow solid (70.9 mg, 99%).

MS (ES+) m/z 302 (MH⁺).

(e) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (70 mg, 0.187 mmol) in chloroform (5 ml) and methanol(0.2 ml) at room temperature under argon was treated with triethylamine(0.078 ml, 0.561 mmol) and stirred for 0.25 h. Everything went intosolution; 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde (for asynthesis see WO2004058144 Example 2(c) or WO03/087098 Example 19(d)))(30.9 mg, 0.187 mmol) was then added and the reaction was stirred atroom temperature for 0.5 h. Sodium triacetoxyborohydride (119 mg, 0.561mmol) was then added and the reaction was stirred at room temperature.After 1.5 h 1 eq more of sodium triacetoxyborohydride was added. After 1h sat NaHCO₃ (50 ml) was added followed by 20% MeOH/DCM (50 ml) and theaqueous layer was extracted and then separated from the organic layer.The aqueous layer was extracted again twice with 20% MeOH/DCM (2×50 ml).The combined organic extracts were dried on MgSO₄, filtered andevaporated to afford 90 mg of crude product which was purified by silicachromatography using a 0-20% methanol/dichloromethane gradient to affordthe free base of the title compound as a pale yellow gum (60 mg, 71%).

δH CDCl₃, (250 MHz) 1.25-1.50 (m, 2H), 1.86 (t, 2H), 2.10-2.75 (m, 6H),2.93 (d, 1H), 3.00-3.15 (m, 1H), 3.79 (s, 2H), 4.20-4.45 (m, 5H),4.50-4.65 (m, 1H), 4.90-5.10 (m, 1H), 6.33 (d, 1H), 6.82 (s, 1H), 7.76(d, 1H), 7.86 (s, 1H), 8.11 (s, 1H).

MS (ES+) m/z 451 (MH⁺).

The title compound was prepared by dissolving the free base in DCM/MeOHand treating it with 2 equivalents of 1M HCl in diethyl ether. This wasthen evaporated to dryness and dried in the vacuum desiccator in thepresence of P₂O₅.

Example 16A(2R)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(a) 2-{[6-(Methyloxy)-3-nitro-2-pyridinyl]amino}-1,3-propanediol

6-Methoxy-2-chloro-3-nitropyridine (36.94 g, 195.9 mmol) and2-aminopropane-1.3-diol (35.65 g, 391.3 mmol, 2 eq.) were stirred inethanol (500 ml) at reflux under argon for 3 hours. The mixture wasallowed to cool to room temperature and left overnight. The solvent waspartially removed under reduced pressure (to ca. 150 ml) and theresulting bright yellow slurry was poured into ice-water (1.5 L) withvigorous stirring. The mixture was stirred for 1 hour then filtered withsuction while cold. The solid was washed with ice-cold water (200 ml)and air-dried. to give the title compound as a bright yellow solid(45.03 g, 94%). LCMS showed desired product (93%) plus 7% startingmaterial. The product was used without further purification.

MS (ES+) m/z 244 (MH⁺)

(b)N-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-3-nitro-2-pyridinamine

2-{[6-(Methyloxy)-3-nitro-2-pyridinyl]amino}-1,3-propanediol (53.93 g,228.7 mmol) was stirred in 2,2-dimethoxypropane (900 ml) under argon andp-toluenesulphonic acid monohydrate (1.00 g) was added. The mixture wasstirred at room temperature overnight. This was diluted withdichloromethane (1 L) and the resulting solution was treated withsaturated aqueous sodium hydrogen carbonate (20 ml) and solid sodiumhydrogen carbonate (20 g) with vigorous stirring (effervescence). Themixture was vigorously stirred for 20 minutes, then the remaining waterwas absorbed by addition of anhydrous sodium sulphate. The mixture wasfiltered with suction and the solids were washed with DCM (500 ml). Thecombined filtrate plus washings were evaporated under reduced pressureto give a yellow solid which was stirred with petroleum ether (40-60°)over the weekend. The solid was isolated by filtration with suction,washed with petroleum ether (40-60°) and air-dried to give the titlecompound as a bright yellow solid 57.83 g, 92%).

MS (ES+) m/z 284 (MH⁺).

(c) N²-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-2,3-pyridinediamine

N-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-3-nitro-2-pyridinamine(35.00 g, 123.6 mmol) was divided into 2 aliquots, each of which wastaken up in 1,4-dioxane (500 ml) and hydrogenated over 10% Pd on carbon(paste, 1:1 w:w with water, 4.00 g) under 1 atm. hydrogen pressure, atroom temperature overnight. The mixtures were filtered with suctionthough Celite, using an argon blanket and taking care to minimisecontact of the product with air. The solution was evaporated underreduced pressure to give the title compound as a deep purple oil. Thiswas used immediately in the next step.

MS (ES+) m/z 254 (MH⁺).

(d) EthylN-[2-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-6-(methyloxy)-3-pyridinyl]glycinate

CrudeN²-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-2,3-pyridinediamineprepared in Example 16A(c) (assumed 123.6 mmol) was dissolved inanhydrous DMF (500 ml) under argon and anhydrous potassium carbonate(37.56 g, 2.2 eq.) was added, followed by ethyl bromoacetate (12.31 ml,0.9 eq.). The mixture was stirred at room temperature overnight. Thesolvent was removed under reduced pressure and the resultingreddish-brown slurry was partitioned between DCM (1.2 L) and water (300ml). The organic phase was separated and washed with water (300 ml),dried over sodium sulphate, filtered and evaporated under reducedpressure to give a dark red oil, this was taken up in a minimum of DCMand purified by column chromatography on silica (eluted with 5%-60%ethyl acetate in petroleum ether (40-60°)). Appropriate fractions werecombined and evaporated under reduced pressure to give the titlecompound as a dark orange oil (35.42 g, 84%).

MS (ES+) m/z 340 (MH⁺)

(e)4-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one

EthylN-[2-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-6-(methyloxy)-3-pyridinyl]glycinate(35.42 g, 104.4 mmol) was dissolved in dry THF (500 ml) and the solutionwas added dropwise over 2 hours to a cooled (0° C.) suspension of sodiumhydride (4.173 g of 60% w:w dispersion in oil, 1.00 eq.) in dry THF (500ml) under argon. During the addition the colour of the suspensionchanged from orange to green. The mixture was stirred at 0° C. for afurther 15 minutes, then allowed to warm to room temperature and stirredat rt for 1 hour. The mixture was cooled to 0° C. and saturated ammoniumchloride (15 ml) was added cautiously with vigorous stirring(effervescence observed). After effervescence had ceased, the mixturewas allowed to warm to room temperature and stirred for 4 hours thendiluted with ethyl acetate (500 ml) and filtered with suction. Thesolids were washed with ethyl acetate (300 ml) and the combined filtrateplus washings were evaporated under reduced pressure to give a darkbrown solid. This was stirred with petroleum ether (40-60°) (500 ml)plus ethyl acetate (20 ml) for 2 h and filtered with suction to give alighter brown solid which was washed with petroleum ether (40-60°) (100ml) and air-dried to afford the title compound as an amorphous tan solid(25.37 g, 82.8%).

MS (ES+) m/z 316 (MNa⁺).

(f)4-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one

4-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one(25.37 g) and activated manganese dioxide (120 g, ˜15 eq.) were stirredin DCM (500 ml) at room temperature for 2 hours then overnight. Themixture was filtered with suction and the solids were washed with DCM(2×100 ml). The combined filtrate plus washings were evaporated underreduced pressure to give a brown foam; this was purified by columnchromatography on silica (eluting with 0%-100% ethyl acetate inpetroleum ether (40-60°)). Appropriate fractions were combined andevaporated under reduced pressure to give the title compound as a lighttan solid (17.40 g, 69%).

MS (ES+) m/z 314 (MNa⁺).

(g)4-[2-Hydroxy-1-(hydroxymethyl)ethyl]-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one

4-(2,2-Dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one(17.40 g, 59.7 mmol) was dissolved in tetrahydrofuran (THF) (220 ml) togive a dark yellow solution. 1M HCl aq. (200 ml) was added (transientblue and green colours appeared in the solution) and the now lightyellow solution was stirred at room temperature for 1 hour. The mixturewas concentrated to ca. 300 ml on a rotary evaporator using a cold waterbath (some solid was precipitated during this procedure) then wasstirred vigorously while solid sodium hydrogen carbonate was added inportions (caution: effervescence) until the mixture was ca. pH 8. Theresulting yellow solid was collected by filtration with suction, washedwith water (2×20 ml) and air-dried to give the title compound as anamorphous yellow solid (13.805 g, 91%).

MS (ES+) m/z 252 (MH⁺).

(h)(3,8-Dioxo-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methylmethanesulfonate

In a 1 L round-bottomed flask was placed4-[2-hydroxy-1-(hydroxymethyl)ethyl]-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one(11.330 g, 45.1 mmol). Anhydrous chloroform (280 ml) was added, followedby triethylamine (31.4 ml, 225 mmol), and methanesulfonic anhydride(31.4 g, 180 mmol) to give a dark yellow-brown solution.

During addition of the methanesulphonic anhydride, an exotherm occurredwhich was sufficient to cause the solvent to boil. The mixture wasstirred vigorously at reflux under argon for 4.5 hours. The mixture wasallowed to cool to room temperature, diluted with DCM to ca. 600 ml, andwashed with water (200 ml). The organic phase was separated, and theaqueous phase was extracted with DCM (2×200 ml). The combined organicextracts were dried over anhydrous sodium sulphate, filtered, andevaporated under reduced pressure to give crude mesylate as a dark brownoil. This was left overnight under 40-60° petroleum ether (200 ml) plusDCM (50 ml). The resulting solid was isolated by filtration withsuction, washed with 4:1 petrol:DCM (2×50 ml) and air-dried to give thetitle compound as a brown amorphous solid (6.950 g, 52%)

MS (ES+) m/z 332 (MNa⁺), 298 (MH⁺).

(i) 1,1-Dimethylethyl{1-[(3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methyl]-4-piperidinyl}carbamate

Crude(3,8-dioxo-1,2,5a,8b-tetrahydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methylmethanesulfonate (6.950 g, 23.38 mmol) was dissolved in dry acetonitrile(200 ml) and the mixture was treated with pyridine (7.55 ml, 94.0 mmol)followed by 1,1-dimethylethyl 4-piperidinylcarbamate (10.30 g, 51.4mmol). The mixture was stirred at reflux under argon for 3 h then at 50°C. over the weekend. The mixture was then stirred at 90° C. for 2 hours,then the volatiles were removed under reduced pressure and the residuewas partitioned between DCM (600 ml) and water (100 ml). The organicphase was separated and the aqueous phase was extracted with DCM (2×200ml). The combined organic extracts were washed with water (2×100 ml)dried over anhydrous sodium sulphate, filtered and evaporated underreduced pressure to give a dark tan solid; this was taken up in aminimum of 5% MeOH in DCM and chromatographed on silica, eluting with0-10% MeOH in DCM. Appropriate fractions were combined and evaporatedunder reduced pressure to give the title compound as an amorphous paletan solid (5.444 g, 56.8%).

MS (ES+) m/z 424 (MNa⁺), 402 (MH⁺).

(j)2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(Racemic and Enantiomer 1 and 2 synthesis) Method A (Racemic Synthesis):

1,1-Dimethylethyl{1-[(3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methyl]-4-piperidinyl}carbamate(1.630 g, 4.06 mmol) was suspended in DCM (30 ml) and 4M HCl in1,4-dioxane (15 ml) was added to give a bright yellow suspension (andgas evolution). The bright yellow mixture was allowed to stand at roomtemperature for 1 hour. LCMS showed no starting material remaining. Thesolvents were removed under reduced pressure and the residue was driedunder reduced pressure overnight to give the dihydrochloride salt of thetitle compound as an amorphous tan solid (1.760 g (>theoretical yieldfor the dihydrochloride owing to the presence of residual solvent).

A portion of the crude dihydrochloride (0.513 g) was dissolved inmethanol (4 ml) plus water (1 ml) and applied to an SCX column (10 g)(preconditioned with 2 column volumes of methanol). The column was theneluted, under gravity, using (i) methanol (2×50 ml), (ii) 0.5M ammoniain methanol (3×50 ml fractions). Appropriate fractions were combined andevaporated under reduced pressure to give the crude title compound as atan amorphous solid (410 mg), which contained methanol-insolublematerial not apparent by LCMS (possibly ammonium chloride). The productwas shaken with methanol (30 ml) and the suspension was filtered. Thesolid was washed with methanol (20 ml) and the combined filtrate andwashings were evaporated under reduced pressure to give the titlecompound (360 mg, 87%).

MS (ES+) m/z 302 (MH⁺).

Method B

1,1-Dimethylethyl{1-[(3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methyl]-4-piperidinyl}carbamate(9.735 g, 24.25 mmol) was suspended in DCM (90 ml) and 4M HCl in1,4-dioxane (45 ml) was added to give a bright yellow suspension (andgas evolution). The bright yellow mixture was stirred at roomtemperature for 1 hour. The solvents were removed under reduced pressureto give the crude dihydrochloride as a bright yellow amorphous solid(10.420 g) containing residual solvent)

The racemic dihydrochloride (10.4 g) was resolved into its twoenantiomers by preparative chiral HPLC using a Chiralpak AD (20 microns)preparative column with 50:50:0.1 acetonitrile:methanol:isopropylamineas the mobile phase in three batches. The alpha value was 3.1 andbaseline resolution was observed for all 3 runs. There was no overlapfraction and both enantiomers (as the free bases) were isolated in >99.8ee each.(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(first component eluted): (3.30 g, light beige solid, chiral HPLC: 100%ee).

MS (ES+) m/z 302 (MH⁺).

Optical rotation: alpha D=−1200 (C=1.00, methanol, 21.8° C.).

(2S)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(second component eluted): (3.30 g, light beige solid, chiral HPLC:99.8% ee).

MS (ES+) m/z 302 (MH⁺).

Optical rotation: alpha D=+122° (C=1.00, methanol, 21.8° C.).

(k) Title Compound

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(100 mg, 0.332 mmol) was stirred with[1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (for a synthesis seeWO2004058144 Example 61) (45 mg, 0.811 eq.) in chloroform:methanol (9:1,v:v, 5 ml) at room temperature for 2 hours; the mixture was then treatedwith sodium triacetoxyborohydride (211 mg, 3.0 eq.) with vigorousstirring at room temperature for 30 mins. The mixture was quenched byaddition of saturated aqueous sodium hydrogen carbonate (1 ml). DCM (10ml) was added and vigorous stirring was continued for 10 mins, followedby separation of the phases (hydrophobic frit). The organic phase wasevaporated under reduced pressure and the crude product was purified bycolumn chromatography on silica (eluting with 0-12% (2M NH₃ in MeOH) inDCM). Appropriate fractions were combined and evaporated under reducedpressure and dried on the vacuum line over the weekend to give the freebase of the title compound as a pale yellow foam (70 mg, 44.3%)

MS (ES+) m/z 453 (MH⁺).

¹H NMR (CDCl₃) 8.00 (1H, s); 7.82 (1H, s); 7.77 (1H, d, J=9.7 Hz); 7.18(1H, s); 6.39 (1H, d, J=9.7 Hz); 5.73 (2H, s); 5.03 (1H, m); 4.55 (1H,dd, J=12.5 Hz, 4.6 Hz); 4.38 (1H, dd, J=12.5 Hz, 9.2 Hz); 3.80 (2H, s);3.13 (1H, dd, J=12.9 Hz, 3.5 Hz); 2.93 (1H, m); 2.70 (1H, dd, J=12.9 Hz,9.0 Hz); 2.67 (1H, m); 2.50 (1H, m); 2.33 (1H, dt, J=11.4 Hz, 2.6 Hz);2.25 (1H, dt, J=11.4 Hz, 2.6 Hz); 1.85 (3H, m); 1.36 (2H, m).

Treatment of the above free base (70 mg) in DCM (1 ml) with oneequivalent of 1M HCl in diethyl ether gave, after removal of solventsunder reduced pressure, the title compound as a pale tan amorphous solid(75 mg).

MS (ES+) m/z 453 (MH⁺).

Example 17A(2S)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2S)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j) (100 mg, 0.332 mmol) was stirredwith [1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (for a synthesis seeWO2004058144 Example 61) (45 mg, 0.811 eq.) in chloroform:methanol (9:1,v:v, 5 ml) at room temperature for 2 hours; the mixture was then treatedwith sodium triacetoxyborohydride (211 mg, 3.0 eq.) with vigorousstirring at room temperature for 30 mins. The mixture was quenched byaddition of saturated aqueous sodium hydrogen carbonate (1 ml). DCM (10ml) was added and vigorous stirring was continued for 10 mins, followedby separation of the phases (hydrophobic frit). The organic phase wasevaporated under reduced pressure and the crude product was purified bycolumn chromatography on silica (2M NH₃ in MeOH) in DCM. Appropriatefractions were combined and evaporated under reduced pressure and driedon the vacuum line over the weekend to give the free base of the titlecompound as a pale yellow foam (91 mg, 61%).

MS (ES+) m/z 453 (MH⁺).

¹H NMR (CDCl₃) (identical to that of (2R) enantiomer, Example 16A) 8.00(1H, s); 7.82 (1H, s); 7.77 (1H, d, J=9.7 Hz); 7.18 (1H, s); 6.39 (1H,d, J=9.7 Hz); 5.73 (2H, s); 5.03 (1H, m); 4.55 (1H, dd, J=12.5 Hz, 4.6Hz); 4.38 (1H, dd, J=12.5 Hz, 9.2 Hz); 3.80 (2H, s); 3.13 (1H, dd,J=12.9 Hz, 3.5 Hz); 2.93 (1H, m); 2.70 (1H, dd, J=12.9 Hz, 9.0 Hz); 2.67(1H, m); 2.50 (1H, m); 2.33 (1H, dt, J=11.4 Hz, 2.6 Hz); 2.25 (1H, dt,J=11.4 Hz, 2.6 Hz); 1.85 (3H, m); 1.36 (2H, m).

Treatment of the above free base in DCM (1 ml) with one equivalent of 1MHCl in diethyl ether gave, after removal of solvents under reducedpressure, the title compound as an amorphous yellow solid (95 mg).

MS (ES+) m/z 453 (MH⁺).

Example 182-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

Racemic2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (400 mg, 1.327 mmol) was stirredwith [1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (for a synthesis seeWO2004058144 Example 61) (200 mg, 0.9 eq.) in chloroform:methanol (9:1,v:v, 15 ml) at room temperature for 30 mins; the mixture was thentreated with sodium triacetoxyborohydride (844 mg, 3.0 eq.) withvigorous stirring at room temperature for 30 mins. The reaction wasquenched by addition of saturated aqueous sodium hydrogen carbonate (5ml) and the mixture was stirred at room temperature for 5 mins. Theorganic phase was separated, dried over anhydrous Na₂SO₄ and evaporatedunder reduced pressure. The crude product was purified by columnchromatography on silica (eluting with 0-12% (2M ammonia in methanol) inDCM, appropriate fractions were combined and evaporated under reducedpressure to give the free base of the (racemic) title compound as a paleyellow foam (290 mg, 46.8%).

MS (ES+) m/z 453 (MH⁺).

¹H NMR (CDCl₃) (identical to those of the homochiral samples (Example16A and 17A) except for the position of the NH) 8.00 (1H, s); 7.82 (1H,s); 7.77 (1H, d, J=9.7 Hz); 7.18 (1H, s); 6.39 (1H, d, J=9.7 Hz); 5.73(2H, s); 5.03 (1H, m); 4.55 (1H, dd, J=12.5 Hz, 4.6 Hz); 4.38 (1H, dd,J=12.5 Hz, 9.2 Hz); 3.80 (2H, s); 3.13 (1H, dd, J=12.9 Hz, 3.5 Hz); 2.93(1H, m); 2.70 (1H, dd, J=12.9 Hz, 9.0 Hz); 2.67 (1H, m); 2.50 (1H, m);2.33 (1H, dt, J=11.4 Hz, 2.6 Hz); 2.25 (1H, dt, J=11.4 Hz, 2.6 Hz); 1.85(2H, m); (NH under HOD peak at 1.70); 1.36 (2H, m).

The free base (290 mg) was dissolved in DCM (5 ml) and treated with oneequivalent of 1M HCl in diethyl ether. Evaporation of the solvents underreduced pressure gave the title compound as a pale yellow amorphoussolid (281 mg).

MS (ES+) m/z 453 (MH⁺)

Example 16B(2R)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionebenzoate and Example 17B(2S)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionebenzoate

Racemic2-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride, 200 mg, was resolved into its two enantiomers bypreparative chiral HPLC (using a 21×250 mm Chiralpak IA, (5 microns)preparative column) with 1:1 acetonitrile (containing 0.1%isopropylamine) and acetonitrile (containing 0.1% TFA) as the mobilephase.(2R)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(first component eluted): (81 mg) Optical rotation: {alpha}D at 23.9°C.=−85.580 (C=0.798 in MeOH)

MS (ES+) m/z 302 (MH⁺).

The free base was dissolved in methanol and treated with benzoic acid (1equivalent). Evaporation of the solvents under reduced pressure gave theproduct (Example 16B) as the benzoate salt.(2S)-2-({4-[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(second component eluted): (76 mg)

Optical rotation: {alpha}D at 23.9° C.=+84.9° (C=0.798 in MeOH)

MS (ES+) m/z 302 (MH⁺).

The free base was dissolved in methanol and treated with benzoic acid (1equivalent). Evaporation of the solvents under reduced pressure gave theproduct (Example 17B) as the benzoate salt.

Example 19A(2R)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (600 mg, 1.991 mmol),2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for a synthesissee WO2004058144, Example 60) (325 mg, 0.900 eq.) and 20 μL acetic acidwere stirred in chloroform:methanol (9:1, v:v, 30 ml) at roomtemperature for 2 hours; the mixture was then treated with sodiumtriacetoxyborohydride (1.266 g, 3.0 eq.) with vigorous stirring at roomtemperature for 30 mins. The mixture was quenched by addition ofsaturated aqueous sodium hydrogen carbonate (6 ml). DCM (60 ml) wasadded and vigorous stirring was continued for 10 mins, followed byseparation of the phases (hydrophobic frit). The organic phase wasevaporated under reduced pressure and the crude product was purified bycolumn chromatography on silica (eluting with 0-12% (2M NH₃ in MeOH) inDCM)

Appropriate fractions were combined and evaporated under reducedpressure and dried under vacuum overnight to give the free base of thetitle compound as a pale yellow amorphous solid (658 mg).

MS (ES+) m/z 467 (MH⁺).

¹H NMR (CDCl₃, 400 MHz) 1.25-1.40 (2H, m), 1.80-1.90 (2H, m), 2.20-2.30(1H, m), 2.30-2.40 (1H, m), 2.45-2.55 (1H, m), 2.65-2.75 (2H, m),2.90-2.95 (1H, m), 3.10-3.20 (3H, m), 3.75 (2H, s), 4.35-4.45 (3H, m),4.50-4.60 (1H, dd), 5.00-5.10 (1H, m), 6.40 (1H, d), 7.00 (1H, s), 7.75(1H, d), 7.85 (1H, s), 8.05 (1H, s).

The free base (650 mg, 1.393 mmol) was suspended in dry DCM (10 ml) anda 1M solution of hydrogen chloride in diethyl ether (1393 μL, 1.000 eq.)was added. The system was kept sealed and shaken for 1 minute then thesolvents were removed under reduced pressure and the residue was driedunder vacuum to give the title compound as an amorphous yellow solid(682 mg).

Example 202-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride Example 19B(2R)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionetrifluoroacetate And Example 21(2S)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

Racemic2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (360 mg, 1.195 mmol) was stirredwith 2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for asynthesis see WO2004058144, Example 60) (195 mg, 0.9 eq.) inchloroform:methanol (9:1, v:v, 15 ml) at room temperature for 30 mins;the mixture was then treated with sodium triacetoxyborohydride (760 mg,3.0 eq.) with vigorous stirring at room temperature for 30 mins. Thereaction was quenched by addition of saturated aqueous sodium hydrogencarbonate (5 ml) and the mixture was stirred at room temperature for 5mins. The organic phase was separated, dried over anhydrous Na₂SO₄ andevaporated under reduced pressure. The crude product was purified bycolumn chromatography on silica (eluting with 0-12% (2M ammonia inmethanol) in DCM, appropriate fractions were combined and evaporatedunder reduced pressure to give the free base of the title compound as apale yellow foam (235 mg, 42%).

NMR and LC-MS identical to product of Example 19A.

The free base (225 mg) was dissolved in DCM (5 ml) and treated with oneequivalent of 1M HCl in diethyl ether. Evaporation of the solvents underreduced pressure gave the title compound (Example 20) as a pale yellowamorphous solid (224 mg).

MS (ES+) m/z 467 (MH⁺).

The title racemic hydrochloride (Example 20), 80 mg, was resolved intoits two enantiomers by preparative chiral HPLC (using a 21×250 mmChiralpak IA, (5 microns) preparative column) with 2:2:1methanol:acetonitrile:t-butanol (containing 0.1% isopropylamine) as themobile phase.(2R)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(first component eluted): (31 mg) MS (ES+) m/z 467 (MH⁺).

The 2R material was of 98.7% purity; further purification was effectedby reverse-phase HPLC on a Kromasil 5 micron C-18 column (21 mm×250 mm)eluted with 9:1 water (+0.1% TFA) and acetonitrile (+0.1% TFA) (3 runs)to give the di-trifluoroacetate salt (Example 19B).(2S)-2-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(second component eluted): (32 mg) (Example 21). The stereochemistry ofthis compound was determined by small molecule x-ray crystallography. MS(ES+) m/z 467 (MH⁺).

Example 222-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

Racemic2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (50 mg, 0.166 mmol) was stirredin 9:1 v:v chloroform:methanol (2 ml) with2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde (for a synthesissee WO2004058144 Example 2(c) or WO03/087098 Example 19(d)) (28 mg, 1.0equivalent) at room temperature for 30 minutes, then the mixture wastreated with sodium triacetoxyborohydride (105 mg, 3.0 equivalents) withvigorous stirring. After a further 25 minutes stirring, the reaction wasquenched by addition of saturated aqueous sodium hydrogen carbonate (2ml), diluted with dichloromethane and stirred vigorously at roomtemperature for 20 minutes. The organic phase was separated (hydrophobicfrit) and evaporated under reduced pressure to give an orange gum; thiswas purified by column chromatography on silica (eluting with 0-12% (2MNH₃ in MeOH) in DCM). Appropriate fractions were combined and evaporatedunder reduced pressure to give the free base of the title compound as acream amorphous solid (30 mg, 40%).

MS (ES+) m/z 451 (MH⁺).

¹H NMR (CD₃OD) δ 7.98 (1H, s); 7.88 (1H, d, J=9.7 Hz); 7.77 (1H, s);6.94 (1H, s); 6.37 (1H, d, J=9.7 Hz); 5.12 (1H, m); 4.43 (2H, m); 4.35(2H, m); 4.29 (2H, m); 3.73 (2H, s); 3.07 (1H, m); 3.03 (1H, m); 2.83(1H, dd, J=13.2 Hz, 8.3 Hz); 2.70 (1H, m); 2.44 (1H, m); 2.26 (1H, dt,J=11.6 Hz, 2.4 Hz); 2.18 (1H, dt, J=11.6 Hz, 2.4 Hz); 1.85 (2H, m); 1.33(2H, m).

The free base was dissolved in DCM (1 ml) and treated with a 1M solutionof hydrogen chloride in diethyl ether (67 μL, 1.0 equivalent); thevessel was sealed and kept at room temperature for 5 minutes then thesolvents were removed under reduced pressure to give the title compound(20 mg; some product lost due to splashing on evaporation of solvents).

MS (ES+) m/z 451 (MH⁺).

Example 23(1R)-1-({4-[(2,3-Dihydro[1,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-4-methyl-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride

(a) 1,1-Dimethylethyl4-methyl-4-({[(phenylmethyl)oxy]carbonyl}amino)-1-piperidinecarboxylate

A solution of1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-methyl-4-piperidinecarboxylicacid (12.092 g, 49.7 mmol) in toluene (300 ml) was treated withtriethylamine (13.85 ml, 99 mmol) and then diphenylphosphoryl azide(21.42 ml, 99 mmol), heated to 90° C. for 2 h (bubbling observed) beforetreatment with benzyl alcohol (10.34 ml, 99 mmol). The reaction was thenheated at 90° C. for a further 18 h, then cooled, treated with saturatedaqueous sodium bicarbonate (500 ml), the organic extracts were separatedand the aqueous extracted with diethyl ether (200 ml), the combinedorganic extracts were dried (MgSO₄), filtered, evaporated, columned(0-50% ethyl acetate:40-60 petroleum ether, Rf=0.4 in 4:1 ethylacetate:40-60 petroleum ether) to give product as a clear oil (15.473 g,89%).

(b) Phenylmethyl (4-methyl-4-piperidinyl)carbamate

A solution of 1,1-dimethylethyl4-methyl-4-({[(phenylmethyl)oxy]carbonyl}amino)-1-piperidinecarboxylate(15.473 g, 44.4 mmol) in DCM (50 ml) under argon at rt, was treated withtrifluoroacetic acid (50 ml, 649 mmol) and stirred at rt for 0.5 h. Thereaction mixture was then evaporated, dissolved in water (200 ml),washed with diethyl ether (3×200 ml). The aqueous phase was thenbasified with solid potassium carbonate, extracted with 20% methanol/DCM(3×200 ml), these organic extracts were then dried (MgSO₄), filtered andevaporated to give the product as a yellow oil (6.327 g, 57%).

MS (ES+) m/z 249 (MH⁺).

(c) Phenylmethyl(1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-methyl-4-piperidinyl)carbamate

A solution of(1S)-1-(hydroxymethyl)-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(g)) (1.494 g, 6.78 mmol) in DCM (50ml) at 0° C. under argon was treated with triethylamine (1.7 ml, 12.20mmol) and then methanesulfonyl chloride (0.800 ml, 10.27 mmol) and thenallowed to warm to rt and stirred at rt for 1 h. The reaction mixturewas then treated with saturated aqueous bicarbonate (200 ml) and themixture was extracted with DCM (3×200 ml). The combined organic solventswere then dried (MgSO₄), filtered, evaporated to give the crude mesylate(2.082 g, 6.987 mmol, 103% crude yield). The mesylate was dissolved indry acetonitrile (30 ml) and then treated with pyridine (1.097 ml, 13.57mmol) and a solution of phenylmethyl (4-methyl-4-piperidinyl)carbamate(3.164 g, 12.74 mmol) in dry acetonitrile (20 ml) and heated at reflux(heating block 95° C.) for 6 h. The reaction mixture was thenevaporated, treated with saturated aqueous NaHCO₃ (200 ml) and themixture was extracted with DCM (3×200 ml). The combined organic solventswere then dried (MgSO₄), filtered, evaporated to give the crude productas an orange solid which was then chromatographed (0-10% methanol/DCM,Rf=0.5 in 10% methanol/DCM) to give product as a yellow solid (1.848 g,61%).

MS (ES+) m/z 451 (MH⁺).

(d)(1R)-1-[(4-Amino-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

A solution of phenylmethyl(1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-methyl-4-piperidinyl)carbamate(1.848 g, 4.10 mmol) in ethanol at rt under argon was treated withpalladium on carbon (10% paste) (0.462 g, 4.34 mmol) (20% w/w) andstirred under 1 atmosphere of hydrogen for 2 h, reaction mixture wasfiltered through a thin pad of Kielselguhr eluting with ethanol (100ml). The filtrate was treated with palladium on carbon (10% paste)(0.462 g, 4.34 mmol) and and stirred under 1 atm of hydrogen for 18 h.The reaction mixture was filtered through a thin pad of Kielselguhreluting with ethanol (500 ml) and the filtrate was then evaporated togive the product as a yellow solid (1.294 g, 100%).

MS (ES+) m/z 317 (MH⁺).

(e)(1R)-1-[(4-Isocyanato-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

A solution of(1R)-1-[(4-amino-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(1.294 g, 4.09 mmol) in DCM (30 ml) under argon at rt was treated withtriethylamine (0.684 ml, 4.91 mmol), then di-tert-butyl dicarbonate(1.045 ml, 4.50 mmol) and finally 4-dimethylaminopyridine (0.050 g,0.409 mmol) and stirred at rt for 1 h. The reaction mixture was treatedwith aq sodium bicarbonate (100 ml) and extracted with DCM (3×200 ml).The combined organic fractions were dried (MgSO₄), filtered andevaporated to give the crude product as a yellow solid which was thenchromatographed (0-10% methanol/DCM, Rf=0.5 in 10% methanol/DCM) to givethe product as a white solid (561 mg, 40%).

MS (ES+) m/z 343 (MH⁺).

(f)(1R)-1-[(4-Amino-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

A solution of(1R)-1-[(4-isocyanato-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(561 mg, 1.638 mmol) in THF (10 ml) and water (10.00 ml) at rt wastreated with sodium hydroxide (5 ml, 10.00 mmol), and stirred at rt for1 h. Reaction was then treated with concentrated HCl (5 ml, 12M) andstirred at rt for 18 h, then evaporated. The resultant solid was treatedwith methanol (20 ml) and then the solvent was decanted from the solidand evaporated to give the product as an impure green solid (687 mg,108%).

MS (ES+) m/z 317 (MH⁺).

(g)N-(1-{[(2R)-4,9-Dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-methyl-4-piperidinyl)-2,2,2-trifluoroacetamide

A solution of(1R)-1-[(4-amino-4-methyl-1-piperidinyl)methyl]-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(687 mg, 1.765 mmol) in DCM (20 ml) and triethylamine (1.476 ml, 10.59mmol) at 0° C. under argon was treated with trifluoroacetic anhydride(0.299 ml, 2.118 mmol) and stirred at rt for 1 h. The reaction wastreated with saturated sodium bicarbonate (50 ml) and extracted with DCM(3×100 ml). The combined organic solvents were then dried (MgSO₄),filtered, evaporated to give the crude product as an orange solid whichwas then chromatographed (0-10% methanol/DCM, Rf=0.4 in 10%methanol/DCM) to give product as an impure yellow solid (375 mg, 52%).

MS (ES+) m/z 413 (MH⁺).

(h)N-(1-{[(1R)-4,9-Dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-4-methyl-4-piperidinyl)-2,2,2-trifluoroacetamide

A solution ofN-(1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-4-methyl-4-piperidinyl)-2,2,2-trifluoroacetamide(375 mg, 0.909 mmol) in 1,4-dioxane (20 ml) at rt was treated with DDQ(248 mg, 1.091 mmol) and then heated at 80° C. for 1 h. The reaction wasthen cooled to rt. The reaction mixture was treated with saturatedaqueous K₂CO₃ (5%, 100 ml), then with DCM (100 ml) and the mixturefiltered through Kieselguhr. The organic fraction was separated and theaqueous layer extracted with DCM (2×100 ml). The combined organicsolvents were then dried (MgSO₄), filtered and evaporated to give thecrude product as a yellow oil. Chromatography on silica (0-10%methanol:DCM, Rf=0.4 in 10% MeOH/DCM) gave the product as a clear oil(171 mg, 46%).

MS (ES+) m/z 411 (MH⁺).

(i)(1R)-1-[(4-Amino-4-methyl-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

N-(1-{[(1R)-4,9-Dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-4-methyl-4-piperidinyl)-2,2,2-trifluoroacetamide(171 mg, 0.417 mmol) was treated with a 7% solution of potassiumcarbonate (450 mg in 2 ml water/5 ml methanol) and stirred at rt for 2h, and then at 70° C. for 18 h then evaporated and dissolved in 5%MeOH/DCM (100 ml), filtered and purified by SCX (5 g, eluting with MeOHand then 0.5M NH₃/MeOH and then 2M NH₃/MeOH). Fractions containingproduct were then evaporated to give product as a pink solid (60 mg,46%)

MS (ES+) m/z 315 (MH⁺).

(j) Title Compound

A suspension of(1R)-1-[(4-amino-4-methyl-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(34 mg, 0.108 mmol) in chloroform (2 ml) and methanol (0.1 ml) at rtunder argon was treated with2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (19.60 mg, 0.108mmol) (for a synthesis see WO2004058144, Example 60) and stirred for 2h. The solution was then treated with sodium triacetoxyborohydride (68.8mg, 0.324 mmol) and stirred at rt for 0.5 h. The reaction was thentreated with saturated aqueous NaHCO₃ (20 ml) and extracted with 20%methanol/DCM (3×100 ml). The combined organic extracts were dried(MgSO₄), filtered, evaporated and chromatographed (0-20% methanol/DCM,Rf=0.4 in 15% methanol/DCM) to give the free base of the title compoundas a light brown solid (32 mg, 0.067 mmol, 62%).

MS (ES+) m/z 517 (MH⁺).

δH (CDCl₃, 250 MHz) 1.14 (3H, s), 1.42-1.70 (4H, m), 2.30-2.45 (1H, m),2.50-2.82 (4H, m), 3.05-3.22 (3H, m), 3.68 (2H, s), 4.28-4.48 (3H, m)4.51-4.63 (1H, m), 4.96-5.11 (1H, m), 6.20-6.35 (2H, m), 7.04 (1H, s),7.46-7.51 (2H, m), 8.00 (1H, s).

The free base in DCM/MeOH 2:1 (10 ml) was treated with 1M HCl in diethylether and then evaporated to give the title mono-hydrochloride salt as awhite solid (34 mg)

Example 24(1R)-1-({4-Methyl-4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-j]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-[(4-amino-4-methyl-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(26 mg, 0.083 mmol) (for a preparation see Example 23(i)) in chloroform(2 ml) and methanol (0.1 ml) at rt under argon was treated with[1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (13.83 mg, 0.083 mmol) (fora synthesis see WO2004058144 Example 61) and stirred at rt for 2 h. Thesolution was then treated with sodium triacetoxyborohydride (52.6 mg,0.248 mmol) and stirred at rt for 0.5 h. The reaction was then treatedwith saturated aqueous NaHCO₃ (10 ml) and extracted with 20%methanol/DCM (3×50 ml). The combined organic fractions were dried(MgSO₄), filtered, evaporated and chromatographed (0-20% methanol/DCM,Rf=0.3 in 15% methanol/DCM) to give the free base of the title compoundas a yellow solid (29 mg, 75%,).

MS (ES+) m/z 466 (MH⁺).

δH (CDCl₃, 250 MHz) 1.14 (3H, s), 1.40-1.71 (4H, m), 2.30-2.46 (1H, m),2.51-2.82 (4H, m), 3.08-3.22 (1H, m), 3.73 (2H, s), 4.28-4.42 (1H, m)4.51-4.65 (1H, m), 4.92-5.09 (1H, m), 5.72 (2H, s), 6.20-6.34 (2H, m),7.25 (1H, s), 7.50-7.51 (2H, m), 7.98 (1H, s).

The free base in DCM/MeOH 2:1 (5 ml) was treated with 1M HCl in diethylether and then evaporated to give the title mono-hydrochloride salt.

Example 25(2R)-2-({4-[(2,1,3-Benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(50 mg, 0.166 mmol) (for a preparation see Example 16(j)) and2,1,3-benzothiadiazole-5-carbaldehyde (25 mg, 0.918 eq.) were stirred in9:1 v:v chloroform:methanol (1 ml) for 2.5 hours. Sodiumtriacetoxyborohydride (105 mg, 3.000 eq.) was then added in one portionand the mixture was stirred vigorously at room temperature for 30 min.Saturated aqueous sodium hydrogen carbonate (0.5 ml) was then added,followed by dichloromethane (10 ml) and the mixture was stirredvigorously at room temperature for 10 min and the phases were separated(hydrophobic frit). The organic phase was evaporated under reducedpressure and the crude product was purified by column chromatography onsilica (eluted with 0-12% (2M NH₃ in MeOH) in DCM). Appropriatefractions were combined and evaporated under reduced pressure to givethe free base of the title compound as a yellow solid (41 mg).

MS (ES+) m/z 450 (MH⁺).

¹H NMR (CDCl₃): δ 7.95 (1H, d, J 9.0 Hz); 7.90 (1H, s); 7.83 (1H, s);7.77 (1H, d, J 9.7 Hz); 7.61 (1H, dd, J=9.2 Hz, 1.8 Hz); 6.39 (1H, d,J=9.7 Hz); 5.03 (1H, m); 4.56 (1H, dd, J=12.5 Hz, 4.6 Hz); 4.39 (1H, dd,J=12.5 Hz, 9.2 Hz); 3.98 (2H, s); 3.14 (1H, dd, J=13.2 Hz, 3.5 Hz); 2.94(1H, broad m); 2.69 (2H, m); 2.56 (1H, m); 2.34 (1H, dt, J=11.4 Hz, 2.6Hz); 2.25 (1H, dt, J=11.4 Hz, 2.6 Hz); 1.89 (2H, m); (NH under HOD peakat 1.48); 1.37 (2H, m).

The free base (35 mg, 0.078 mmol) was dissolved in DCM (1 ml) andhydrogen chloride (1.0M) in diethyl ether (78 μL, 1.0 eq.) was added.The system was sealed and shaken at room temperature for 1 minute, thenthe solvents were removed under reduced pressure to give the titlecompound as a yellow solid (38 mg).

MS (ES+) m/z 450 (MH⁺).

Example 26(2R)-2-[(4-{[(7-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(50 mg, 0.166 mmol) (for a preparation see Example 16(j)) and7-fluoro-2,3-dihydro-benzo[1,4]dioxin-6-carboxaldehyde (28 mg, 0.926eq.) (for a synthesis see WO2002056882, Example 23(a)) were stirred in9:1 v:v chloroform:methanol (1 ml) for 2.5 hours. Sodiumtriacetoxyborohydride (105 mg, 3.000 eq.) was then added in one portionand the mixture was stirred vigorously at room temperature for 30 min.Saturated aqueous sodium hydrogen carbonate (0.5 ml) was then added,followed by dichloromethane (10 ml) and the mixture was stirredvigorously at room temperature for 10 min and the phases were separated(hydrophobic frit). The organic phase was evaporated under reducedpressure and the crude product was purified by column chromatography onsilica (eluted with 0-12% (2M NH₃ in MeOH) in DCM. Appropriate fractionswere combined and evaporated under reduced pressure to give the freebase of the title compound as a white solid (48 mg).

MS (ES+) m/z 468 (MH⁺).

¹H NMR (CDCl₃): δ 7.82 (1H, s); 7.76 (1H, d, J=9.7 Hz); 6.79 (1H, d, J7.2 Hz); 6.57 (1H, d, J 10.5 Hz); 6.38 (1H, d, J=9.7 Hz); 5.03 (1H, m);4.54 (1H, dd, J=12.5 Hz, 4.4 Hz); 4.38 (1H, dd, J=12.5 Hz, 9.4 Hz); 4.23(4H, m); 3.71 (2H, s); 3.12 (1H, dd, J=12.9 Hz, 3.3 Hz); 2.92 (1H, m);2.68 (2H, m); 2.68 (2H, m); 2.47 (1H, m); 2.33 (1H, dt, J=11.4 Hz, 2.6Hz); 2.24 (1H, dt, J=11.4 Hz, 2.6 Hz); 1.83 (2H, m); (NH under HOD peakat 1.50); 1.33 (2H, m).

The free base (48 mg, 0.103 mmol) was dissolved in DCM (1 ml) andhydrogen chloride (1.0M) in diethyl ether (103 μL, 1.0 eq.) was added.The system was sealed and shaken at room temperature for 1 minute, thenthe solvents were removed under reduced pressure to give the titlecompound as a yellow solid (55 mg)

MS (ES+) m/z 468 (MH⁺).

Example 27(2R)-2-({4-[(3,4-Dihydro-2H-[1,4]oxathiepino[2,3-c]pyridin-8-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(50 mg, 0.166 mmol) (for a preparation see Example 16(j)) and3,4-dihydro-2H-[1,4]oxathiepino[2,3-c]pyridine-8-carbaldehyde (29 mg,0.895 eq.) (may be prepared analogously to the synthesis of2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (WO2004058144,Example 60) but replacing dibromoethane with dibromopropane) werestirred in 9:1 v:v chloroform:methanol (1 ml) for 2.5 hours. Sodiumtriacetoxyborohydride (105 mg, 3.000 eq.) was then added in one portionand the mixture was stirred vigorously at room temperature for 30minutes. Saturated aqueous sodium hydrogen carbonate (0.5 ml) was thenadded, followed by dichloromethane (10 ml) and the mixture was stirredvigorously at room temperature for 10 min and the phases were separated(hydrophobic frit). The organic phase was evaporated under reducedpressure and the crude product was purified by column chromatography onsilica (eluted with 0-12% (2M NH₃ in MeOH) in DCM). Appropriatefractions were combined and evaporated under reduced pressure to givethe free base of the title compound as a pale yellow solid (65 mg).

MS (ES+) m/z 481 (MH⁺).

¹H NMR (CDCl₃): δ 8.12 (1H, s); 7.82 (1H, s); 7.76 (1H, d, J=9.7 Hz);7.17 (1H, s); 6.38 (1H, d, J 9.7 Hz); 5.03 (1H, m); 4.55 (1H, dd, J=12.5Hz, 4.5 Hz); 4.37 (3H, m); 3.79 (2H, s); 3.13 (3H, m); 2.94 (1H, m);2.69 (2H, m); 2.52 (1H, m); 2.30 (4H, m); 1.86 (3H, m); 1.37 (2H, m).

The free base (60 mg, 0.125 mmol) was suspended in dry DCM (1 ml) and a1M solution of hydrogen chloride in diethyl ether (125 μL, 1.000 eq.)was added. The system was kept sealed and shaken for 1 minute then thesolvents were removed under reduced pressure and the residue was driedon the vacuum line to give the title compound as an amorphous yellowsolid (64 mg).

MS (ES+) m/z 481 (MH⁺).

Example 28(2R)-2-({4-[([1,3]Oxathiolo[4,5-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(a) [1,3]Oxathiolo[4,5-c]pyridine-6-carbaldehyde

The title compound was prepared by: (i) treatment of[5-({[4-(methyloxy)phenyl]methyl}oxy)-4-oxo-1,4-dihydro-2-pyridinyl]methylacetate (for a synthesis see WO2004058144, Example 60(c)) withtriphenylphospine, diisopropylazodicarboxylate and benzyl alcohol togive{5-({[4-(methyloxy)phenyl]methyl}oxy)-4-[(phenylmethyl)oxy]-2-pyridinyl}methylacetate; (ii) treatment of{5-({[4-(methyloxy)phenyl]methyl}oxy)-4-[(phenylmethyl)oxy]-2-pyridinyl}methylacetate with trifluoroacetic acid and triethylsilane to give{5-hydroxy-4-[(phenylmethyl)oxy]-2-pyridinyl}methyl acetatetrifluoroacetate; (iii) treatment of{5-hydroxy-4-[(phenylmethyl)oxy]-2-pyridinyl}methyl acetatetrifluoroacetate with1,1,1-trifluoro-N-phenyl-N-[(trifluoromethyl)sulfonyl]methanesulfonamideand triethylamine to give(4-[(phenylmethyl)oxy]-5-{[(trifluoromethyl)sulfonyl]oxy}-2-pyridinyl)methylacetate; (iv) treatment of(4-[(phenylmethyl)oxy]-5-{[(trifluoromethyl)sulfonyl]oxy}-2-pyridinyl)methylacetate with (R)-(+)-2,2 bis(diphenylphosphino)-1,1-binaphthyl,palladium acetate and sodium 2-methyl-2-propanethiolate to give{5-[(1,1-dimethylethyl)thio]-4-[(phenylmethyl)oxy]-2-pyridinyl}methylacetate; (v) treatment of{5-[(1,1-dimethylethyl)thio]-4-[(phenylmethyl)oxy]-2-pyridinyl}methylacetate with palladium on carbon under 1 atmosphere of hydrogen to give{5-[(1,1-dimethylethyl)thio]-4-oxo-1,4-dihydro-2-pyridinyl}methylacetate; (vi) treatment of{5-[(1,1-dimethylethyl)thio]-4-oxo-1,4-dihydro-2-pyridinyl}methylacetate with concentrated hydrochloric acid to give2-(hydroxymethyl)-5-mercapto-4(1H)-pyridinone; (vii) treatment of2-(hydroxymethyl)-5-mercapto-4(1H)-pyridinone with potassium carbonateand dibromomethane to give [1,3]oxathiolo[4,5-c]pyridin-6-ylmethanol and(viii) treatment of [1,3]oxathiolo[4,5-c]pyridin-6-ylmethanol withmanganese dioxide to give the title compound.

(b) Title Compound

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(50 mg, 0.166 mmol) (for a preparation see Example 16(j)) and[1,3]oxathiolo[4,5-c]pyridine-6-carbaldehyde (25 mg, 0.901 eq.) werestirred in 9:1 v:v chloroform:methanol (1 ml) for 2.5 hours. Sodiumtriacetoxyborohydride (105 mg, 3.000 eq.) was then added in one portionand the mixture was stirred vigorously at room temperature for 30 min.Saturated aqueous sodium hydrogen carbonate (0.5 ML) was then added,followed by dichloromethane (10 ml) and the mixture was stirredvigorously at room temperature for 10 min and the phases were separated(hydrophobic frit). The organic phase was evaporated under reducedpressure and the crude product was purified by column chromatography onsilica (eluted with 0-12% (2M NH₃ in MeOH) in DCM). Appropriatefractions were combined and evaporated under reduced pressure to givethe free base of the title compound as a pale yellow amorphous solid (48mg).

¹H NMR (CDCl₃) δ 8.22 (1H, s); 7.82 (1H, s); 7.76 (1H, d, J=9.7 Hz);6.80 (1H, s); 6.38 (1H, d, J=9.7 Hz); 5.77 (2H, s); 5.03 (1H, m); 4.55(1H, dd, J=12.5 Hz, 4.6 Hz); 4.38 (1H, dd, J=12.5 Hz, 9.4 Hz); 3.81 (2H,s); 3.13 (1H, dd, J=13.0 Hz, 3.5 Hz); 2.93 (1H, m); 2.68 (2H, m); 2.49(1H, m); 2.33 (1H, dt, J=11.4 Hz, 2.6 Hz); 2.24 (1H, dt, J=11.4 Hz, 2.6Hz); 1.84 (3H, m); (NH under HOD peak at 1.66); 1.34 (2H, m).

MS (ES+) m/z 453 (MH⁺).

The free base of the title compound (48 mg, 0.106 mmol) was suspended indry DCM (1 ml) and a 1M solution of hydrogen chloride in diethyl ether(106 μL, 1.000 eq.) was added. The system was kept sealed and shaken for1 minute then the solvents were removed under reduced pressure and theresidue was dried on the vacuum line to give the title compound as anamorphous yellow solid (48 mg).

MS (ES+) m/z 453 (MH⁺).

Example 29(2R)-2-[(4-{[(3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(2R)-2-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(50 mg, 0.166 mmol) (for a preparation see Example 16(j)) and3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde (29 mg,0.90 eq.) (for a synthesis see WO2003087098, Example 301(d)) werestirred in 9:1 chloroform:methanol (1 ml) at room temperature for 3hours, then sodium triacetoxyborohydride (105 mg, 3.00 eq.) was added.The mixture was stirred at room temperature for a further 30 minutes,then saturated aqueous sodium hydrogen carbonate (0.5 ml) was added, andthe organic phase was diluted with DCM (10 ml). The mixture was stirredvigorously for 10 minutes, then the organic phase was separated(hydrophobic frit) and evaporated under reduced pressure. The residuewas taken up in DCM (ca. 3 ml)+1 drop MeOH and purified by columnchromatography on silica (eluted with 0-12% (2M NH₃ in MeOH) in DCM).Appropriate fractions were combined and evaporated to give the free baseof the title compound as a yellow amorphous solid.

¹H NMR (CDCl₃) δ 8.58 (1H, broad s); 7.83 (1H, s); 7.77 (1H, d, J=9.7Hz); 7.57 (1H, d, J 7.8 Hz); 6.97 (1H, d, J 7.8 Hz); 6.38 (1H, d, J=9.7Hz); 5.04 (1H, m); 4.55 (1H, dd, J=12.5 Hz, 4.5 Hz); 4.38 (1H, dd,J=12.5 Hz, 9.3 Hz); 3.82 (2H, s); 3.47 (2H, s): 3.14 (1H, dd, J=13.0 Hz,3.5 Hz); 2.94 (1H, m); 2.69 (2H, m); 2.51 (1H, m); 2.33 (1H, dt, J=11.4Hz, 2.4 Hz); 2.25 (1H, dt, J=11.4 Hz, 2.4 Hz); (NH under HOD peak at2.06); 1.85 (2H, m); 1.37 (2H, m).

MS (ES+) m/z 480 (MH⁺).

The free base of the title compound (43 mg, 0.090 mmol) was dissolved inDCM (2 ml) and a 1M solution of hydrogen chloride in diethyl ether wasadded. The system was kept sealed and shaken for 1 minute then thesolvents were removed under reduced pressure and the residue was driedon the vacuum line to give the title compound as an amorphous yellowsolid (38 mg).

MS (ES+) m/z 480 (MH⁺).

The solvents were removed and the solid dried in the desiccator (P₂O₅)overnight to afford the product as a white solid (51 mg, LCMS and NMRconsistent with product).

Example 30(1R)-1-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (60 mg, 0.161mmol) in chloroform (2 ml) and methanol (0.100 ml) at rt under argon wastreated with triethylamine (0.067 ml, 0.482 mmol) and stirred at rt for15 h. The solution was then treated with2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (commerciallyavailable)(23.75 mg, 0.145 mmol) and stirred for a further 30 min. Thesolution was then treated with sodium triacetoxyborohydride (102 mg,0.482 mmol) and stirred at rt for 30 min, LC-MS after 30 min showed somestarting material present, more sodium triacetoxyborohydride (19 mg) wasadded, the reaction was stirred for 15 min. This was then treated withsaturated aqueous NaHCO₃ (10 ml) and extracted with 20% methanol/DCM(3×25 ml). The combined organic extracts were dried (MgSO₄), filtered,evaporated and chromatographed (0-20% methanol/DCM) to give the titlecompound as the free base (48 mg, 67%) as a yellow gum.

¹H NMR δH CDCl₃, (250 MHz) 1.28-1.51 (m, 2H), 1.75-1.99 (m, 2H),2.13-2.38 (m, 2H), 2.41-2.80 (m, 3H), 2.90-3.15 (m, 2H), 3.75 (s, 2H),4.22 (s, 4H), 4.31-4.42 (m, 1H), 4.51-4.62 (m, 1H), 4.90-5.08 (m, 1H),6.20-6.32 (m, 2H), 6.81 (m, 2H), 6.84 (m, 1H), 7.42-7.53 (m, 2H).

MS (ES+) m/z 449 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether and thenevaporated to give the title compound as the mono-HCl salt (44 mg, 53%).LCMS was consistent with product.

Example 31(1R)-1-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-({4-[(1,2,3-benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochoride (for a preparation see Example 5A(j)) (50 mg, 0.134 mmol)in chloroform (2 ml) and methanol (0.100 ml) at rt under argon wastreated with triethylamine (0.056 ml, 0.402 mmol) and stirred at rt for15 min. The solution was then treated with8-fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (for a synthesis seeWO2007122258, Example 8(b)) (21.96 mg, 0.121 mmol) and stirred for afurther 30 min. The solution was treated with sodiumtriacetoxyborohydride (85 mg, 0.402 mmol) and stirred at rt for 30 min,LCMS after 30 min showed there was still starting material and the imineof the product. So more sodium triacetoxyborohydride (40 mg) was added,the reaction was stirred for a further 30 min. LCMS after this timeshowed that the reaction was complete. The reaction was then treatedwith saturated aqueous NaHCO₃ (10 ml) and extracted with 20%methanol/DCM (3×25 ml). The combined organic fractions were dried(MgSO₄), filtered, evaporated and chromatographed (0-20% methanol/DCM)to give the free base of the title compound (6 mg, 9.6%) as a paleyellow solid and some crude product (15 mg, 24%) as an impure paleyellow solid which was purified using an SCX column to give moreidentical title compound, free base.

¹H NMR δH CDCl₃, (250 MHz) 1.15-1.50 (m, 2H), 1.70-2.10 (m, 2H),2.15-2.39 (m, 2H), 2.41-2.58 (m, 1H), 2.60-2.74 (2H, m), 2.85-3.11 (m,1H), 3.11-3.15 (m, 1H), 3.69 (s, 2H), 4.22-4.45 (m, 5H), 4.50-4.62 (m,1H), 4.90-5.09 (m, 1H), 6.20-6.35 (m, 2H), 6.60-6.72 (m, 2H), 7.41-7.52(m, 2H).

MS (ES+) m/z 467 (MH⁺).

The free base of the title compound was then treated with one equivalentof 1M HCl in diethyl ether to give the title compound as the monohydrochloride salt (16.7 mg, 27.5%). LCMS was consistent with product.

Example 32(1R)-1-[(4-{[(7-Chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-Q]-1,8-naphthyridine-4,9-dionedihydrochloride

In a 10 mL round-bottomed flask(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(j) (80 mg, 0.266 mmol),7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carbaldehyde(for a synthesis see WO2003064421, Example 15(c)) (62.3 mg, 0.293 mmol),and sodium bicarbonate (100 mg, 1.190 mmol) in DCM (4 ml) and methanol(1 ml) were combined to give a brown solution. Sodium sulfate (200 mg,1.408 mmol) was added and the reaction was allowed to stir at rtovernight. After 15 h sodium triacetoxyborohydride (113 mg, 0.533 mmol)was added and the reaction was allowed to stir at 25° C. under nitrogenfor 4 h. The reaction mixture was adsorbed onto silica and purifiedusing 0-10% MeOH/DCM (1% NH₄OH). The LCMS and 1H NMR of the product wereconsistent with the title compound as the free base.

¹H NMR δH D-4 MeOH, (400 MHz) 1.24-1.45 (m, 2H), 1.79-1.96 (m, 2H),2.22-2.31 (m, 2H), 2.46-2.53 (m, 1H), 2.59-2.68 (m, 1H), 2.87-3.09 (m,4H), 3.89 (s, 2H), 4.42-4.51 (m, 2H), 4.69 (s, 2H), 5.07-5.15 (m, 1H),6.26-6.35 (m, 2H), 7.39 (s, 1H), 7.75-7.81 (m, 2H),

MS (ES+) m/z 497/499 (MH⁺).

The free base of the title compound was taken up in 10% MeOH/DCM andtreated with 1N HCl to form title compound as the diHCl salt (55 mg,36.2%)

Example 33(1R)-1-[(4-{[(4-Chloro-7-oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]oxazin-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dione

In a 10 mL round-bottomed flask were combined(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(j)) (60 mg, 0.178 mmol),4-chloro-7-oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]oxazine-2-carbaldehyde(for a synthesis see WO2008009700, Example 124(g)) (38 mg, 0.178 mmol),and sodium bicarbonate (150 mg, 1.78 mmol) in DCM (5 ml) and methanol (1ml) to give a brown solution. Sodium sulfate (200 mg, 1.408 mmol) wasadded and the reaction was allowed to stir at rt overnight. After 15 hsodium triacetoxyborohydride (113 mg, 0.533 mmol) was added and thereaction was allowed to stir at 25° C. under nitrogen for 4 h. Thereaction mixture was adsorbed onto silica and purified using 0-20%MeOH/DCM (1% NH₄OH) to give the title compound (4 mg orange solid,4.51%).

¹H NMR δH CDCl₃, (250 MHz) 1.28-1.51 (m, 2H), 1.75-1.99 (m, 2H),2.13-2.38 (m, 2H), 2.41-2.80 (m, 3H), 2.90-3.15 (m, 2H), 3.75 (s, 2H),4.31-4.42 (m, 1H), 4.51-4.62 (m, 1H), 4.8 (s, 2H), 4.90-5.08 (m, 1H),6.25-6.32 (m, 2H), 7.51-7.53 (m, 2H),

MS (ES+) m/z 498/500 (MH⁺).

Example 34(1R)-1-[(4-{[(7-Oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]thiazin-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionedihydrochloride

(a) Ethyl [(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)thio]acetate

A solution of 5-bromo-2,4 (1H,3H)-pyrimidinedione (15 g, 79 mmol) andethyl mercaptoacetate (8.58 ml, 79 mmol) in DMF (200 mL) was treatedwith tetrabutylammonium hydrogen sulfate (6.67 g, 19.64 mmol) andpotassium carbonate (23.88 g, 173 mmol) and stirred at ambienttemperature overnight. The solution was filtered and concentrated underreduced pressure to yield crude title compound as a yellow oil whichfoams up under reduced pressure.

MS (ES+) m/z 231.1 (MH⁺).

(b) Ethyl [(2,4-dichloro-5-pyrimidinyl)thio]acetate

A suspension of ethyl[(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)thio]acetate (crudematerial) (18.19 g, 79 mmol) in phosphorus oxychloride (100 ml, 1073mmol) was treated with dimethyl aniline (2.500 ml, 19.72 mmol), and thereaction was heated to reflux and stirred for 2 hours. The solution wasallowed to cool to room temperature and poured slowly onto ice to quenchthe excess phosphorus oxychloride. Once quenched, the aqueous layer wasextracted with CH₂Cl₂ (3×). The organic layers were combined, dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The crudematerial was chromatographed using a gradient of 0-50% EtOAc/Hexanes.The product was isolated as a dark yellow oil. 1H NMR (400 MHz,chloroform-d) ppm 1.22 (t, J=7.07 Hz, 3H) 3.71 (s, 2H) 4.15 (d, J=7.33Hz, 1H) 8.53 (s, 1H)

(c) Ethyl [(4-amino-2-chloro-5-pyrimidinyl)thio]acetate

A solution of ethyl [(2,4-dichloro-5-pyrimidinyl)thio]acetate (2.0 g,7.49 mmol) in DMF (75 ml) was treated with ammonia in isopropanol (7.49ml, 14.97 mmol) in a pressure tube. The tube was capped, and thereaction was stirred at ambient temperature. Upon completion, thesolution was concentrated under reduced pressure and pumped on to removeany residual DMF. The crude material was chromatographed using agradient of 0-10% acetone/chloroform. The product contained a smallamount of cyclized material (which is the product of the next step). Theproduct was isolated as a light yellow solid.

MS (ES+) m/z 248.0 (MH⁺).

(d) 2-Chloro-1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one

A suspension of ethyl [(4-amino-2-chloro-5-pyrimidinyl)thio]acetate(0.786 g, 3.17 mmol) in ethanol (50 ml) was heated to 70° C. Cesiumcarbonate (1.034 g, 3.17 mmol) was added and the solution was heated fora further 5 minutes. A white solid precipitated out of solution almostimmediately. The solution was concentrated under reduced pressure. Theresidue was dissolved in water and brought to pH=5 with 1N HCl. Theaqueous layer was extracted with CH₂Cl₂ (2×). The organic layers werecombined, dried over Na₂SO₄, filtered, and concentrated under reducedpressure to yield a light yellow solid.

MS (ES+) m/z 202.0 (MH⁺).

(e) 2-Ethenyl-1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one

2-Chloro-1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one (0.639 g, 3.17 mmol)was treated with tributylvinyl tin (1.388 ml, 4.76 mmol), andtetrakis(triphenylphosphine) palladium(0) (0.293 g, 0.254 mmol) in1,4-dioxane (4 ml) and toluene (4 mL) in a microwave vial. The reactionwas heated in the microwave at 140° C. for 20 minutes. The solution wasdiluted with EtOAc and washed with saturated NaHCO₃ solution. Theaqueous layer was extracted with EtOAc (2×). The organic solution werecombined, dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The crude material was chromatographed using a gradient of0-60% CH₂Cl₂/(CH₂Cl₂/MeOH/NH₄OH) (90:10:1). The product was isolated asa mixture of the desired product and triphenylphosphine. Pure materialwas obtained by triturating and washing with diethyl ether. The productwas isolated as an orange solid.

MS (ES+) m/z 194.0 (MH⁺).

(f) 7-Oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]thiazine-2-carbaldehyde

A solution of 2-ethenyl-1H-pyrimido[5,4-b][1,4]thiazin-7(6H)-one (0.262g, 1.356 mmol) in methanol/DCM was cooled to −78° C. and treated withozone until the solution turned blue. The solution was stirred at −78°C. for an additional 5 minutes. Dimethyl sulfide (5.0 ml, 67.6 mmol) wasadded and the solution was allowed to warm to room temperature and stirovernight. The solution was concentrated onto silical gel and the crudematerial was chromatographed using a gradient of 0-100%CH₂Cl₂/(CH₂Cl₂/MeOH/NH₄OH) (90:10:1). The product was isolated as alight yellow solid.

MS (ES+) m/z 195.9 (MH⁺).

(g) Title Compound

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(j)) (0.060 g, 0.179 mmol) in 1:1CH₂Cl₂/MeOH (10 mL) was treated with7-oxo-6,7-dihydro-1H-pyrimido[5,4-b][1,4]thiazine-2-carbaldehyde (0.035g, 0.179 mmol) and sodium bicarbonate (0.151 g, 1.793 mmol). ExcessNa₂SO₄ was added and the reaction stirred at room temperature for 18hours. Sodium triacetoxyborohydride (0.114 g, 0.538 mmol) was added andthe reaction stirred at room temperature for 1 hour. The solution wasconcentrated onto silica gel and the crude material was chromatographedusing a gradient of 0-100% CH₂Cl₂/(CH₂Cl₂/MeOH/NH₄H) (90:10:1). The freebase of the title compound was isolated as a yellow solid (0.027 g).

MS (ES+) m/z 480.1 (MH⁺).

1H NMR (400 MHz, CHLOROFORM-d) ppm 1.62 (d, J=2.53 Hz, 1H) 1.61 (br. s.,1H) 1.90-2.09 (m, 3H) 2.20-2.42 (m, 2H) 2.59-2.78 (m, 2H) 3.14 (dd,J=12.88, 3.03 Hz, 2H) 3.53 (s, 2H) 4.05-4.14 (m, 2H) 4.41 (dd, J=12.38,9.35 Hz, 1H) 4.57 (dd, J=12.63, 4.04 Hz, 1H) 5.04 (dd, J=7.96, 4.42 Hz,1H) 5.32 (s, 1H) 6.28 (dd, J=16.29, 9.22 Hz, 2H) 7.49 (d, J=3.28 Hz, 1H)7.50-7.57 (m, 1H).

The title di-HCl salt was formed by dissolving the free base in CH₂Cl₂and adding 0.113 mL 1N HCl/ether.

Example 35(1R)-1-({4-[(1,2,3-Benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-({4-[(1,2,3-benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochoride (for a preparation see Example 5A(j)) (60 mg, 0.161 mmol)in chloroform (2 ml) and methanol (0.100 ml) at rt under nitrogen wastreated with triethylamine (0.067 ml, 0.482 mmol) and stirred at rt for15 h. The solution was then treated with1,2,3-benzothiadiazole-5-carbaldehyde (for a synthesis see WO0208224Example 20(a)) (23.75 mg, 0.145 mmol) and stirred for a further 30 min.The solution was then treated with sodium triacetoxyborohydride (102 mg,0.482 mmol) and stirred at rt for 45 min, LC-MS after 45 min showedreaction complete. This was then treated with saturated aqueous NaHCO₃(10 ml) and extracted with 20% methanol/DCM (3×25 ml). The combinedorganic extracts were dried (MgSO₄), filtered, evaporated andchromatographed (0-5% methanol/DCM 5% methanol/DCM) to give the freebase of the title compound (26 mg, 36%) as a pale yellow solid.

¹H NMR δH CDCl₃, (400 MHz) 1.30-1.49 (m, 2H), 1.80-1.98 (m, 2H),2.21-2.39 (m, 2H), 2.51-2.61 (m, 1H), 2.61-2.75 (m, 2H), 2.90-3.02 (m,1H), 3.05-3.19 (m, 1H), 4.04 (s, 2H), 4.31-4.42 (m, 1H), 4.51-4.61 (m,1H), 4.92-5.05 (m, 1H), 6.20-6.31 (m, 2H), 7.45-7.53 (2H, m), 7.71 (d,1H). 8.11 (d, 1H), 8.56 (s, 1H)

MS (ES+) m/z 449 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether and thenevaporated to give the title compound as the mono-HCl salt (16.2 mg,20.8%). LCMS consistent with product.

Example 36(1R)-1-({4-[(2,3-Dihydro-1-benzofuran-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A suspension of(1R)-1-({4-[(1,2,3-benzothiadiazol-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochoride (for a preparation see Example 5A(j)) (60 mg, 0.161 mmol)in chloroform (2 ml) and methanol (0.100 ml) at rt under nitrogen wastreated with triethylamine (0.067 ml, 0.482 mmol) and stirred at rt for15 min. The solution was then treated with2,3-dihydro-1-benzofuran-5-carbaldehyde (commercially available) (0.020ml, 0.161 mmol) and stirred for a further 30 min. The solution was thentreated with sodium triacetoxyborohydride (102 mg, 0.482 mmol) andstirred at rt for 45 min. This was then treated with saturated aqueousNaHCO₃ (10 ml) and extracted with 20% methanol/DCM (3×25 ml). Thecombined organic fractions were dried (NaSO₄), filtered, evaporated andchromatographed (5-25% methanol/DCM) to give the free base of the titlecompound (24 mg, 34.5%) as a white solid.

¹H NMR δH CDCl₃, (400 MHz) 1.22-1.49 (m, 2H), 1.79-2.10 (m, 2H),2.21-2.40 (m, 2H), 2.45-2.58 (m, 1H), 2.61-2.72 (m, 2H), 2.90-3.01 (m,1H), 3.05-3.15 (m, 1H), 3.21 (t, 2H), 3.72 (s, 2H), 4.32-4.42 (m, 1H),4.51-4.62 (m, 3H), 4.95-5.05 (m, 1H), 6.22-6.33 (m, 2H), 6.72 (d, 1H),7.14 (d, 1H), 7.19 (s, 1H), 7.45-7.52 (2H, m),

MS (ES+) m/z 433 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether and thenevaporated to give the title compound as the mono-HCl salt (22.7 mg,28.6%). LCMS consistent with product.

Example 37(1R)-1-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k) or 15(d)) (50 mg,0.100 mmol) in chloroform (4 ml) and methanol (0.200 ml) at roomtemperature under nitrogen was treated with triethylamine (0.042 ml,0.301 mmol) and stirred for 0.25 h (the suspension turned into asolution). 3,4-Dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde (for asynthesis see WO2004058144, Example 126(e)) (16.35 mg, 0.100 mmol) wasthen added and the reaction was stirred at room temperature for 0.5 h.Sodium triacetoxyborohydride (67.1 mg, 0.301 mmol) was then added andthe reaction was stirred at room temperature. After 3 h there was stillsome starting material so 30 mg of sodium triacetoxyborohydride wereadded. After 1 h a saturated aqueous solution of sodium bicarbonate (25mL) was added followed by 20% methanol/DCM (25 mL) and the aqueous layerwas extracted and then separated from the organic layer. The aqueouslayer was extracted again twice with 20% methanol/DCM (2×25 mL). Thecombined organic layers were dried on sodium sulphate, filtered andevaporated to afford 60 mg of crude product. The crude product waspurified by silica chromatography (0-20% MeOH/DCM) to afford the freebase of the title compound as a yellow solid (39 mg, 87%).

¹H NMR δH CDCl₃, (400 MHz) 1.25-1.45 (m, 2H), 1.78-2.08 (m, 4H),2.22-2.38 (m, 2H), 2.45-2.60 (m, 1H), 2.62 (d, 1H), 2.67-2.80 (m, 3H),2.93 (d, 1H), 3.05-3.14 (m, 1H), 3.78 (s, 2H), 4.15-4.25 (m, 2H),4.30-4.45 (m, 1H), 4.50-4.60 (m, 1H), 4.95-5.05 (m, 1H), 6.33 (d, 1H),6.96 (s, 1H), 7.75 (s, 1H), 7.87 (s, 1H), 8.07 (s, 1H).

MS (ES+) m/z 449 (MH⁺).

The free base of the title compound was dissolved in a small amount ofmethanol/DCM and treated with 1 eq of 1M hydrochloric acid in diethylether.

The solvents were removed and the solid was dried in the desiccator (inthe presence of P₂O₅) over the weekend to afford the title compound asthe mono-HCl salt as a yellow solid (40.6 mg, 79%). LCMS was consistentwith product.

Example 38(1R)-1-({4-[(2,3-Dihydrofuro[2,3-c]pyridin-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k) or 15(d)) (50 mg,0.100 mmol) in chloroform (20 ml) and methanol (0.800 ml) at roomtemperature under nitrogen was treated with triethylamine (0.042 ml,0.301 mmol) and stirred for 0.25 h (the suspension turned into asolution). 2,3-Dihydrofuro[2,3-c]pyridine-5-carbaldehyde (for asynthesis see WO2007122258, Example 43(f)(14.94 mg, 0.100 mmol) was thenadded and the reaction was stirred at room temperature for 0.5 h. Sodiumtriacetoxyborohydride (67.1 mg, 0.301 mmol) was then added and thereaction was stirred at room temperature. After 3 h there was still somestarting material so 30 mg of sodium triacetoxyborohydride were added.After 1 h a saturated aqueous solution of sodium bicarbonate (25 mL) wasadded followed by 20% methanol/DCM (25 mL) and the aqueous layer wasextracted and then separated from the organic layer. The aqueous layerwas extracted again twice with 20% methanol/DCM (2×25 mL). The combinedorganic extracts were dried on sodium sulphate, filtered and evaporatedto afford 50 mg of crude product. The crude product was purified bysilica chromatography (0-20% methanol/DCM) to afford the free base ofthe title compound as a yellow solid (31 mg, 71.2%).

¹H NMR δH CDCl₃, (250 MHz) 1.25-1.43 (m, 2H), 1.81-2.00 (m, 2H),2.22-2.35 (m, 2H), 2.49-2.54 (m, 1H), 2.66 (d, 1H), 2.71-2.74 (m, 1H),2.92 (d, 1H), 3.07-3.12 (m, 1H), 3.19-3.24 (m, 2H), 3.82 (s, 2H),4.37-4.42 (m, 1H), 4.56-4.62 (m, 3H), 4.96-5.06 (m, 1H), 6.33 (d, 1H),7.18 (s, 1H), 7.76 (d, 1H), 7.86 (s, 1H), 8.06 (s, 1H).

MS (ES+) m/z 435 (MH⁺).

The free base of the title compound was dissolved in a small amount ofmethanol/DCM and treated with 1 eq of 1M hydrochloric acid in diethylether. The solvents were removed and the solid was dried in thedesiccator (in the presence of P₂O₅) over the weekend to afford thetitle compound as the mono-HCl salt as an orange solid (33.5 mg, 67.4%).LCMS was consistent with product.

Example 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (60 mg, 0.199 mmol) and3,4-dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde (for a synthesis seeWO2004058144, Example 126(e)) (29.2 mg, 0.179 mmol) in chloroform (2 ml)and methanol (0.061 ml) at rt under nitrogen was treated with sodiumtriacetoxyborohydride (127 mg, 0.597 mmol) and stirred at rt for 30 min.The reaction was then treated with saturated aqueous NaHCO₃ (10 ml) andextracted with 20% methanol/DCM (3×20 ml). The combined organic extractswere dried (MgSO₄), filtered, evaporated and purified using silicachromatography (0-20% MeOH/DCM) to give the free base of the titlecompound as a light brown solid

¹H NMR δH CDCl₃, (400 MHz) 1.28-1.40 (m, 2H), 1.78-1.86 (m, 2H),1.96-2.01 (m, 2H), 2.14-2.34 (m, 2H), 2.45-2.52 (m, 1H), 2.62-2.74 (m,4H), 2.91 (m, 1H), 3.07-3.11 (m, 1H), 3.74 (s, 2H), 4.16-4.18 (m, 2H),4.32-4.37 (m, 1H), 4.48-4.52 (m, 1H), 4.97-5.03 (m, 1H), 6.34 (d, 1H),6.93 (s, 1H), 7.72 (d, 1H), 7.77 (s, 1H), 8.03 (s, 1H),

MS (ES+) m/z 449 (MH⁺).

The free base of the title compound in a small amount of DCM was treatedwith one equivalent of 1M HCl in diethyl ether (0.17 ml), evaporated anddried in a dessicator overnight to give the title compound as themono-HCl salt (57.3 mg, 56.4% yield). LCMS consistent with product.

Example 40(2R)-2-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (60 mg, 0.199 mmol) and2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (commercially available)(29.4 mg, 0.179 mmol) in chloroform (2 ml) and methanol (0.100 ml) at rtunder nitrogen was treated with sodium triacetoxyborohydride (127 mg,0.597 mmol) and stirred for 90 min, LC-MS after 90 min showed reactioncomplete. This was treated with saturated aqueous NaHCO₃ (10 ml) andextracted with 20% methanol/DCM (3×25 ml). The combined organic extractswere dried (MgSO₄), filtered, evaporated and chromatographed (0-20%methanol/DCM) to give the free base of the title compound (46.8 mg,58.4%) as a yellow gum.

¹H NMR δH CDCl₃, (400 MHz) 1.20-1.41 (m, 2H), 1.73-1.91 (m, 2H),2.09-2.38 (m, 2H), 2.42-2.55 (m, 1H), 2.61-2.72 (m, 2H), 2.85-2.95 (m,1H), 3.05-3.15 (m, 1H), 3.68 (s, 2H), 4.32 (m, 4H). 4.32-4.42 (m, 1H),4.49-4.59 (m, 1H), 4.95-5.06 (m, 1H), 6.39 (d, 1H), 6.71-6.85 (m, 3H),7.75 (d, 1H), 7.81 s, 1H).

MS (ES+) m/z 450 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether and thenevaporated to give the title compound as the mono-HCl salt (43.8 mg,53.4%). LCMS consistent with product.

Example 41(2R)-2-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (58.5 mg, 0.194 mmol) and8-fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (for a synthesis seeWO2007122258, Example 8(b)) (31.8 mg, 0.175 mmol) in chloroform (2 ml)and methanol (0.100 ml) at room temperature under nitrogen was stirredfor 0.5 h. This was then treated with sodium triacetoxyborohydride (123mg, 0.582 mmol) and stirred for 90 min. This was then treated withsaturated aqueous NaHCO₃ (10 ml) and extracted with 20% methanol/DCM(3×25 ml). The combined organic extracts were dried (NaSO₄), filtered,evaporated and purified using silica chromatography (0-20% methanol/DCM)to give the free base of the title compound as a yellow gum (44.9 mg,49.5%).

¹H NMR δH CDCl₃, (400 MHz) 1.24-1.55 (m, 2H), 1.78-1.85 (m, 2H),2.21-2.36 (m, 2H), 2.44-2.51 (m, 1H), 2.64-2.73 (m, 2H), 2.92 (d, 1H),3.10-3.14 (m, 1H), 3.65 (s, 2H), 4.26-4.30 (m, 4H), 4.35-4.40 (m, 1H),4.52-4.56 (m, 1H), 4.99-5.05 (m, 1H), 6.38 (d, 1H), 6.62-6.67 (m, 2H),7.76 (d, 1H), 7.81 (s, 1H),

MS (ES+) m/z 468 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether and thenevaporated and dried in a desiccator overnight to give the titlecompound as the mono-HCl salt (30.1 mg, 29.2%). LCMS consistent withproduct.

Example 427-{[(1-{[(2R)-3,8-Dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl]methyl}-4-piperidinyl)amino]methyl}-2,3-dihydro-1,4-benzodioxin-5-carbonitrilehydrochloride

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (60 mg, 0.199 mmol) and7-formyl-2,3-dihydro-1,4-benzodioxin-5-carbonitrile (for a synthesis seeWO06014580 Preparation 13 or WO2007122258, Example 31(d)) (37.7 mg,0.199 mmol) in chloroform (2 ml) and methanol (0.100 ml) at roomtemperature under nitrogen was treated with sodium triacetoxyborohydride(127 mg, 0.597 mmol) and stirred for 90 min. This was then treated withsaturated aqueous NaHCO₃ (10 ml) and extracted with 20% methanol/DCM(3×25 ml). The combined organic extracts were dried (NaSO₄), filtered,evaporated and purified using silica chromatography (0-20% methanol/DCM)to give the free base of the title compound as a yellow gum (40 mg,42.3%).

¹H NMR δH CDCl₃, (400 MHz) 1.24-156 (m, 2H), 1.79-1.86 (m, 2H),2.21-2.36 (m, 2H), 2.43-2.50 (m, 1H), 2.65-2.72 (m, 2H), 2.93 (d, 1H),3.12-3.16 (m, 1H), 3.68 (s, 2H), 4.29-4.41 (m, 5H), 4.53-4.57 (m, 1H),5.00-5.06 (m, 1H), 6.39 (d, 1H), 7.06-7.09 (m, 2H), 7.77 (d, 1H), 7.83(s, 1H),

MS (ES+) m/z 475 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM, treated with one equivalent of 1M HCl in diethyl ether, evaporatedand dried in a dessicator overnight to give the title compound as themono-HCl salt (45 mg, 42%) as a pale yellow solid. LCMS consistent withproduct.

Example 43(2R)-2-({4-[(2,3-Dihydrofuro[2,3-c]pyridin-5-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione(for a preparation see Example 16A(j)) (70 mg, 0.232 mmol) and2,3-dihydrofuro[2,3-c]pyridine-5-carbaldehyde (for a synthesis seeWO2007122258, Example 43(f) (34.6 mg, 0.232 mmol) in chloroform (5 ml)and methanol (0.250 ml) at room temperature under nitrogen was stirredfor 0.5 h (the suspension turned into a solution). Sodiumtriacetoxyborohydride (155 mg, 0.697 mmol) was then added and thereaction was stirred at room temperature. After 3 h there was nostarting material left so a saturated aqueous solution of sodiumbicarbonate (25 mL) was added followed by 20% methanol/DCM (25 mL) andthe aqueous layer was extracted and then separated from the organiclayer. The aqueous layer was extracted again twice with 20% methanol/DCM(2×25 mL). The combined organic extracts were dried on sodium sulphate,filtered and evaporated to afford 90 mg of crude product. The crudeproduct was purified by silica chromatography (0-20% MeOH/DCM) to affordthe free base of the title compound as a pale yellow solid (77 mg, 76%).

¹H NMR δH CDCl₃, (400 MHz) 1.28-1.48 (m, 2H), 1.81-1.89 (m, 2H),2.21-2.36 (m, 2H), 2.43-2.55 (m, 1H), 2.64-2.72 (m, 2H), 2.93 (d, 1H),3.10-3.14 (m, 1H), 3.19-3.23 (m, 2H), 3.81 (s, 2H), 4.34-4.40 (m, 1H),4.52-4.61 (m, 3H), 4.95-5.08 (m, 1H), 6.37 (d, 1H), 7.17 (s, 1H), 7.76(d, 1H), 7.81 (s, 1H), 8.06 (s, 1H).

MS (ES+) m/z 435 (MH⁺).

The free base of the title compound was dissolved in a small amount ofmethanol/DCM and treated with 1 eq of 1M hydrochloric acid in diethylether. The solvents were removed and the solid was dried in thedesiccator (in the presence of P₂O₅) over the weekend to afford thetitle compound as the mono-HCl salt as an off-white solid (78.9 mg,68.5%). LCMS was consistent with product.

Example 44(1R)-1-({4-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k) or 15(d)) (50 mg,0.100 mmol) in chloroform (4 ml) and methanol (0.200 ml) at roomtemperature under nitrogen was treated with triethylamine (0.042 ml,0.301 mmol) and stirred for 0.25 h (the suspension turned into asolution). 2,3-Dihydro-1,4-benzodioxin-6-carbaldehyde (commerciallyavailable) (16.45 mg, 0.100 mmol) was then added and the reaction wasstirred at room temperature for 0.5 h. Sodium triacetoxyborohydride(67.1 mg, 0.301 mmol) was then added and the reaction was stirred atroom temperature. After 3 h 40 mg more of sodium triacetoxyborohydridewas added. After 1 h 30 mg more of sodium triacetoxyborohydride wasadded. After 1 h saturated NaHCO₃ (25 mL) was added followed by 20%MeOH/DCM (25 mL) and the aqueous layer was separated from the organiclayer. The aqueous layer was extracted again twice with 20% MeOH/DCM(2×25 mL). The combined organic extracts were dried NaSO₄, filtered andevaporated to afford the crude product. The crude product was purifiedby chromatography on silica (0-20% MeOH/DCM) to give 27 mg of the freebase of the title compound (59.9% total yield).

¹H NMR δH CDCl₃, (400 MHz) 1.21-1.42 (m, 2H), 1.70-1.92 (m, 2H),2.21-2.36 (m, 2H), 2.41-2.55 (m, 1H), 2.58-2.78 (m, 2H), 2.88-2.98 (m,1H), 3.05-3.14 (m, 1H), 3.68 (s, 2H), 4.25 (s, 4H), 4.43-4.52 (m, 1H),4.51-4.62 (m, 1H), 4.98-5.06 (m, 1H), 6.34 (d, 1H), 6.75-6.84 (m, 3H),7.76 (d, 1H), 7.87 (s, 1H).

MS (ES+) m/z 450 (MH⁺).

The free base of the title compound was dissolved in a small amount ofMeOH/DCM and treated with 1 eq of a 1M solution of HCl in Et₂O.

The solvents were removed and the solid dried in the desiccator (P₂O₅)overnight to afford the title compound as the momo-HCl salt (26 mg,0.051 mmol, 50.7% yield) as a yellow solid.

Example 45(1R)-1-({4-[([1,2,5]Thiadiazolo[3,4-b]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

To(1R)-1-[(4-amino-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochoride (for a preparation see Example 5A(j) (60 mg, 0.161 mmol)was added chloroform (3 ml), methanol (0.3 ml) and triethylamine (0.067ml, 0.482 mmol). The reaction was stirred under a nitrogen atmospherefor 30 mins, then [1,2,5]thiadiazolo[3,4-b]pyridine-6-carbaldehyde (fora preparation see Example 49(b)) (25.2 mg, 0.153 mmol) was added. Thereaction was stirred for a further 2 hrs then sodiumtriacetoxyborohydride (102 mg, 0.482 mmol) was added and stirringcontinued for 16 hours. Further sodium triacetoxyborohydride (102 mg,0.482 mmol) was added and stirred for 30 mins. Further sodiumtriacetoxyborohydride (102 mg, 0.482 mmol) was added and stirringcontinued for 2 hours. The reaction was partitioned between sat. NaHCO₃and 20% MeOH in DCM. The aqueous was further extracted with 20% MeOH inDCM and the combined organic extracts passed thought a hydrophobic fritand concentrated to give a reddish brown solid (˜65 mg). This waspurified by silica chromatography eluting with 0-20% MeOH in DCM to givethe free base of the title compound as a pale tan gum (18 mg).

¹H NMR δH CD₃OD 400 MHz 1.30 (m, 1H), 1.42 (m, 1H), 1.88 (br d, 1H),1.98 (br d, 1H), 2.28 (q, 2H), 2.63 (m, 2H), 2.89 (dd, 1H), 3.01 (dd,1H), 3.06 (br d, 1H), 4.08 (s, 2H), 4.45 (m, 2H), 5.10 (m, 1H), 6.28(dd, 2H), 7.76 (d, 2H), 8.41 (br d, 1H), 9.08 (br d, 1H)

MS (ES+) m/z 450 (MH⁺).

The free base of the title compound was dissolved in 2:1 DCM:MeOH (1 ml)and HCl (1M in diethyl ether) (0.040 ml, 0.04 mmol) was added. Thesolvent was evaporated to give a pale brown solid (22 mg, 28%).

Example 46(1R)-1-[(4-{[(4-Fluoro-1H-benzimidazol-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-Ij]-1,8-naphthyridine-4,9-dionedihydrochloride

To a 10 mL round-bottomed flask were added(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(j)) (80 mg, 0.238 mmol),4-fluoro-H-benzimidazole-2-carbaldehyde (for a synthesis seeWO2003087098, Example 320) (42.9 mg, 0.261 mmol), and sodium bicarbonate(100 mg, 1.190 mmol) in DCM (4 ml) and methanol (1 ml) to give a brownsuspension. Sodium sulfate (200 mg, 1.408 mmol) was added and thereaction was stirred at rt overnight. After 15 h sodiumtriacetoxyborohydride (101 mg, 0.475 mmol) was added and the reactionwas stirred at 25° C. under nitrogen for 4 h. The reaction mixture wasadsorbed onto silica and purified using 0-10% MeOH/DCM (1% NH₄OH) togive the free base of the title compound. The LCMS and 1H NMR wereconsistent with the desired product.

¹H NMR δH D-4 MeOH, (400 MHz) 1.35-1.55 (m, 2H), 1.90-1.96 (m, 2H),2.30-2.41 (m, 2H), 2.71-2.81 (m, 2H), 2.91-2.99 (m, 1H), 3.05-3.15 (m,2H), 4.20 (s, 2H), 4.41-4.50 (m, 2H), 4.69 (s, 2H), 5.10-5.20 (m, 1H),6.25-6.36 (m, 2H), 6.91-7.05 (m, 1H), 7.16-7.25 (m, 1H), 7.31-7.39 (m,1H), 7.75-7.81 (m, 2H),

MS (ES+) m/z 449 (MH⁺).

The free base of the title compound was taken up in 10% MeOH/DCM andtreated with 1N HCl to form the title compound as the diHCl salt (17 mg,0.033 mmol, 13.73% yield).

Example 47(1R)-1-[((2S)-2-{[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]methyl}-4-morpholinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

(a) 1,1-Dimethylethyl[((2S)-4-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-2-morpholinyl)methyl]carbamate

In a 100 mL round-bottomed flask were(1S)-1-(hydroxymethyl)-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(for a preparation see Example 5A(g)) (450 mg, 2.043 mmol) andtriethylamine (0.342 ml, 2.452 mmol) in DCM (20 ml) at 0° C. to give aorange solution. Methane sulfonylchloride (0.174 ml, 2.248 mmol) wasadded and the reaction was allowed to warm to rt and stirred for 1 h.LCMS indicated that the methanesulfonate had formed. The reactionmixture was diluted with DCM (100 mL) and washed with 2×25 mL of asaturated aqueous NaHCO₃ solution. The organic phase was separated anddried over Na₂SO₄. The solution was concentrated under vacuum, and takenup in acetonitrile (20.00 ml). Pyridine (0.500 ml) was added followed by1,1-dimethylethyl [(2R)-2-morpholinylmethyl]carbamate (for a synthesissee WO2008009700 Example 89(e)) (884 mg, 4.09 mmol), and the reactionwas heated to 75° C. The reaction was stirred for 5 h at which time LCMSindicated a complete reaction. The reaction was cooled to rt andconcentrated under vacuum. The reaction mixture was diluted with DCM(100 mL) and washed with 25 mL of a saturated aqueous NaHCO₃ solution.The organic phase was separated and dried over Na₂SO₄. The resultingresidue was purified on silica 0-10% MeOH/DCM and the title compound(805 mg, 1.539 mmol, 75% yield) was isolated as a red oil.

MS (ES+) m/z 419 (MH⁺).

(b) 1,1-Dimethylethyl[((2S)-4-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-2-morpholinyl)methyl]carbamate

To a 50 mL round-bottomed flask was added 1,1-dimethylethyl[((2S)-4-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-2-morpholinyl)methyl]carbamate(805 mg, 1.924 mmol) in 1,4-dioxane (10 ml) at rt under nitrogen to givea orange solution. DDQ (655 mg, 2.89 mmol) was added and the reactionbecame very dark. The reaction was heated to 90° C. on an oil bath andstirred for 30 min. The reaction was cooled to rt, 200 mL of a 5%aqueous K₂CO₃ solution was added and the reaction was extracted with DCM(3×200 mL). The combined organic layers were washed with saturatedaqueous NaCl solution; the organic layer was separated and dried overNa₂SO₄, and concentrated to give the crude product. The crude productwas added to a silica gel column and was eluted with 0-20% MeOH/CHCl₃ togive the title compound (830 mg, 1.794 mmol, 93% yield) as a red oil.

MS (ES+) m/z 417 (MH⁺).

(c)(1R)-1-{[(2S)-2-(Aminomethyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(HCl)

To a 50 mL round-bottomed flask was added 1,1-dimethylethyl[((2S)-4-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-2-morpholinyl)methyl]carbamate(830 mg, 1.993 mmol) in DCM (10 ml) to give a brown solution. 4N HCl indioxane (2.491 ml, 9.96 mmol) was added and the reaction mixture stirredat rt. After 30 min the solution became cloudy so 2 mL of methanol wasadded and the reaction was stirred for another 30 min. The reaction wasconcentrated under vacuum to give the desired product as an HCl salt(520 mg, 1.474 mmol, 74.0% yield) as a brown solid which was usedwithout further purification.

(d) Title Compound

To a 10 mL round-bottomed flask were added(1R)-1-{[(2S)-2-(aminomethyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(HCl)(85 mg, 0.241 mmol), [1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (40.3mg, 0.241 mmol) (for a synthesis see WO2004058144 Example 61), andNaHCO₃ (60.7 mg, 0.723 mmol) in DCM (4 ml) and methanol (1 ml) to give ayellow suspension. The reaction was stirred overnight and sodiumtriacetoxyborohydride (102 mg, 0.482 mmol) was added. The reaction wasstirred for 4 h, then filtered through celite and the pad washed with10% MeOH/DCM. Chromatography on silica eluting with 0-10% MeOH/CHCl₃ (1%NH₄OH) gave the free base of the title compound in which the LCMS,

¹H NMR were consistent.

¹H NMR δH D-4 MeOH, (400 MHz) 2.02-2.13 (m, 1H), 2.34-2.49 (m, 2H),2.60-2.78 (m, 2H), 2.85-3.08 (m, 2H), 3.40-3.68 (m, 2H), 3.72-3.89 (m,1H), 4.40-4.51 (m, 2H), 4.89 (s, 2H), 5.10-5.20 (m, 1H), 5.80-5.89 (m,2H), 6.23-6.38 (m, 2H), 7.72-7.82 (m, 2H), 7.90-7.96 (m, 2H),

MS (ES+) m/z 468 (MH⁺).

The free base of the title compound was taken up in 10% MeOH/DCM andtreated with 500 uL 1N HCl in ether. The solution was concentrated undervacuum to give the title compound as the diHCl salt (49 mg, 0.091 mmol,37.6% yield) as a tan solid.

Example 48(1R)-1-{[(2S)-2-({[(7-Chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}methyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

To a 10 mL round-bottomed flask were added(1R)-1-{[(2S)-2-(aminomethyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(HCl)(for a preparation see Example 47(c)) (85 mg, 0.241 mmol),7-chloro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carbaldehyde (51.0 mg,0.241 mmol) (for a synthesis see WO2003064421, Example 15(c)), andNaHCO₃ (60.7 mg, 0.723 mmol) in DCM (4 ml) and methanol (1 ml) to give ayellow suspension. Na₂SO₄ (171 mg, 1.205 mmol) was added, the reactionwas stirred overnight, and sodium triacetoxyborohydride (102 mg, 0.482mmol) was added. The reaction was stirred for 4 h, filtered throughcelite, and the pad washed with 10% MeOH/DCM. Chromatography on silicaeluting with 0-10% MeOH/CHCl₃ (1% NH₄OH) gave the free base of the titlecompound in which the LCMS, 1H NMR were consistent with desired product.

¹H NMR δH D-4 MeOH, (400 MHz) 2.05-2.13 (m, 1H), 2.32-2.49 (m, 2H),2.59-2.80 (m, 2H), 2.88-3.07 (m, 3H), 3.42 (s, 2H), 3.40-3.49 (m, 1H),3.58-3.67 (m, 1H), 3.72-3.96 (m, 3H), 4.42-4.51 (m, 2H), 4.68 (s, 2H),5.10-5.18 (m, 1H), 6.22-6.35 (m, 2H), 7.39 (s, 1H) 7.72-7.80 (m, 2H).

MS (ES+) m/z 513/515 (MH⁺).

The free base of the title compound was taken up in 10% MeOH/DCM andtreated with 500 uL 1N HCl in ether. The solution was concentrated undervacuum to give the title compound as the diHCl salt (61 mg, 0.104 mmol,43.2% yield) as a pale yellow solid.

Example 49(2R)-2-({4-[([1,2,5]Thiadiazolo[3,4-b]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

(a) 6-[(E)-2-Phenylethenyl][1,2,5]thiadiazolo[3,4-b]pyridine

To 6-bromo[1,2,5]thiadiazolo[3,4-b]pyridine (for a preparation seeIndian Journal of Chemistry, Section B: Organic Chemistry IncludingMedicinal Chemistry (1979), 17B(1), 13-16) (1.9 g, 8.79 mmol),[(E)-2-phenylethenyl]boronic acid (1.561 g, 10.55 mmol) andtetrakistriphenylphosphine palladium(0) (0.508 g, 0.440 mmol) was added1,4-dioxane (38 ml) and then potassium carbonate (1.276 g, 9.23 mmol) inwater (19 ml). The reaction was then stirred at reflux for 1.5 hours.The cooled reaction was partitioned between chloroform and water. Thephases were separated with a hydrophobic frit and the organic extractsconcentrated to give a black solid/gum (˜2.4 g). This crude material waspurified by chromatography on silica eluting with 20-50% EtOAc incyclohexane to give the product as a yellow/brown solid (0.88 g).

¹H NMR δH D6-DMSO 400 MHz 7.36 (t, 1H), 7.45 (t, 2H), 7.55 (d, 1H), 7.70(d, 2H), 7.78 (d, 1H), 8.3 (s, 1H), 9.51 (s, 1H)

MS (ES+) m/z 240 (MH⁺).

(b) [1,2,5]Thiadiazolo[3,4-b]pyridine-6-carbaldehyde

To 6-[(E)-2-phenylethenyl][1,2,5]thiadiazolo[3,4-b]pyridine (0.88 g,3.68 mmol) was added acetone (30 ml), N-methyl-morpholine-N-oxide, 50wt. % in water (1.525 ml, 7.35 mmol) and then osmium tetroxide in water(0.225 ml, 0.037 mmol). The reaction was then stirred for 20 hours. Tothe pale brown solution was added sodium periodate (3.15 g, 14.71 mmol)and stirring continued for 45 mins. The solvent was reduced by rotaryevaporation and the remainder partitioned between chloroform and water.The aqueous was further extracted with chloroform and the combinedorganic extracts passed through a hydrophobic frit and concentrated togive brown/black solid (0.6 g). A portion of this material (0.575 g) waspurified by chromatography on silica eluting with 20% EtOAc incyclohexane to a pale yellow solid (160 mg).

¹H NMR δH D6-DMSO 400 MHz 9.18 (s, 1H), 9.49 (s, 1H), 10.30 (s, 1H)

(c) Title Compound

To(2R)-2-[(4-aminocyclohexyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 16A(j)) (100 mg, 0.333mmol) was added chloroform (3 ml), methanol (0.300 ml) and triethylamine(0.139 ml, 0.999 mmol). The mixture was stirred for 20 mins then[1,2,5]thiadiazolo[3,4-b]pyridine-6-carbaldehyde (52.2 mg, 0.316 mmol)was added. The reaction was stirred overnight then sodiumtriacetoxyborohydride (212 mg, 0.999 mmol) was added and stirringcontinued for 1 hour. Further sodium triacetoxyborohydride (212 mg,0.999 mmol) was added and the reaction stirred for 1 hour. The reactionwas partitioned between sat. NaHCO₃ and 20% MeOH in chloroform. Theaqueous was further extracted with 20% MeOH in chloroform and thecombined organic extracts were passed through a hydrophobic frit andconcentrated. This crude material (˜110 mg) was purified bychromatography eluting with 0-20% MeOH in DCM to furnish product (46 mg,27%). This was freeze dried from 1,4-dioxane to give the title compoundas a pale brown solid (45 mg, 25%)).

¹H NMR δH CDCl₃ 400 MHz 1.38 (m, 2H), 1.91 (t, 2H), 2.25 (dt, 1H), 2.35(dt, 1H), 2.58 (m, 1H), 2.71 (m, 2H), 2.96 (br d, 1H), 3.16 (dd, 1H),4.06 (s, 2H), 4.40 (dd, 1H), 4.56 (dd, 1H), 5.04 (m, 1H), 6.40 (d, 1H),7.78 (d, 1H), 7.83 (s, 1H), 8.26 (s, 1H)

MS (ES+) m/z 451 (MH⁺).

Example 50(1R)-1-({4-[(3,4-Dihydro-2H-chromen-7-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A solution of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see example 5A(j)) (188 mg, 0.503mmol) and triethylamine (0.175 ml, 1.256 mmol) in chloroform (4.5 ml)and methanol (0.5 ml) at rt was stirred at rt for 15 min then3,4-dihydro-2H-chromene-7-carbaldehyde (for a synthesis see WO2007067511Example 19 (chromane-7-carbaldehyde)) (68 mg, 0.419 mmol) in chloroform(2 ml) was added dropwise at rt. The reaction mixture was stirred at rtfor 1 h then sodium triacetoxyborohydride (444 mg, 2.096 mmol) was addedin one portion and the reaction mixture was stirred at rt overnight.LCMS showed a mixture of product, some residual aldehyde. Additionalsodium triacetoxyborohydride (267 mg, 1.258 mmol) was added and thereaction stirred at rt for 6 h. The reaction was quenched with NaHCO₃(aq) (20 ml) and extracted with 20% MeOH/DCM (3×30 ml). The combinedorganic layers were dried over MgSO₄, filtered, evaporated andchromatographed (0-50% MeOH/DCM) to deliver the free base of the titlecompound as a pale yellow clear oil (49 mg, 0.11 mmol, 26%).

¹H NMR δH CDCl₃, (400 MHz) 1.28-1.42 (m, 2H), 1.78-1.87 (m, 2H),1.97-2.01 (m, 2H), 2.17-2.31 (m, 2H), 2.47-2.55 (m, 1H), 2.62-2.68 (m,2H), 2.74-2.77 (m, 2H), 2.95 (d, 1H), 3.07 (dd, 1H) 3.71 (m, 2H), 4.17(t, 2H), 4.35 (dd, 1H), 4.56 (dd, 1H), 4.96-5.02 (m, 1H), 6.23-6.31 (m,2H), 6.72 (s, 1H), 6.77 (dd, 1H), 6.98 (d, 1H), 7.47-7.50 (m, 2H).

MS (ES+) m/z 447 (MH⁺).

The free base of the title compound in 2 ml DCM was treated with oneequivalent of 1M HCl in diethyl ether and then evaporated to give thetitle compound as the mono-HCl salt as a pale orange powder (51 mg,25%). LCMS was consistent with product.

Example 51(1R)-1-({4-[(2,3-Dihydro-1-benzofuran-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

(a) 2,3-Dihydro-1-benzofuran-6-carbaldehyde

To a solution of 6-bromo-2,3-dihydro-1-benzofuran (190 mg, 0.955 mmol)in THF (4 ml) at −78° C. was added n-BuLi (1.313 ml, 2.100 mmol). Thereaction mixture was stirred at −78° C. for 45 min then a solution ofDMF (1.109 ml, 1.6 M in hexanes, 14.32 mmol) in THF (2 ml) was addeddropwise and the reaction was stirred at −78° C. for 10 min then warmedto rt and stirred for 1 h. LCMS showed no starting material remaining.The reaction was stirred at rt for a further 2.5 h. The reaction mixturewas poured cautiously into 2 M HCl (50 ml) and extracted with ethylacetate (3×50 ml). The combined organic extracts were washed with brine(50 ml), dried over MgSO₄, filtered, evaporated and chromatographed(eluting 0-100% EtOAc/Hexane). The relevant fractions were combined andevaporated to deliver the product as a clear, colourless oil (44 mg,0.297 mmol, 31%).

¹H NMR δH CDCl₃, (400 MHz) 3.28 (t, 2H), 4.64 (t, 2H), 7.26 (s, 1H),7.33-7.39 (m, 2H), 9.91 (s, 1H).

(b) Title Compound

A solution of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (133 mg, 0.356mmol) and triethylamine (0.124 ml, 0.891 mmol) in chloroform (4.5 ml)and methanol (0.5 ml) at rt was stirred at rt for 15 min then2,3-dihydro-1-benzofuran-6-carbaldehyde (44 mg, 0.297 mmol) inchloroform (2 ml) was added dropwise at rt. The reaction mixture wasstirred at rt overnight. The reaction was quenched with NaHCO₃ (aq) (20ml), extracted with 20% MeOH/DCM (3×30 ml). The combined organic layerswere dried over MgSO₄, filtered, evaporated and chromatographed (0-50%MeOH/DCM). The relevant fractions were combined and evaporated todeliver the free base of the title compound as a pale yellow clear oil(18 mg, 0.04 mmol, 26%).

¹H NMR δH CDCl₃, (400 MHz) 1.40-1.53 (m, 2H), 1.85-1.92 (m, 2H),2.16-2.30 (m, 2H), 2.54-2.68 (m, 3H), 2.98 (d, 1H), 3.08 (dd, 1H), 3.16(t, 2H), 3.78 (s, 2H), 4.33-4.38 (m, 1H), 4.52-4.57 (m, 3H), 4.96-5.02(m, 1H), 6.24 (d, 1H), 6.29 (d, 1H), 6.79 (s, 1H), 6.84 (d, 1H), 7.13(d, 1H), 7.47-7.50 (m, 2H).

MS (ES+) m/z 433 (MH⁺).

The free base of the title compound in 2 ml DCM was treated dropwisewith 1 M HCl in diethyl ether (0.04 ml, 0.04 mmol) to give the titlecompound as the mono-HCl salt as an orange powder (20 mg, 14%).

Example 52(1R)-1-({4-[(3,4-Dihydro-2H-chromen-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionehydrochloride

A solution of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (12 mg, 0.032mmol) and triethylamine (0.139 ml, 0.999 mmol) in DCM (4.5 ml) andmethanol (0.5 ml) at rt was stirred for 5 min.3,4-Dihydro-2H-chromene-6-carbaldehyde (commercially available) (45 mg,0.277 mmol) was added and the resulting solution was stirred overnightfor 18 h. LCMS showed that aldehyde remained and no amine remained.Additional(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(120 mg, 0.321 mmol) and additional triethylamine (0.138 ml, 0.999 mmol)were added and the resulting mixture stirred for 1 h. Additional sodiumtriacetoxyborohydride (294 mg, 1.387 mmol) was added and resultingsolution was stirred for 60 h. The reaction was diluted with DCM (10 ml)and sodium bicarbonate solution (10 ml) and stirred at rt for 10 minsand extracted with methanol:DCM (20%, 3×150 ml). The combined organicextracts were dried (MgSO₄), filtered, evaporated and chromatographed(0-50% methanol:DCM). The column waste was concentrated to afford abrown oil that was re-chromatographed (0-50% methanol:DCM). The relevantfractions were combined to afford the free base of the title compound asa white solid (27 mg, 0.06 mmol, 22%).

¹H NMR δH CDCl₃, (400 MHz) 1.76-1.86 (m, 2H), 1.91-1.97 (m, 2H),2.04-2.06 (mm, 2H), 2.15 (t, 1H), 2.24 (t, 1H), 2.62 (dd, 1H), 2.75-2.81(m, 4H), 3.06-3.14 (m, 2H), 3.85 (s, 2H), 4.12 (t, 2H), 4.40 (dd, 1H),4.51 (dd, 1H), 4.96-5.02 (m, 1H), 6.22-6.29 (m, 2H), 6.77 (d, 1H),7.25-7.27 (m, 2H), 7.47-7.50 (m, 2H).

MS (ES+) m/z 447 (MH⁺).

The free base of the title compound in chloroform (5 ml) and methanol (3ml) was treated dropwise with hydrochloric acid in ether (1M, 0.06 ml,0.06 mmol) to give the title compound as the mono-HCl salt as a whitesolid (6 mg, 4%).

Example 53(2R)-2-[(4-{[(5-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

(a)₅-Fluoro-2,3-dihydro-1,4-benzodioxin

A solution of 3-fluoro-1,2-benzenediol (5.278 g, 41.2 mmol) in DMF (50ml) was treated with potassium carbonate (17.08 g, 124 mmol) and1,2-dibromoethane (3.91 ml, 45.3 mmol) and stirred at rt for 72 h. Thereaction was treated with water (200 ml) and extracted 3×200 ml (EtOAc).The combined organic extracts were washed with water (200 ml), brine(200 ml), dried (MgSO₄), evaporated and chromatographed (0-20%EtOAc-Cyclohexane) to give product as a clear oil. (2.437 g, 38%).

¹H NMR δH CDCl₃, (400 MHz) 4.22-4.39 (m, 4H), 6.60-6.82 (m, 3H).

(b) 6-Bromo-5-fluoro-2,3-dihydro-1,4-benzodioxin

solution of 5-fluoro-2,3-dihydro-1,4-benzodioxin (0.335 g, 2.173 mmol)in methanol (10 ml) at 0° C. was treated with bromine (0.134 ml, 2.61mmol) and allowed warm to rt over 10 min and stirred at rt for 18 h.Reaction was then treated with saturated aqueous sodium metabisulfate(100 ml), extracted 3×100 ml (DCM), the combined organic extracts dried(MgSO₄), filtered, evaporated, chromatographed (0-50% EtOAC:Cyclohexane)to give product as a clear oil, which solidified in the freezer to givea white solid (351 mg, 59%).

¹H NMR δH CDCl₃, (400 MHz) 4.20-4.39 (m, 4H), 6.52-6.65 (m, 1H),6.91-7.05 (m, 1H).

(c) 5-Fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde

A solution of 6-bromo-5-fluoro-2,3-dihydro-1,4-benzodioxin (146 mg,0.627 mmol) in THF (5 ml) at −78° C. was treated with n-BuLi (0.551 ml,1.378 mmol) under a nitrogen atmosphere and stirred at −78° C. for 15min before treatment with a solution of DMF (0.243 ml, 3.13 mmol) inTHF)(2.00 ml). The reaction was stirred for 10 min at −78° C. and thenthe reaction was allowed warm to rt over 10 min and stirred at rt for0.5 h. Reaction was treated with 2M HCl (20 ml) and extracted with ethylacetate (3×100 ml). The organic extracts were evaporated, dried (MgSO₄),filtered, evaporated, chromatographed (0-100% EtOAC:Cyclohexane) to giveproduct as a white solid (25 mg, 22%).

MS (ES+) m/z 183 (MH⁺).

(d) Title Compound

A suspension of(2R)-2-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 16A(j), amine wasconverted into dihydrochloride after chiral hplc purification) (51.3 mg,0.137 mmol) in chloroform (5 ml) and methanol (0.1 ml) at rt under argonwas treated with triethylamine (0.057 ml, 0.411 mmol) and stirred at rtfor 0.25 h. The solution was then treated with5-fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (24.95 mg, 0.137mmol) and stirred for a further 0.5 h. The solution was then treatedwith sodium triacetoxyborohydride (174 mg, 0.822 mmol) and stirred at rtfor 2 h, more sodium triacetoxyborohydride (174 mg, 0.137 mmol) wasadded, reaction stirred for a further 1 h, the reaction was then treatedwith saturated aqueous NaHCO₃ (20 ml) and extracted with 20%methanol/DCM (3×20 ml). The combined organic extracts were dried (MgSO₄)and chromatographed (0-20% methanol:DCM) to give the free base of thetitle compound as a white solid (29 mg, 0.062 mmol, 45%,).

¹H NMR δH CDCl₃, (400 MHz) 1.20-1.46 (m, 2H), 1.73-1.95 (m, 2H),2.15-2.39 (m, 2H), 2.41-2.55 (m, 1H), 2.61-2.75 (m, 2H), 2.88-3.00 (m,1H), 3.10-3.20 (m, 1H), 3.78 (s, 2H), 4.22-4.42 (m, 5H). 4.51-4.60 (m,1H), 4.95-5.09 (m, 1H), 6.38 (d, 1H), 6.62 (m, 1H), 6.71-6.80 (m, 1H),7.76 (d, 1H), 7.81 (s, 1H)

MS (ES+) m/z 468 (MH⁺).

The free base of the title compound (29 mg) in DCM/MeOH 2:1 (5 ml) wastreated with 1M HCl in diethyl ether 62 ul) and then evaporated to givethe title compound as the mono-HCl salt (31 mg, 0.062 mmol) as a yellowsolid.

Example 54(1R)-1-{[(2S)-2-({[(7-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}methyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

To a 10 mL round-bottomed flask were added(1R)-1-{[(2S)-2-(aminomethyl)-4-morpholinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(HCl)(85 mg, 0.241 mmol) (for a preparation see Example 47(c)),7-fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (48.3 mg, 0.265mmol) (for a synthesis see WO2002056882, Example 23(a)), and NaHCO₃(60.7 mg, 0.723 mmol) in DCM (4 ml) and methanol (1 ml) to give a yellowsuspension. Sodium sulfate (171 mg, 1.205 mmol) was added, the reactionwas stirred overnight at which point sodium triacetoxyborohydride (102mg, 0.482 mmol) was added. The reaction was stirred for 4 h at whichpoint LCMS showed the reaction to be complete. The reaction mixture wasdiluted with 10% MeOH in DCM (20 mL), filtered, adsorbed onto silica andpurified by chromatography on silica eluting with 0-10% MeOH/CHCl₃ (1%NH₄OH) to give the free base of the title compound in which the LCMS, ¹HNMR were consistent with the desired product.

¹H NMR δH D-4 MeOH, (400 MHz) 2.03-2.10 (m, 1H), 2.33-2.49 (m, 2H),2.51-2.68 (m, 2H), 2.83-2.95 (m, 2H), 2.99-3.07 (m, 1H), 3.39 (s, 2H),3.41-3.50 (m, 1H), 3.55-3.63 (m, 1H), 3.68-3.80 (m, 3H), 4.42-4.51 (m,2H), 4.79 (s, 2H), 5.08-5.18 (m, 1H), 6.22-6.32 (m, 2H), 6.58-6.62, (m,1H), 6.81-6.88 (m, 1H), 7.73-7.80 (m, 2H).

MS (ES+) m/z 483 (MH⁺).

The free base of the title compound was diluted in 5% MeOH/CHCl₃ andtreated with 1N HCl in ether 100 uL and concentrated to give the titlecompound as the diHCl salt (55 mg, 0.099 mmol, 41.1% yield) as a paleyellow solid.

Example 55(1R)-1-[((3S)-3-{[([1,3]Oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]methyl}-1-pyrrolidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride

(a) 1,1-Dimethylethyl(3S)-3-{[(trifluoroacetyl)amino]methyl}-1-pyrrolidinecarboxylate

To a 100 mL round-bottomed flask was added 1,1-dimethylethyl(3S)-3-(aminomethyl)-1-pyrrolidinecarboxylate (commercially available)(750 mg, 3.74 mmol) in (DCM) (20 ml) to give a colorless solution.Triethylamine (1.044 ml, 7.49 mmol) was added and the reaction wascooled to 0° C. Trifluoroaceticanhydride (0.635 ml, 4.49 mmol) was addedand the reaction was allowed to warm to rt while stirring for 14 h. Thesolution was diluted with 100 mL DCM and washed with saturated aqueoussolution of NaHCO₃, and a saturated aqueous solution of NaCl. Theorganic layer was separated, dried over Na₂SO₄, filtered andconcentrated. The residue was subjected to chromatography on silica togive the product (0.990 g, 3.34 mmol, 89% yield) as a pale yellow oil.

MS (ES+) m/z 297 (MH⁺).

(b) 2,2,2-Trifluoro-N-[(3R)-3-pyrrolidinylmethyl]acetamide hydrochloride

To a 100 mL round-bottomed flask was added 1,1-dimethylethyl(3S)-3-{[(trifluoroacetyl)amino]methyl}-1-pyrrolidinecarboxylate (830mg, 2.80 mmol) in DCM (25 ml) at 25° C. to give a colorless solution. 4NHCl (3.50 ml, 14.01 mmol) in dioxane was added and the reaction wasallowed to stir o/n. The reaction was concentrated under vacuum to givethe desired compound as colorless oil which was used in the nextreaction without further purification. Isolated2,2,2-trifluoro-N-[(3R)-3-pyrrolidinylmethyl]acetamide (550 mg, 2.364mmol, 84% yield).

MS (ES+) m/z 197 (MH⁺).

(c)N-[((3S)-1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-3-pyrrolidinyl)methyl]-2,2,2-trifluoroacetamide

To a 100 mL round-bottomed flask was added(1S)-1-(hydroxymethyl)-1,2,5,6-tetrahydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dioneHCl (for a preparation see Example 47(c)) (350 mg, 1.589 mmol),triethylamine (0.266 ml, 1.907 mmol) in DCM (20 ml) 0° C. to give aorange solution. Methane sulfonylchloride (0.135 ml, 1.748 mmol) wasadded and the reaction was allowed to warm to rt and stir for 1 h. LCMSindicated that the methanesulfonate had formed. The reaction was dilutedwith DCM (100 mL) and washed with 2×25 mL of a saturated aqueous NaHCO₃solution. The organic phase was separated and dried over Na₂SO₄. Thesolution was concentrated under vacuum, diluted with acetonitrile (20.00ml) and pyridine (0.500 ml) was added.2,2,2-trifluoro-N-[(3R)-3-pyrrolidinylmethyl]acetamide (550 mg, 2.364mmol) was added and the reaction was heated to 80° C. and stirred for 25h. LCMS indicated a complete reaction. The reaction was cooled to rt andconcentrated under vacuum. The reaction mixture was diluted with DCM(100 mL) and washed with 25 mL of a saturated NaHCO₃ solution. Theorganic phase was separated and dried over Na₂SO₄. The crude product waspurified on silica eluting with 0-15% MeOH/DCM to give product (240 mg,0.602 mmol, 37.9% yield) as a pale yellow oil.

MS (ES+) m/z 399 (MH⁺).

(d)N-[((3S)-1-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-3-pyrrolidinyl)methyl]-2,2,2-trifluoroacetamide

To a 25 mL round-bottomed flask was addedN-[((3S)-1-{[(2R)-4,9-dioxo-1,2,8,9-tetrahydro-4H,7H-imidazo[1,2,3-ij]-1,8-naphthyridin-2-yl]methyl}-3-pyrrolidinyl)methyl]-2,2,2-trifluoroacetamide(240 mg, 0.602 mmol) in 1,4-dioxane (5 ml) at rt under nitrogen to givea orange solution. DDQ (205 mg, 0.904 mmol) was added and the reactionbecame very dark. The reaction was heated to 80° C. on an oil bath andstirred for 10 h. The reaction was cooled to rt. 5% Aqueous K₂CO₃ (20mL) was added and the reaction was extracted with DCM (3×100 mL). Thecombined organic layers were washed with a saturated aqueous NaClsolution and the organic phase was dried over Na₂SO₄, filtered andconcentrated to give the crude product. The crude product was added to asilica gel column and was eluted with 0-20% MeOH/CHCl₃ to give product(85 mg, 0.214 mmol, 35.6% yield) as an orange solid.

MS (ES+) m/z 397 (MH⁺).

(e)(1R)-1-{1[(3S)-3-(aminomethyl)-1-pyrrolidinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

To a 25 mL round-bottomed flask was addedN-[((3S)-1-{[(1R)-4,9-dioxo-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridin-1-yl]methyl}-3-pyrrolidinyl)methyl]-2,2,2-trifluoroacetamide(85 mg, 0.214 mmol) in methanol (9 ml) and water (1.00 ml) to give ayellow solution. Potassium carbonate (59.3 mg, 0.429 mmol) was added andthe reaction was stirred overnight. LCMS indicated a complete reaction.The reaction was diluted with 20% MeOH/DCM (100 mL), dried over Na₂SO₄,filtered and concentrated to give the product (60 mg, 0.200 mmol, 93%yield) as an orange solid.

MS (ES+) m/z 301 (MH⁺).

(f) Title Compound

To a 10 mL round-bottomed flask were added(1R)-1-{[(3S)-3-(aminomethyl)-1-pyrrolidinyl]methyl}-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(60 mg, 0.200 mmol), [1,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (33.4mg, 0.200 mmol) (for a synthesis see WO2004058144 Example 61), andsodium sulfate (250 mg, 1.760 mmol) in DCM (4 ml) and methanol (1.00 ml)to give an orange suspension. The reaction was stirred overnight undernitrogen. Sodium triacetoxyborohydride (85 mg, 0.400 mmol) was added andthe reaction was stirred for 3 h. The reaction mixture was diluted with10% MeOH/DCM (20 mL), filtered, adsorbed onto silica and then purifiedby silica chromatography eluting with 0-10% MeOH/DCM (1% NH₄OH) to givethe free base of the title compound as a yellow oil. LCMS/NMR consistentwith the desired product.

¹H NMR δH D-4 MeOH, (400 MHz) 1.34-1.43 (m, 1H), 1.85-1.96 (m, 1H),2.15-2.30 (m, 2H), 2.38-2.51 (m, 3H), 2.68-2.75 (m, 1H), 2.04-3.17 (m,2H), 3.41-3.50 (m, 1H), 3.69 (s, 2H), 4.42-4.51 (m, 2H), 5.08-5.18 (m,1H), 5.83 (s, 2H), 6.26-6.32 (m, 2H), 7.33 (s, 1H), 7.73-7.78 (m, 2H),7.94 (s, 1H).

MS (ES+) m/z 452 (MH⁺).

The free base of the title compound was diluted with 10% MeOH/CHCl₃, 100uL of 1N HCl in ether was added and the mixture concentrated undervacuum to give the title compound as the dihydrochloride salt (47 mg,0.090 mmol, 44.9% yield) as a tan solid.

Example 567-{[(1-{[(1R)-3,8-Dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-1-yl]methyl}-4-piperidinyl)amino]methyl}-2,3-dihydro-1,4-benzodioxin-5-carbonitrilehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k) or 15(d)) (50 mg,0.100 mmol) in chloroform (4 ml) and methanol (0.121 ml) at rt undernitrogen was treated with triethylamine (0.587 ml, 4.21 mmol) andstirred for 15 min (the suspension turned into a solution).7-Formyl-2,3-dihydro-1,4-benzodioxin-5-carbonitrile (for a synthesis seeWO06014580 Preparation 13 or WO2007122258, Example 31(d)) ((18.95 mg,0.100 mmol) was then added and the reaction was stirred for 30 min.Sodium triacetoxyborohydride (63.7 mg, 0.301 mmol) was then added andthe reaction was stirred for 1 h. LC-MS after 1 h showed some imineintermediate so more sodium triacetoxyborohydride (63.7 mg, 0.301 mmol)was added and the reaction stirred for 2 h. LCMS after this time stillshowed imine intermediate, More sodium triacetoxyborohydride (63.7 mg,0.301 mmol) was added and the reaction left stirring overnight (16 h),LCMS after this time showed no starting material. Saturated NaHCO₃ (10mL) was added followed by 20% MeOH/DCM (20 ml) and the aqueous phase wasextracted and then separated from the organic layer. The aqueous phasewas extracted again with 20% MeOH/DCM (2×20 ml). The combined organicextracts were dried (NaSO₄), filtered and evaporated to give crudeproduct. The crude product was purified on a silica column (0-20%MeOH/DCM) to give the free base of the title compound (33 mg, 69.4%).

¹H NMR δH CDCl₃, (400 MHz) 1.15-1.41 (m, 2H), 1.72-1.91 (m, 2H),2.19-2.39 (m, 2H), 2.40-2.52 (m, 1H), 2.53-2.78 (m, 2H), 2.89-2.98 (m,1H), 3.02-3.14 (m, 1H), 3.68 (s, 2H), 4.22-4.49 (m, 5H), 4.51-4.62 (m,1H), 4.98-5.08 (m, 1H), 6.32 (d, 1H), 7.06 (m, 2H), 7.78 (d, 1H), 7.88(s, 1H).

MS (ES+) m/z 475 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM and treated with one equivalent of 1M HCl in diethyl ether. Thisgave the title compound as the mono HCl salt (33 mg, 65%).

Example 57(1R)-1-[(4-{[(7-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k)) or 15(d) (50 mg,0.100 mmol) in chloroform (3 ml) and methanol (0.150 ml) at roomtemperature under nitrogen was treated with triethylamine (0.042 ml,0.301 mmol) and stirred for 0.25 h (the suspension turned into asolution). 7-Fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (for asynthesis see WO2002056882, Example 23(a)) (18.25 mg, 0.100 mmol) wasthen added and the reaction was stirred at room temperature for 0.5 h.Sodium triacetoxyborohydride (67.1 mg, 0.301 mmol) was then added andthe reaction was stirred at room temperature. After 1 h more sodiumtriacetoxyborohydride (67.1 mg, 0.301 mmol) was added and the reactionstirred at rt overnight. More sodium triacetoxyborohydride (67.1 mg,0.301 mmol) was then added and the reaction stirred at rt. After 1 h nostarting material remained. Saturated NaHCO₃ (30 mL) was added followedby 20% MeOH/DCM (30 mL) and the aqueous phase was extracted and thenseparated from the organic layer. The aqueous phase was extracted againtwice with 20% MeOH/DCM (2×30 mL). The combined organic extracts weredried NaSO₄, filtered and evaporated to afford the crude product. Thecrude product was purified by chromatography on silica (0-20% MeOH/DCM)to afford 35 mg of the free base of the title compound as a yellow solid(74.7%).

¹H NMR δH CDCl₃, (400 MHz) 1.21-1.41 (m, 2H), 1.76-1.92 (m, 2H),2.10-2.39 (m, 2H), 2.41-2.52 (m, 1H), 2.61-2.79 (m, 2H), 2.86-2.98 (m,1H), 3.05-3.14 (m, 1H), 3.72 (s, 2H), 4.18-4.29 (m, 4H), 4.38-4.43 (m,1H), 4.51-4.62 (m, 1H), 4.94-5.05 (m, 1H), 6.33 (d, 1H), 6.58 (d, 1H),6.80 (1H, d), 7.77 (d, 1H), 7.86 (s, 1H).

MS (ES+) m/z 468 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM/MeOH and treated with 1 eq of a 1M solution of HCl in Et₂O. Thesolvents were removed and the solid dried in the desiccator (P₂O₅) toafford the title compound as the hydrochloride salt as a dark yellowsolid (36 mg).

Example 58(1R)-1-[(4-{[(8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionedihydrochloride (for a preparation see Example 13(k) or 15(d)) (50 mg,0.100 mmol) in chloroform (25 ml) and methanol (1.250 ml) at roomtemperature under nitrogen was treated with triethylamine (0.042 ml,0.301 mmol) and stirred for 0.25 h (the suspension turned into asolution). 8-Fluoro-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde (for asynthesis see WO2007122258, Example 8(b))(19.62 mg, 0.100 mmol) was thenadded and the reaction was stirred at room temperature for 0.5 h. Sodiumtriacetoxyborohydride (67.1 mg, 0.301 mmol) was then added and thereaction was stirred at room temperature. After 1 h still startingmaterial so sodium triacetoxyborohydride (67.1 mg, 0.301 mmol) was addedand the reaction stirred at rt overnight. Still starting material sosodium triacetoxyborohydride (67.1 mg, 0.301 mmol) was added and thereaction stirred at rt for 1 h. Saturated NaHCO₃ (30 mL) was addedfollowed by 20% MeOH/DCM (30 mL) and the aqueous phase was extracted andthen separated from the organic layer. The aqueous phase was extractedagain twice with 20% MeOH/DCM (2×30 mL). The combined organic extractswere dried NaSO₄, filtered and evaporated to afford the crude product.The crude product was purified by chromatography on silica (0-20%MeOH/DCM) to afford 26 mg of the free base of the title compound as ayellow solid.

¹H NMR δH CDCl₃, (400 MHz) 1.20-1.41 (m, 2H), 1.72-1.89 (m, 2H),2.09-2.35 (m, 2H), 2.42-2.52 (m, 1H), 2.55-2.78 (m, 2H), 2.85-2.99 (m,1H), 3.08-3.15 (m, 1H), 3.63 (s, 2H), 4.22-4.48 (m, 5H), 4.51-4.63 (m,1H), 4.95-5.06 (m, 1H), 6.32 (d, 1H), 6.61-6.72 (m, 2H), 7.75 (d, 1H),7.89 (s, 1H).

MS (ES+) m/z 468 (MH⁺).

The free base of the title compound was dissolved in a small amount ofDCM/MeOH and treated with 1 eq of a 1M solution of HCl in Et₂O. Thesolvents were removed and the solid dried in the desiccator (P₂O₅)overnight to afford the title compound as the hydrochloride salt as ayellow solid (26.6 mg, consistent with product).

Example 59(1R)-1-[(4-{[(2-Oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

To a 10 mL round-bottomed flask were added(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (80 mg, 0.266mmol), 2-oxo-2H-chromene-7-carbaldehyde (for a synthesis seeWO2008009700 Example 224) (46.4 mg, 0.266 mmol), and NaHCO₃ (100 mg,1.190 mmol) in dichloromethane (DCM) (4 ml) and methanol (1 ml) to givea brown solution. Sodium sulfate (200 mg, 1.408 mmol) was added and thereaction was allowed to stir at rt overnight. After 15 h sodiumtriacetoxyborohydride (113 mg, 0.533 mmol) was added and the reactionwas allowed to stir at 25° C. under nitrogen for 4 h. The reactionmixture was adsorbed onto silica and purified using 0-10% MeOH/DCM (1%NH₄OH) to give the title compound as a free base (30 mg, 0.064 mmol,24.07% yield) as a tan solid. LCMS & 1H NMR consistant with desiredproduct.

¹H NMR δH D-4 MeOH, (400 MHz) 1.20-1.39 (m, 2H), 1.72-1.89 (m, 2H),1.90-2.09 (m, 1H), 2.13-2.31 (m, 2H), 2.39-2.50 (m, 1H), 2.56-2.70 (m,2H), 2.90-3.10 (m, 2H), 3.83 (s, 2H), 4.32-4.58 (m, 2H), 4.98-5.18 (m,1H), 6.20-6.39 (m, 3H), 7.19-7.28 (m, 2H), 7.39-7.51 (m, 3H), 7.62-7.71(m, 1H).

MS (ES+) m/z 459 (MH⁺).

Example 60(1R)-1-[(4-{[(2-oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

To a 10 mL round-bottomed flask were added(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (45 mg, 0.134mmol), 7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carbaldehyde(prepared by (1) reduction of7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carbaldehyde(for a synthesis see WO2003064421 Example 15(c)) with LiAlH₄ to give(7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methanol and then(2) oxidation with MnO₂) (29.2 mg, 0.147 mmol), and NaHCO₃ (100 mg,1.190 mmol) in dichloromethane (DCM) (4 ml) and methanol (1 ml) to givea brown suspension. Sodium sulfate (200 mg, 1.408 mmol) was added andthe reaction was stirred at rt overnight. After 15 h sodiumtriacetoxyborohydride (56.6 mg, 0.267 mmol) was added and the reactionwas stirred at 25° C. under nitrogen for 4 h. The reaction mixture wasadsorbed onto silica and purified using 0-10% MeOH/DCM (1% NH₄OH) togive the title compound as a free base (9.4 mg, 0.019 mmol, 14.57%yield).

¹H NMR δH D-4 MeOH, (400 MHz) 1.49-1.70 (m, 2H), 2.00-2.17 (m, 2H),2.28-2.49 (m, 2H), 2.72-2.81 (m, 1H), 2.89-2.94 (m, 1H), 3.05-3.20 (m,3H), 3.38 (s, 2H), 3.50-3.58 (m, 1H), 4.18 (s, 2H) 4.20-4.24 (m, 2H),4.43-4.50 (m, 2H), 5.08-5.18 (m, 1H), 6.28-6.35 (m, 2H), 7.06 (s, 1H),7.78-7.83 (m, 2H).

MS (ES+) m/z 483/485 (MH⁺).

Example 61(1R)-1-[(4-{[(2-oxo-2H-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione

To a 10 mL round-bottomed flask were added(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (75 mg, 0.223mmol), 7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde(prepared by (1) reduction of7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde(for a synthesis see WO2003087098 Example 306(e)) with LiAlH₄ to give(7-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methanol andthen (2) oxidation with MnO₂)) (47.8 mg, 0.223 mmol), and NaHCO₃ (100mg, 1.190 mmol) in DCM (4 ml) and methanol (1 ml) to give a brownsuspension. Sodium sulfate (200 mg, 1.408 mmol) was added and thereaction was allowed to stir at rt overnight. After 15 h sodiumtriacetoxyborohydride (94 mg, 0.445 mmol) was added and the reaction wasallowed to stir at 25° C. under nitrogen for 4 h. The reaction mixturewas adsorbed onto silica and purified using 0-10% MeOH/DCM (1% NH₄OH) togive the title compound as a free base (45 mg, 0.090 mmol, 40.5% yield).LCMS & 1H NMR were consistent with the desired product.

¹H NMR δH D-4 MeOH, (400 MHz) 1.20-1.45 (m, 2H), 1.65-1.92 (m, 2H),2.19-2.39 (m, 2H), 2.42-2.71 (m, 2H), 2.82-3.10 (m, 5H), 3.65-3.80 (m,4H), 4.40-4.50 (m, 2H), 5.05-5.20 (m, 1H), 6.25-6.35 (m, 2H), 7.22 (s,1H), 7.72-7.83 (m, 2H).

MS (ES+) m/z 483/485 (MH⁺).

Example 62(1R)-1-({4-[(3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dione

A suspension of(1R)-1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dionedihydrochloride (for a preparation see Example 5A(j)) (0.075 g, 0.201mmol) in dichloromethane (5 ml) and methanol (1 ml) at rt under argonwas treated with3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (prepared by(1) reduction of3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde (for asynthesis see WO2003087098, Example 301(d)) with LiAlH₄ to give3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethanol and then (2)oxidation with MnO₂)) (0.036 g, 0.201 mmol), sodium bicarbonate (0.150g, 1.786 mmol) and sodium sulfate (0.300 g, 2.112 mmol) and stirred atrt for 5 h. The solution was then treated with sodiumtriacetoxyborohydride (0.128 g, 0.603 mmol) and stirred over weekend for65 hours. The solution was evaporated, taken up in CH₃OH, adsorbed ontosilica gel and chromatographed on silica (0-15% CH₃OH in DCM (with 1%NH₄OH)) to give the title compound as the free base (59 mg, 63%) as abeige solid.

¹H NMR DMSO-D6, (400 MHz) 1.02-1.27 (m, 2H), 1.61-1.78 (m, 2H),1.81-1.96 (s, 1H), 2.01-2.19 (m, 2H), 2.28-2.38 (m, 1H), 2.67-2.79 (m,1H), 2.82-2.98 (m, 4H), 3.50 (s, 2H), 3.55-3.61 (m, 2H), 4.21-4.34 (m,2H), 4.91-4.99 (m, 1H), 6.10-6.19 (m, 2H), 6.48-6.52 (d, 1H), 6.69-6.75(s, 1H), 7.12-7.19 (d, 1H), 7.71-7.82 (d, 2H)

MS (ES+) m/z 465 (MH⁺).

Example 631-[(4-{[(3-Oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-]-1,8-naphthyridine-4,9-dionehydrochloride (2:1 Mixture of R:S)

The title compound was prepared from1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(2:1 mixture of R:S, for a preparation see Example 11(d)) and2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for a synthesissee WO2004058144, Example 60) according to the general method of Example12.

¹H NMR, LC-MS and mono-hydrochloride salt formation as for Example 6A.

Example 641-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4H,9H-imidazo[1,2,3-j]-1,8-naphthyridine-4,9-dione(2:1 Mixture of S:R)

The title compound was prepared from1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione(2:1 mixture of S:R prepared analogously to Example 11(a-d)) but using7-(methyloxy)-1-[(2R)-2-oxiranylmethyl]-3,4-dihydro-1,8-naphthyridin-2(1H)-one(for a synthesis see example 5(f)) and2,3-dihydro[1,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for a synthesissee WO2004058144, Example 60) according to the general method of Example12.

¹H NMR, LC-MS and mono-hydrochloride salt formation as for Example 6A.

TABLE 1 Made using the specified starting materials according to themethod of Example 5(k) Starting materials Ex (for a preparation see #Salt form Structure referenced examples) 65 di-HCl MS (ES+) mz 432(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 1H-imidazo[4,5-b]pyridine-2- carbaldehyde (commercial) 66 Freebase MS (ES+) mz 431(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 1H-pyrrolo[2,3-b]pyridine-2- carbaldehyde (commercial) 67 di-HClMS (ES+) mz 480(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 8-Fluoro-3-oxo-3,4-dihydro- 2H-1,4-benzoxazine-6- carbaldehyde(for a synthesis see WO2006014580 Preparation 15) 68 di-HCl MS (ES+) mz466(MH⁺)

(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dionedihydrochloride (Example 5A(j)) 8-fluoro-3,4-dihydro-2H-1,4-benzoxazine-6-carbaldehyde Prepared by (1) reduction of8-fluoro-3-oxo-3,4-dihydro-2H-1,4- benzoxazine-6-carbaldehyde (for asynthesis see WO2006014580 Preparation 15) with LiAlH₄ to give(8-fluoro-3,4-dihydro-2H-1,4- benzoxain-6-yl)methanol and then (2)oxidation with MnO₂)) 69 Free base MS (ES+) mz 484(MH⁺)

(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dionedihydrochloride (Example 5A(j))7,8-Difluoro-3,4-dihydro-2H-1,4-benzoxazine- 6-carbaldehyde Prepared by(1) reduction of methyl 7,8-difluoro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate with LiAlH₄ to give(7,8-difluoro-3,4-dihydro- 2H-1,4-benzoxazin-6-yl)methanol and then (2)oxidation with MnO₂)) 70 Free base MS (ES+) mz 513/515 (MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 7-Chloro-3-oxo-3,4-dihydro- 2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (for a synthesis see WO03087098 Ex306(e)) 71 Mono-HCl MS(ES+) mz 453(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 6,7-Dihydro-5H-thieno[3,2-b]pyran- 2-carbaldehyde (for asynthesis see WO2007122258 Example 88(c)) 72 Mono-HCl MS (ES+) mz454(MH⁺)

(2R)-2-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8- dione (Example 16A(j) method B)6,7-Dihydro-5H-thieno[3.2- b]pyran-2-carbaldehyde (for a synthesis seeWO2007122258 Example 88(c)) 73 Mono-HCl MS (ES+) mz 454(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8- dione dihydrochloride (Example 13A(k) or15(d)) 6,7-Dihydro-5H-thieno[3.2- b]pyran-2-carbaldehyde (for asynthesis see WO2007122258 Example 88(c)) 74 Di-HCl MS (ES+) mz 448(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2- dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride(commercial) 75 Di-HCl MS (ES+) mz 492(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]- 1,8-naphthyridine-4,9-dionedihydrochloride (Example 5A(j)) 4-Oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-7- carbaldehyde (for a synthesis see WO2004058144Example 128(e) 76 Di-HCl MS (ES+) mz 463(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 8-Methyl-2,3-dihydro-1,4-benzodioxin-6- carbaldehyde (Preparedfrom 8-bromo-2,3- dihydro-1,4-benzodioxin-6-carbaldehyde (for asynthesis see WO2007122258 Example 31(c)) by palladium catalysed Stillecoupling with tetramethyltin) 77 Free base MS (ES+) mz 464(MH⁺)

(1R)-1-[(4-Amino-1- piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dione dihydrochloride (Example5A(j)) 3,4-Dihydro-2H-1,4- benzothiazin-6-carbaldehyde (for a synthesissee WO2003087098 Example 214) 78 Di-HCl MS (ES+) mz 478(MH⁺)

(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dionedihydrochloride (Example 5A(j)) 2,3,4,5-Tetrahydro-1,5-benzothiazepin-7-carbaldehyde (prepared from methyl 4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-7- carboxylate (for a synthesissee WO2007016610, Preparation 18(c)) by treatment with Borane-THF togive methyl 2,3,4,5-tetrahydro-1,5-benzothiazepine-7- carboxylate, thentreatement of this with LiAlH₄ to give 2,3,4,5-tetrahydro-1,5-benzothiazepin-7-ylmethanol and finally treatment with MnO₂ 79 Di-HCl MS(ES+) mz 466(MH⁺)

(1R)-1-[(4-Amino-1-piperidinyl)methyl]-1,2-dihydro-4H,9H-imidazo[1,2,3-ij]-1,8- naphthyridine-4,9-dionedihydrochloride (Example 5A(j)) 7-Fluoro-3,4-dihydro-2H-1,4-benzoxazine-6-carbaldehyde (prepared from 7-fluoro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6- carbonitrile (for a synthesis seeWO2002056882, Example 8(b)) by treatment with diisobutylaluminiumhydride)

Preparation A: 6,7-Dihydro[1,4]dioxino[2,3-c]pyridazine-3-carbaldehyde(a) 3,4,6-Trichloropyridazine

This was prepared by a slight variation on the method of Kasnar et al,Nucleosides &Nucleotides (1994), 13(1-3), 459-79.

Hydrazine sulphate salt (51 g) was suspended in water (250 ml), heatedto reflux and bromomaleic anhydride (90.38 g) was added dropwise. Themixture was heated at reflux for 4 hours then cooled to roomtemperature. The reaction was repeated with 29 g hydrazine sulphate, 53g bromomaleic anhydride and 130 ml water. The precipitates werecollected by filtration, washed with water and acetone and dried as acombined batch in vacuo to afford4-bromo-1,2-dihydro-3,6-pyridazinedione as a white solid (113 g).

The solid in two batches was treated with phosphorus oxychloride (2×200ml) and heated to reflux for 3.5 hours. The mixture was cooled,evaporated and azeotroped with toluene. The residue was partitionedbetween dichloromethane and saturated aqueous sodium bicarbonatesolution and extracted with DCM twice more. The organic extracts weredried and evaporated. This residue was re-dissolved in dichloromethane,and chromatographed on silica gel (300 g) (DCM as eluent) to give awhite solid (101.5 g, 87%).

(LC/MS analysis showed ca 20-30% impurity, isomers ofbromo-dichloropyridazine).

MS (+ve ion electrospray) m/z 184/185/186 (MH+), trichloropyridazine.

MS (+ve ion electrospray) m/z 228/229/231 (MH+),bromo-dichloropyridazine.

(b) 2-[(3,6-Dichloro-4-pyridazinyl)oxy]ethanol

A solution of ethylene glycol (55 ml) in tetrahydrofuran (200 ml) wastreated at around 0° C. (ice bath cooling) with sodium hydride (60%dispersion in oil, 5.9 g) over 40 minutes. After the addition wascomplete, 3,4,6-trichloropyridazine (27 g) containing isomers ofbromo-dichloropyridazine as impurity was added portionwise and washed inwith more dry THF (50 ml) and the mixture was stirred at 0° C. for 1hour and then at room temperature overnight. The mixture wasconcentrated (to ⅓ volume) then diluted with aqueous sodium bicarbonatesolution and extracted with chloroform (5×) and ethyl acetate (3×). Thecombined organic extracts were washed with water, dried over sodiumsulphate and evaporated and the solids filtered off and washed withCHCl₃ (×3) and dried in a vacuum oven overnight at 40° C. affording awhite solid (25.5 g, 83%), containing some bromo-derivative (10-15%).

MS (+ve ion electrospray) m/z 209/211 (MH+).

MS (+ve ion electrospray) m/z 255/7 (MH+), bromo-derivative.

(c) 3-Chloro-6,7-dihydro[1,4]dioxino[2,3-c]pyridazine

A solution of 2-[(3,6-dichloro-4-pyridazinyl)oxy]ethanol containing somebromo-derivative (15.46 g; 0.0703 mol) in dry 1,4-dioxane (1.2 L) wastreated with lithium hydride (2.3 g; 0.28 mol) in portions and stirredat room temperature for 1 hour under argon, then heated at 110° C.overnight. The reaction mixture was quenched with wet 1,4-dioxane, theniced-water. The solution was evaporated to half volume, taken to pH 8with 5M hydrochloric acid and evaporated to dryness. Water was added andthe residue was extracted 5× with chloroform, dried (sodium sulphate)and evaporated to afford a white solid (12.4 g, ca. 77%) (containing ca.15% of a bromo species).

MS (+ve ion electrospray) m/z 173/5 (Cl MH⁺); 217/9 (Br MH⁺)

(d) 3-Ethenyl-6,7-dihydro[1,4]dioxino[2,3-c]pyridazine

A solution of 3-chloro-6,7-dihydro[1,4]dioxino[2,3-c]pyridazine (13.6 g,0.079 mol) containing ca. 15% of a bromo species in dimethoxyethane (400ml) was degassed under argon for 10 min thentetrakis(triphenylphosphine)palladium (0) (2 g), potassium carbonate(10.33 g), 2,4,6-trivinylcyclotriboroxane pyridine complex (11.32 g) andwater (55 ml) were added. The mixture was heated at 95° C. for 48 hoursand cooled and evaporated to dryness. The mixture was treated withaqueous sodium bicarbonate solution and extracted (5×) with DCM.Extracts were dried (sodium sulphate), evaporated and the residuechromatographed on silica gel (500 g), eluting with 0-100% ethylacetate-hexane, affording the product (6.43 g, 50%); [also some impurefractions (1.8 g)].

MS (+ve ion electrospray) m/z 165 (MH⁺).

(e) Title Compound

A solution of 3-ethenyl-6,7-dihydro[1,4]dioxino[2,3-c]pyridazine (11.58g) in 1,4-dioxane/water (600 ml/180 ml), cooled in ice, was treated withan aqueous solution of osmium tetroxide (4% w/v, 25 ml) and sodiumperiodate (43 g). This mixture was allowed to warm to room temperatureand after 7 hours under stirring the mixture was evaporated to drynessand azeotroped with 1,4-dioxane. Silica gel, 1,4-dioxane and chloroformwere added and the mixture was evaporated to dryness overnight, thenadded to a silica column (400 g) and chromatographed, eluting withchloroform then 0-100% ethyl acetate in hexane, to afford a white solid(7.55 g, 64%).

MS (+ve ion electrospray) m/z 167 (MH⁺).

Biological Activity Antimicrobial Activity Assay:

Whole-cell antimicrobial activity was determined by broth microdilutionusing the Clinical and Laboratory Standards Institute (CLSI) recommendedprocedure, Document M7-A7, “Methods for Dilution Susceptibility Testsfor Bacteria that Grow Aerobically”. The compounds were tested in serialtwo-fold dilutions ranging from 0.016 to 16 mcg/ml.

The minimum inhibitory concentration (MIC) was determined as the lowestconcentration of compound that inhibited visible growth. A mirror readerwas used to assist in determining the MIC endpoint.

Compounds were evaluated against Gram-positive organisms, selected fromStaphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes,Enterococcus faecalis and Enterococcus faecium.

In addition, compounds were evaluated against Gram-negative organismsselected from Haemophilus influenzae, Moraxella catarrhalis, Escherichiacoli, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter cloacae,Enterobacter aerogenes, Klebsiella pneumoniae and Stenotrophomonasmaltophilia.

Each of the listed Examples, as identified in the present application,except Examples 71-73 and 76-79, was tested in at least one exemplifiedsalt or free base form. Unless otherwise noted, the tested Examples hada MIC≤2 μg/ml against a strain of at least one of the organisms listedabove, with the exception of Example 9 which had an MIC≤4 μg/ml againsta strain of at least one of the organisms listed above. For at least onestrain of every organism listed above, at least one Example had a MIC≤2μg/ml.

Mycobacterium tuberculosis H37Rv Inhibition Assay

The measurement of the minimum inhibitory concentration (MIC) for eachtested compound was performed in 96 wells flat-bottom, polystyrenemicrotiter plates. Ten two-fold drug dilutions in neat DMSO starting at400 μM were performed. Five μl of these drug solutions were added to 95μl of Middlebrook 7H9 medium. (Lines A-H, rows 1-10 of the platelayout). Isoniazid was used as a positive control, 8 two-fold dilutionof Isoniazid starting at 160 μgml⁻¹ was prepared and 5 μl of thiscontrol curve was added to 95 μl of Middlebrook 7H9 (Difco catalogueRef. 271310)+ADC medium (Becton Dickinson Catalogue Ref. 211887). (Row11, lines A-H). Five μl of neat DMSO were added to row 12 (growth andBlank controls).

The inoculum was standardised to approximately 1×10⁷ cfu/ml and diluted1 in 100 in Middlebrook 7H9+ ADC medium and 0.025% Tween 80 (SigmaP4780), to produce the final inoculum of H37Rv strain (ATCC25618). Onehundred of this inoculum was added to the entire plate but G-12 and H-12wells (Blank controls). All plates were placed in a sealed box toprevent drying out of the peripheral wells and they were incubated at37° C. without shaking for six days. A resazurin solution was preparedby dissolving one tablet of resazurin (Resazurin Tablets for MilkTesting; Ref 330884Y VWR International Ltd) in 30 ml sterile PBS(phosphate buffered saline). 25 of this solution was added to each well.Fluorescence was measured (Spectramax M5 Molecular Devices, Excitation530 nm, Emission 590 nm) after 48 hours to determine the MIC value.

Examples 1-4, 5A, 6A, 7-9, 12, 13A, 14, 15, 16A, 17A, 19A, 20, 23-32,34, 37-44, 46-50, 53-57, 59 and 63 were tested in the Mycobacteriumtuberculosis H37Rv inhibition assay. Examples 2, 4, 5A, 6A, 7, 8, 12,13A, 14, 16A, 19A, 20, 23-26, 28-32, 34, 37, 39, 40, 42, 44, 46, 49, 50,56, 59 and 63 showed an MIC value of lower than 2.0 μg/ml. Examples 4,5A, 7, 8, 12, 13A, 14, 16A, 19A, 25, 26, 30-32, 37, 40, 49, 50, and 56showed an MIC value of 1.0 μg/ml or lower.

Invitro Assay

Studies were conducted to assess the in vitro activity of compounds ofthe present invention.

In particular, Example 39 in the present invention (i.e., identified as(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride) was tested against 30 strains of Neisseria gonorrhoeaecollected between 2003 through 2007.

Ceftriaxone and ciprofloxacin were included as comparators. Minimuminhibitory concentrations (MICs) for Example 39 and comparators weredetermined by agar dilution according to Clinical and LaboratoryStandards Institute (CLSI) approved methodology and guidelines (i.e.,see Clinical Laboratory Standards Institute (CLSI). Approved StandardM07-A9. Methods for Dilution Antimicrobial Susceptibility Tests forBacteria That Grow Aerobically. Ninth Edition. Wayne, Pa., 2012).

The MIC₉₀ (MIC which inhibits 90% of the isolates tested) for Example 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride was 0.5 μg/mL against 30 isolates of N. gonorrhoeae.

This MIC₉₀ value was at least 16-fold higher than that of ceftriaxone(<0.03 μg/ml) and at least 8-fold lower than ciprofloxacin (>2 μg/mL).The modal value of Example 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride remained unchanged against the 9 ciprofloxacin-resistantN. gonorrhoeae tested.

A second study tested Example 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride by CLSI agar dilution against 145 isolates of N.gonorrhoeae, the majority of which were collected in 2013. The MIC₉₀ forExample 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride against all isolates tested was 0.5 μg/mL. Against asubset of 37 ciprofloxacin-nonsusceptible isolates, the MIC₉₀ forExample 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride was 1 μg/mL.

These studies demonstrate the in vitro activity of Example 39(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride against N. gonorrhoeae, including ciprofloxacin-resistantstrains.

In Vivo Assay Data

A mouse model of N. gonorrhoeae vaginal colonization was performed toevaluate the efficacy of compounds of the present invention. Twoindependent studies were performed by the same laboratory.

In particular, Example 39 (i.e.,(2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dionehydrochloride) was tested in this model following a single oral dose ora total of two oral doses administered on the same day. Female mice wereprimed for colonization using estradiol; trimethoprim sulfate andstreptomycin were administered to control commensals. On day 0, micewere inoculated intravaginally with N. gonorrhoeae MS11 (Example 39—MIC1 μg/ml). Successful colonization was confirmed via vaginal swab cultureon days 1 and 2. Single oral doses at 100 mg/kg and 200 mg/kg or a totalof two oral doses at 100 mg/kg each of Example 39 were administered onday 2. Vaginal swabs for quantitative culture were collected dailythrough day 10 (8 days post treatment).

In one study, blood samples were collected terminally from a separategroup of mice at 1, 2, 6 and 12 hours post Example 39 administration(n=3 per time point and dose) to allow for estimation of PK parameters.

Example 39 at a single oral dose of 100 or 200 mg/kg or two 100 mg/kgdoses administered on the same day eliminated colonization with N.gonorrhoeae MS11 in 70-80%, 90-100% and 100% of mice, respectively, bythe end of the study while 0-10% of mice receiving the saline vehicledemonstrated bacterial clearance. The fAUC₀₋₂₄ values for these doseswere estimated to be 8, 22 and 16 μg·h/mL, respectively.

In the first study, one mouse in each of the Example 39 dose groupsdemonstrated initial clearance of N. gonorrhoeae for several consecutivedays, followed by regrowth to a high number of organisms by the end ofthe study. Although this regrowth was not observed in the follow-upstudy, colonies of N. gonorrhoeae MS11 recovered from GSK2140944-treatedmice were evaluated and did not demonstrate any change in susceptibilityto GSK2140944 compared with stock cultures of the organism.

It is to be understood that the invention is not limited to theembodiments illustrated hereinabove and the right is reserved to theillustrated embodiments and all modifications coming within the scope ofthe following claims.

The various references to journals, patents, and other publicationswhich are cited herein comprise the state of the art and areincorporated herein by reference as though fully set forth.

What is claimed is:
 1. A method for treating gonorrhea in a subject inneed thereof, which comprises administering to the subject an effectiveamount of(2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dioneas shown below:

or a pharmaceutically acceptable salt thereof.
 2. The method accordingto claim 1, wherein the pharmaceutically acceptable salt is an acidaddition salt formed from an acid selected from the group consisting ofhydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, acetic acid, fumaric acid, succinic acid, maleic acid,citric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid,naphthalenesulfonic acid and tartaric acid.
 3. The method according toclaim 1, wherein the pharmaceutically acceptable salt is an acidaddition salt formed from methanesulfonic acid.
 4. The method accordingto claim 1, wherein the subject is a human.
 5. The method according toclaim 1, wherein the subject has cervicitis, proctitis, urethritis,pelvic inflammatory disease, epididymitis, orchitis, prostatitis,conjunctivitis, or pharyngitis.